Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 1of 130Clinical Study Protocol
Study Intervention AZD1222
Study Code D8110C00001
Version Amendment 6
Date 19February 2021
TITLE PAGE
A Phase III Randomized, Double -blind, Placebo -controlled 
Multicenter Study in Adults to Determine the Safety , Efficacy , and 
Immunogenicity of AZD1222, a Non- replicating ChAdOx1 V ector 
Vaccine, for the Prevention of COVID -19
Sponsor Name: [CONTACT_245011]: 151 85 Södertälje, Sweden
Regulatory Agency Identifier Number(s): IND number [ZIP_CODE]
[STUDY_ID_REMOVED]
EudraCT number [ADDRESS_1198065] procedures. The Clinical Study Protocol is publicly registered and the results are 
disclosed and/or published according to the [COMPANY_008] Global Policy  on Bi oethics and in 
compliance wi th prevailing laws and regulat ions.
Clinical Study Protocol - Amendment 6 [COMPANY_008]
AZD1222 - D8110C00001
CONFIDENTIAL AND PROPRIETARY 2 of 130Protocol Number: D8110C00001
Amendment Number: 6
Study Intervention: AZD1222
Study Phase: III
Short Title: Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention 
of COVID-[ADDRESS_1198066] Information will be provided separately
[LOCATION_003] Coordinating Investigators:
University of [COMPANY_002]ster School of Medicine[COMPANY_002]ster, NY
Columbia University
[LOCATION_001], NY[COMPANY_003]
[COMPANY_003]
Clinic al Study  Protocol -Amendment [ADDRESS_1198067] 2020
Original Protocol 15 July  2020
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 4of 130Amendment 6(19February 2021)
This amendment is considered to be substant ial based on the cri teria set forth in Art icle 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council o f theEuropean Unio n.
Overall Rationale for the Amendment:
The principal reason for this amendment was to remo ve the extended dosing interval 
assessment and to remove adolescents from the study  populati onthat were added to 
Amendment 5 .(Note: Amendment 5 was n otimplemented .)
Section # and Name [CONTACT_670790]/
Non-substantial
Title Page,
1.1 SynopsisRem oved “and Adolescents” 
from the titleGiven removal of 
adolescents from the 
study populationSubstantial
1.1 Synopsis,
2.1Study RationaleRem oved text from the study 
rationale regarding adolescents
1.1 SynopsisReduced the number of study 
sites from 300 to 150To more realistically 
align with the actual 
number of sitesNon-substantial
1.1 Synopsis,
3 Objective and 
Endpoints,
Appendix F (Table 15)Upgraded exploratory 
endpoint 5 to secondary 
endpoint 9To gain information on 
efficacy following a 
single dose of AZD1222Substantial
1.1 Synopsis,
1.2 Schema,
1.3 Schedule of 
Activities
3 Objectives and 
Endpoints,
4.1 Overall Design,
4.2 Scientific Rationale 
for Study Design,
4.3 Justification for 
Dose,
4.4 End of Study 
Definitio n,
5 Study  Populatio n,
6.1.2 Dosing 
Instructio ns,
6.3 Measures to 
Minimize Bias: 
Randomization and 
Blinding,
7.1 Discontinuation of 
Study Interventio n
8 Study  Assessments Rem oved Appendix G Part 2
and any cross -references to 
Appendix G Part 2
Given removal of Part 2 
from the protocolSubstantial
Rem oved the “Part 1” label 
from the main study and 
corresponding substudy and 
immunogenicity cohortSubstantial
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 5of 130Section # and Name [CONTACT_670790]/
Non-substantial
and Procedures,
9 Statistical 
Considerations,
Appendix G Part 2 
1.1 Synopsis,
Appendix F 
(Table 15)Rem oved specification that 
primary  objective 3and
secondary objectives [ADDRESS_1198068],
11 References,
Appendix ERem oved the Serazin et al 2020 
and Vogel et al 2020 referencesGiven removal of the 
multisystem 
inflammatory syndrome 
in children and adults 
(MIS -C/A) and acute 
respi[INVESTIGATOR_296043] (ARDS) terms 
from Appendix E, 
Table 13Non-substantial
[IP_ADDRESS] SARS -CoV -[ADDRESS_1198069] 
viral variantsClarification Non-substantial
[IP_ADDRESS] Secondary 
Endpoints,
Appendix F (Table 15)Revised the list of secondary 
endpoints to align with the 
Synopsis and Section 3 of the 
protocolConsistency Non-substantial
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 6of 130Section # and Name [CONTACT_670790]/
Non-substantial
A5 Committee 
StructureRevised this sectionTo align with the current 
version of the statistical 
analy sis planNon-substantial
Appendix E 
(Table 13)Rem oved reference to MIS-C/A 
and ARDSGiven removal of the 
adolescent populationNon-substantial
Appendix G Part [ADDRESS_1198070] ivities....................................................................................... 18
2 INTRODUCTION ............................................................................................ 27
2.1 Study  Rati onale ................................................................................................ 27
2.2 Background ...................................................................................................... 27
2.3 Benefit/Risk Assessment ................................................................................... 29
2.3.1 Risk Assessment ............................................................................................... 30
2.3.2 Benefit Assessment ........................................................................................... 30
2.3.3 Overall Benefit: Risk Conclusio n...................................................................... [ADDRESS_1198071] igational Products .................................................................................... 43
6.1.2 Dosing Instructions ........................................................................................... 44
6.2 Preparati on/Handling/Storage/Accountabilit y................................................... 44
6.2.1 Dose Preparation and Administration ................................................................ 45
[IP_ADDRESS] AZD1222 .......................................................................................................... 45
[IP_ADDRESS] Placebo ............................................................................................................. 45
6.3 Measures to Minimize Bias: Rando mizat ion and Blinding ................................ 45
6.3.1 Randomization .................................................................................................. 45
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 8of 1306.3.2 Blinding ............................................................................................................ 46
6.3.3 Procedures for Unblinding ................................................................................ 46
6.4 Study  Intervent ion Compliance ......................................................................... 47
6.5 Concomitant Therapy ........................................................................................ 47
6.5.1 Permi tted Concomitant Medications ................................................................. 47
6.5.2 Prohibited Conco mitant Medi cations................................................................ 47
6.6 Dose Modificat ion............................................................................................ 48
6.7 Intervention After the End of the Study ............................................................. 48
7 DISCONTINUATION OF S TUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITH DRAWAL .......................................................... [ADDRESS_1198072] to Follow -up............................................................................................. 50
8 STUDY ASSESSMENTS AN D PROCEDURES ............................................. 50
8.1 Efficacy Assessments ........................................................................................ 51
8.1.1 Monitoring COVID -19 Symptoms .................................................................... 51
8.1.2 Illness Visit s..................................................................................................... 52
[IP_ADDRESS] SARS -CoV -2 Testing and Other Virology  Assessments .................................... 53
[IP_ADDRESS] Digital Heal th Device ....................................................................................... 53
[IP_ADDRESS] Illness e -Diary.................................................................................................. [ADDRESS_1198073] ing AE and SAE Informat ion................ 57
8.3.2 Follow-up of  AEs and SAEs ............................................................................. 57
8.3.3 Causalit y Collection.......................................................................................... 58
8.3.4 Adverse Events Based on Signs and Symptom s................................................ 59
8.3.5 Adverse Events Based on Examinat ions and Tests ............................................ 59
8.3.6 Hy’s Law .......................................................................................................... 59
8.3.7 Solicited Ad verse Events (Only for Substudy ).................................................. [ADDRESS_1198074] .................................................................... 61
[IP_ADDRESS] Potenti al Neurol ogical AESIs ........................................................................... 61
8.3.10 Reporting of Serious Adverse Events ................................................................ 63
8.3.11 Pregnancy ......................................................................................................... 63
[IP_ADDRESS] Maternal Exposure ............................................................................................ 63
8.3.12 Medicat ion Error ............................................................................................... 64
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 9of 1308.3.13 Medical Device Deficiencies ............................................................................. 64
8.4 Overdose .......................................................................................................... 65
8.5 Hum an Bi ological  Samples ............................................................................... 65
8.5.1 Pharmacokinet ics.............................................................................................. 65
8.5.2 Immunogenicit y Assessments ........................................................................... 66
[IP_ADDRESS] SARS -CoV -2 Serol ogy Assessments ................................................................ 66
[IP_ADDRESS] SARS -CoV -2 Neutralizing Ant ibody  Assessments ........................................... 66
[IP_ADDRESS] Assessment of Mucosal Responses ................................................................... 66
[IP_ADDRESS] Assessment of Cell -mediated Immune Responses ............................................. 66
[IP_ADDRESS] Addit ional Serum Immunogenicit y................................................................... [ADDRESS_1198075] ion of Mandatory  Samples for Bi omarker Analysis ................................ 67
[IP_ADDRESS] Virologic Assessments ...................................................................................... 67
[IP_ADDRESS] Assessment of Viral Shedding .......................................................................... 68
8.6.2 Other Study -related Bi omarker Research .......................................................... 68
8.7 Optional Genomics Ini tiative Sample ................................................................ 68
8.8 Medical Resource Utilizat ion and Healt h Economics ........................................ 68
9 STATISTICAL CONSIDER ATIONS ............................................................... 68
9.1 Statistical Hypotheses ....................................................................................... 68
9.2 Sample Size Determinat ion............................................................................... 69
9.3 Popul ations for Analyses .................................................................................. 70
9.4 Statistical Analyses ........................................................................................... 71
9.4.1 General Considerations ..................................................................................... 72
9.4.2 Efficacy ............................................................................................................ 73
[IP_ADDRESS] Primary Endpo int.............................................................................................. 73
[IP_ADDRESS] Secondary  Endpo ints........................................................................................ 75
[IP_ADDRESS] Exploratory  Endpo ints...................................................................................... 77
9.4.3 Safety............................................................................................................... 77
[IP_ADDRESS] Primary Endpo ints............................................................................................ 77
[IP_ADDRESS] Other Safet y Endpo ints..................................................................................... [ADDRESS_1198076] ivities: Screening Period ................................................. [ADDRESS_1198077] ivities: Treatm ent and Fo llow-up Peri od – Main Study 
(Excl uding Substudy  and Immunogenicit y Cohort Parti cipants) ............... 20
Table 3 Schedule of Activities: Treatment and Fo llow-up Peri od – Substudy and 
Immunogenicit y Cohort ([LOCATION_003] Parti cipants Only) .................................... [ADDRESS_1198078] ivities: Illness Visits (Participants with Qualifying 
Clinical Symptoms) ................................................................................. [ADDRESS_1198079] of Predefined Solicited Adverse Events for Reactogenicit y 
Assessment .............................................................................................. 60
Table 9 Popul ations for Analysis .......................................................................... 70
Table 10 Tables for Clinical Abnormalit ies: Loca l React ions to Injectable Product 94
Table 11 Tables for Clinical Abnormalit ies: Vital Signs ......................................... 95
Table 12 Tables for Clinical Abnormalit ies: Systemic (General or Illness) ............. [ADDRESS_1198080] OF APPENDICES
Appendix A Regulatory , Ethical , and Study  Oversight Consi derati ons......................... 81
Appendix B Adverse Events: Definit ions and Procedures for Recording, Evaluating, 
Follow-up, and Reporting ........................................................................ [ADDRESS_1198081] ........................................................... 97
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 11of 130Appendix F Overview of Primary  and Secondary  Efficacy  Objectives, Endpoints, and 
Associ ated Case Definit ions................................................................... 101
Appendix G Abbreviat ions........................................................................................ 109
Appendix H Protocol  Amendment Hi story................................................................. 111
Clinical Stu dy Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 12of 1301 PROTOCOL SUMMARY
1.1 Synopsis
Protocol Title: A Phase III Rando mized, Double -blind, Placebo -controlled Mult icenter Study  
in Adult sto Determine the Safet y, Efficacy , and Immunogenicit y of AZD1222, a 
Non-replicat ing ChAdOx1 Vector Vaccine, for the Prevent ion of COVID-19
Short Title: Phase III Double-blind, Pl acebo -controlled Study  of AZD12 22 for the Prevent ion 
of COVID -19in Adults
Rationale: The aim o f the study  is to assess the safet y, efficacy , and immunogenicit y of 
AZD1222 for the prevention o f COVID -19. The COVID -[ADDRESS_1198082].
Objectives and Endpoints
Objective aEstimand bDescription/Endpoint
PRIMARY
1 To estimate the efficacy of 2 IM doses of 
AZD1222 compared to saline placebo 
for the prevention of COVID -19 Population: Fully vaccinated analy sis set
Endpoint: A binary response, whereby a participant with 
negative serostatus at baseline is defined as a COVID -[ADDRESS_1198083] case of SARS -CoV -2 RT -PCR -positive 
symptomatic illness occurs ≥ [ADDRESS_1198084] second dose of 
study intervention. Otherwise, a particip ant is not defined as 
a COVID -19 case.
Intercurrent events : For participants who withdraw from 
the study  prior to having met the criteria for the primary 
efficacy endpoint , absence of data following these 
participants’ withdrawal will be treated as missing (ie ,
counted as not having met the criteria); participants who 
withdraw before [ADDRESS_1198085] second dose will be excluded from 
primary endpoint analy sis.Participants unblinded to 
treatment assign ment prior to having met the criteria for the 
primary  efficacy  endpoint will be censored at the date of 
unblinding.
Summary measure: VE, calculated as 1 -relative risk.  
(Relative risk is the incidence in the vaccine group relative to 
the incidence in the control group.)
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 13of 130Objective aEstimand bDescription/Endpoint
2 To assess the safety and tolerability of 
2IM doses of AZD1222 compared to 
saline placebo a) Incidence of AEs for 28days post each dose of study 
interventio n
b) Incidence of SAEs, MAAEs, and AESIs from Day [ADDRESS_1198086] 
treatment through Day 730
3 To assess the reactogenicity of 2 IM 
doses of AZD1222 compared to saline 
placebo 
(Substud yonly)Incidence of local and systemic solicited AEs for [ADDRESS_1198087]-treatment response (negative 
at baseline to positive post treatment with study intervention) 
for SARS -CoV -2 Nucleocapsid antibodies occurring 
≥ [ADDRESS_1198088] case of SARS -CoV -2 RT -PCR -
positive symptomatic illness occurring ≥ [ADDRESS_1198089] case of SARS -CoV -2 RT -PCR -
positive symptomatic illness occurring ≥ [ADDRESS_1198090] case of SARS -CoV -2 RT -PCR -
positive symptomatic illness occurring ≥ [ADDRESS_1198091] second 
dose of study intervention regardless of evidence of prior 
SARS -CoV -2 infectionc
5 To estimate the efficacy of 2 IM doses of 
AZD1222 compared to saline placebo 
for the prevention of severe or critical 
symptomatic COVID -19 a)The incidence of SARS -CoV -2 RT -PCR -positive severe 
or critical sy mptomatic illness occurring ≥ [ADDRESS_1198092] 
second dose of study intervention c
b)The incidence of SARS -CoV -[ADDRESS_1198093] do se of 
study intervention
6 To estimate the efficacy of 2 IM doses of 
AZD1222 compared to saline placebo 
for the prevention of COVID -19-related 
Emergency Department visitsThe incidence of COVID -19-related Emergency Department 
visits occurring ≥15days post second dose of study 
interventio nc
7 To assess antibody responses to 
AZD1222 S antigen following 2 IM 
doses of AZD1222 or saline placebo
(Substud yand Illness Visits only)a) Post-treatment GMTs and GMFRs from day of dosing 
baseline value to [ADDRESS_1198094] each dose in SARS -CoV -2 
S, RBD antibodies (MSD serology assay)
b) The proportion of participants who have a post -treatment 
seroresponse ( ≥ 4-fold rise in titers from day of dosing 
baseline value to [ADDRESS_1198095] each dose) to the S, RBD 
antigens of AZD1222 (MSD serology assay)
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 14of 130Objective aEstimand bDescription/Endpoint
8 To determine anti -SARS -CoV -2 
neutralizing antibody levels in serum 
following 2 IM doses of AZD1222 or 
saline placebo
(Substud yand Illness Visits only)a) Post-treatment GMTs and GMFRs from day of dosing 
baseline value to [ADDRESS_1198096] each dose in SARS -CoV -2 
neutralizing antibodies (wild -type assay  or 
pseudo -neutralization assay)
b) Proportio n of participants w ho have a post -treatment 
seroresponse ( ≥ 4-fold rise in titers from day of dosing 
baseline value to [ADDRESS_1198097] each dose) to AZD1222 as 
measured by [CONTACT_7544] -CoV -2neutralizing antibodies 
(wild -typeassay  or pseudo-neutralization assay)
[ADDRESS_1198098] dose of study 
interventio n
aSubstudy: The substudy will be conducted only in the [LOCATION_003]. The first participants randomized in each 
age group in the [LOCATION_003] , including 1 500 participants 18 to 55 years of age, 750 participants 56 to 69 years 
of age, and 750 participants ≥ 70 years of age , will also participate in a substudy assessing the 
reactogenicity and immunogenicity of AZD1222 .
Illness Visits: Participants w ho present with qualifying symptoms will be tested for SARS -CoV -[ADDRESS_1198099], the variable (or endpoint) of 
interest, the specification of how intercurrent events are reflected in the scientific question of interest, 
and the population -level summary for the variable.
cKey secondary  endpoint.
AE = adverse event ; AESI = adverse event of special interest; CDC = Centers for Disease Control and 
Preventio n; COVID -19 = coronavirus disease 2019 ; GMFR = geometric mean fold rise; GMT = geometric 
mean titer; IFN -γ = interferon -gamma; IM = intramuscular; MAAE = medically a ttended adverse event; 
MSD = Meso Scale Discovery; RT -PCR = reverse transcriptase polymerase chain reaction; RBD = receptor
binding domain; S = Spi[INVESTIGATOR_2531]; SAE = serious adverse event; SARS -CoV -2 = severe acute respi[INVESTIGATOR_7686] -
coronavirus -2; [LOCATION_003] = United S tates of America; VE = vaccine efficacy .
For expl oratory  object ives, see Section 3. 
Overall Design : D8110C00001 is a Phase III randomized, doubl e-blind, pl acebo -controlled ,
multicenter study  assessing the safety , efficacy, and immunogenicit y of AZD1222 compared 
to saline placebo for the prevent ion of COVID- 19. Approximately  150 sites gl obally will
participate in this study .
Participants will be adults ≥[ADDRESS_1198100] medically -stable chronic 
diseases , and are at i ncreased risk for SARS- CoV -2 acqui sition and COVID -19. 
Approximately  [ZIP_CODE] parti cipants will be randomized in a 2:1 ratio to receive 2 IM doses of 
either 5× 1010vp (nominal , ± 1.5 × 1010vp) AZD1222 (n =approximately [ZIP_CODE]) or saline 
placebo (n =approximately  10 000) 4 weeks apart, on Days 1 and 29 . Rando mizat ion will be 
stratified by [CONTACT_654] ( ≥ 18 to<65 years, and ≥
65years), wi th at least 25% of participants to be 
enrolled in the older age stratum. Parti cipants who received their first dose of study  
intervent ion between [ADDRESS_1198101] participants rando mized in 
each age group in the [LOCATION_003] , including 1 500 participants 18 to 55 years of age, 
750participants 56 to 69 years of age, and 750 participants ≥ [ADDRESS_1198102] igate cell -mediated immunogenicity , in parti cular Th1/Th2 responses, after 
AZD1222 or saline placebo administration, a n immunogenicit y cohort of approxi mately  
300participants w asadded.
A PSRT will provide support for blinded safet y surveillance during the study . Additionally, an 
independent COVID -[ADDRESS_1198103] dose of study  
intervent ion (Day  730). If AZD1222 is proven to be safe and efficacious based on the primary  
endpo intanalysis, fo llowing discussio n at that time with the US FDA, other Regulators if 
appropriate, and the COVID -19 Vaccine DSMB, participants allocated to the saline placebo 
group will be offered AZD1222 when doses are available. Saline p lacebo participants t reated 
with AZD1222 will cont inue to be fo llowed in the study . 
Disclosure Statement: This is a parallel -group prevent ive study  with [ADDRESS_1198104] igator -, and Sponsor- blinded.
Number of Participants: Approximately [ZIP_CODE] parti cipants will be screened to achieve up 
to approximately 30 000 participants rando mly assigned to study  interventi on, including 
approximately  [ZIP_CODE] parti cipants randomized to the AZD1222 arm and approximately  
[ZIP_CODE] participants randomized to the saline placebo arm . 
Note : ‘Enrolled ’meansa parti cipant's, or their legally  acceptable representative’s, agreement 
to parti cipate in a clinical study  following com pletion of the informed consent process. 
Potenti al parti cipants who are screened for the pu rpose of determining eligibilit y for the study , 
but are not randomly assigned in the study , are consi dered ‘screen failures ’. 
Intervention Groups and Duration: Participants will be randomized in a 2:1 ratio to receive 
2 IM dose sof 5 × 1010vp (nominal , ±1.5 × 1010vp) AZD1222 or saline placebo. Study 
intervent ion will be administered on Day s1 and 29. 
Data Monitoring Committee: Yes 
Clinical Study Protocol -Amendment [ADDRESS_1198105] case of SARS -CoV -2 
RT-PCR -positive symptom atic illness occurs ≥ [ADDRESS_1198106] second dose of study 
intervent ion. Otherwise, a participant is not defined as a COVID -19 case .
Samp le size
Approximately  [ZIP_CODE] parti cipants will be screened such that a pproximately 
30 000 participants will be rando mized in a 2:1 ratio to receive 2 IM dose sof either 
5 × 1010vp (nominal , ± 1.5 × 1010vp) AZD1222 (the act ive group, n = approximately [ZIP_CODE]) 
or saline placebo (the con trol group, n = approximately 10 000) 4 weeks apart, on Day s 1 and 
29.
The sample size calculat ions are based on the primary  efficacy endpo int and were derived 
following a m odified Poisson regressio n approach (Zou 2004 ). The calculat ions account for an 
interim and primary  analysis , and the timing of these analyses will be driven by [CONTACT_859758] . The interim analysis will be carried out when approximately 
50% of the total a mount of statistical informat ion is available. A Lan-DeMets al pha-spending 
funct ion has been used to control the overall type I error at 5% with 0.31% alpha at the interim 
analysis and 4.9% at the primary analysis . The calcul ations assume minimal loss to f ollow-up 
as it is ant icipated that participants will remain engaged in the study . All participants will be 
followed for the ent ire durati on of  the study .
For the primary  efficacy analysis, approximately  [ADDRESS_1198107] a VE of 60% wi th > 90% power. These 
calculat ions assume an observed attack rate of approximately  0.8%and are based on a 2-sided 
test, where the lower bound of the 2 -sided 95.10 % CI for VE is required to be greater than
30% withan observed point estimate of at least 50 %. 
An interim efficacy analysis will be conducted when approximately 75events meet ing the 
primary  endpoint definit ion have been reported across the active and control groups within the 
popul ation of participants who are sero negative at baseline , which will give > 70% power to 
detect a VE of 70% and > 90% power to detect a VE of 75% . These calculat ions assume an 
observed attack rate of approximately 0.4% and are based on a [ADDRESS_1198108], where the lower 
bound of the 2- sided 9 9.69% CI for VE i s requi red to be greater than 30% with an observed 
point estimate of at least 50% . A stati stically significant finding at the interim analysis will not 
be considered a reason to stop the study , but instead will be interpreted as early  assessment of 
efficacy . 
Clinical Study Protocol -Amendment [ADDRESS_1198109] imand consists of 
participants who withdraw fro m the study  or are unblinded to treatment assignment prior to 
having met the primary  efficacy endpoint. The intercurrent event of early  study  withdrawal  
will be handled using the treatm ent policy strategy and the absence of data fo llowing these 
participants’ withdrawal will be treated as missing (ie, counted as not having met the criteria) .
Parti cipants unblinded to treatment assignment prior to having met the criteria fo r the primary 
efficacy  endpoint will be censored at the date of unblinding. Participants who wi thdraw before 
[ADDRESS_1198110] variance (Zou 2004 )to analyze the primary  efficacy  endpoint, 
includ ingstudy  arm and age as covariates as well as the log o f the follow-up time as an offset . 
The VE will be est imated fro m the model, which will give the RRR in the incidence o f 
SARS -CoV -2 RT -PCR -posit ive symptomat ic illness. VE is calculated as 
RRR = 100*(1 -relative risk), which is the incidence in the vaccine g roup rel ative to the 
incidence in the control group expressed as a percentage. Atthe interim analysis ,the VE will 
be presented with a 2- sided 99.69% CI, and statistical significance will be achieved if the 2 -
sided 99.69% CI i s > 30% . The success criterion for the interim analysis will be statist ical 
significance wi th an observed VE point estimate of at least 50%. At the primary analysis ,VE 
will be presented with a 2 -sided 95.10% CI, and statist ical significance will be achieved if the 
2-sided 95. 10% CI i s > 30% . The success criterion for the primary analysis o f the study  will 
be stati stical significance wi th an observed VE point estimate of at least 50%.  
Model  assumpt ions will be checked and the robustness of the primary analysis will be 
assessed. The Poisson regressio n model with robust vari ance has the flexibilit y for expl oring 
multiple imputation approaches using, eg, the observed placebo attack rate to impute missing 
data. If the Poisson regressio n model with robust vari ance fails to converge , an al ternative 
approach will be implemented. Full details will be documented in the SAP.
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 18of 1301.2 Schema
Figure 1 Study Design
aParticipants who present with qualifying symptoms will be tested for SARS -CoV -2 and if positive, will 
complet e illness visits.
Red bars (Day  1 and Day 29) : Administration of study intervention. 
Gray  bars(Day  8 and Day  36):Visits will be telephone contacts , not study site visits .
Blue bars (Day 15 and Day 43): Visits will only be for participants in the substudy. The first participants 
randomized in each age group in the [LOCATION_003] , including 1 500 participants 18 to 55 years of age, 750 participants 
56to 69 years of age, and 750 participants ≥ 70 years of age, will also participate in the substudy assessing the
reactogenicity and immunogenicity of AZD1222. 
COVID -19 = coronavirus disease 2019; IM = intramuscular; SARS -CoV -2 = severe acute respi[INVESTIGATOR_244089] -coronavirus -2;[LOCATION_003] = [LOCATION_002] of America; vp = viral particles.
1.3 Schedule of Activities
The SoA tab les include:
Table 1, Screening Period
Table 2, Treatm ent and Fo llow-up Peri od – Main Study  (Excl uding Substudy  and 
Immunogenicit y Cohort Participants)
Table 3, Treatm ent and Fo llow-up Peri od – Substudy and Immunogenicit y Cohort
([LOCATION_003] Parti cipants Only )
Table 4, Illness Visits (Parti cipants wi th Qualifying Clinical Symptoms)

Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 19of 130Table 1 Schedule of Activities: Screening Period
Procedure / Study Day Day -14 to Day 1aFor details see Section
Informed consent : main study X 5.1
Assignment SID number X 6.3
Medical history X 5.1, 5.2
Complete physical examination, including height and weight X 8.2.1
Vital signs (including pulse oximetry) X 8.2.[ADDRESS_1198111] –urine or serum (WOCBP only) bX 8.2.3
Assessment of SAEs X 8.3
Concomitant medications X 6.5
Verify  eligibility criteria X 5.1, 5.2
aIf screening and dosing occur at the same visit, only one evaluation is required. 
bIf urine tests positive or indeterminate, a quantitative serum β-hCG will be performed for confirmation.
β-hCG = beta -human chorionic gonadotropin; SAE = serious adverse event; SID = subject identification; 
WOCBP = women of childbearing potential.
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 20of 130Table 2 Schedule of Activities: Treatment and Follow -up Period –Main Study (Excl uding Substudy and 
Immunogenicity Cohort Participants)
Procedure Treatment and Follow -up Period
For details 
see SectionDay 1 8a29 36a57 90 180 360 730
Window (days) NA ± 3 -3 to +7 ± 3 ± 3 ± 5 ± 10 ± 15 ± 30
Medical history X 5.1, 5.2
Targeted physical examination X 8.2.1
Vital signs (including pulse oximetry) X 8.2.[ADDRESS_1198112] –urine or serum (WOCBP only) b X
(predose)X
(predose)8.2.3
Concomitant medications X X X X XAs applicable, for treatment of 
SAE, MAAE, or AESIc 6.5
Verify  eligibility  criteria X 5.1, 5.2
Study intervention administration X X 6.1, 6.2
Efficacy assessments
Weekly telephone/email/text contacts -
monitoring for COVID -19 qualifying symptoms d
8.1.1
Nasal swab for SARS -CoV -2 RT -PCR 
(local laboratory)X
(predose)
Serum sample for SARS -CoV -2 serology testing X
(predose)X
(predose)X X X X X 8.5.2
Immunogenicity assessments
Serum sample for exploratory assessment X
(predose)X
(predose)X [IP_ADDRESS]
Safety assessments
AEs X X X X X
8.[ADDRESS_1198113] udy Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 21of 130Table 2 Schedule of Activities: Treatment and Follow -up Period –Main Study (Excl uding Substudy and 
Immunogenicity Cohort Participants)
Procedure Treatment and Follow -up Period
For details 
see SectionDay 1 8a29 36a57 90 180 360 730
Window (days) NA ± 3 -3 to +7 ± 3 ± 3 ± 5 ± 10 ± 15 ± 30
aNot a study site visit; participants will be contact[CONTACT_859759] .
bIf urine tests positive or indeterminate, a quantitative serum β-HCG will be performed for confirmation.
cVaccin ations, other than AZD1222, for prevention of SARS -CoV-[ADDRESS_1198114] qualifying symptoms .
AE = adverse event; AESI = adverse event of special interest; β-hCG = beta -human chorionic gonadotropin; MAAE = medically attended ad verse event;
NA= not applicable; SAE = serious adverse event; SARS -CoV -2 = severe acute respi[INVESTIGATOR_7686] -coronavirus -2; WOCBP = women of childbearing 
potential.
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 22of 130Table 3 Schedule of Activities: Treatment and Follow -up Period –Substudy and Immunogenicity Cohort ([LOCATION_003]
Participants Only)
Procedure Treatment and Follow -up Period
For details 
see SectionDay 1 8 a15 29 36 a43 57 90 180 360 730
Window (days) NA ± 3 ± 1 -3 to +7 ± 3 ± 3 ± 3 ± 5 ± 10 ± 15 ± 30
Medical history X 5.1, 5.2
Targeted physical examination X 8.2.1
Vital signs (including pulse oximetry) X 8.2.[ADDRESS_1198115] –urine or serum
(WOCBP only) bX
(predose)X
(predose)8.2.3
Concomitant medications X X X X X X XAs applicable, for treatment of 
SAE, MAAE, or AESIc6.5
Verify  eligibility  criteria X 5.1, 5.2
Study intervention administration X Xd 6.1.1
Efficacy assessments
Weekly telephone/email/text contacts -
monitoring for COVID -19 qualifying 
symptoms e8.1.1
Nasal swab for SARS -CoV -2 RT -PCR 
(local laboratory)X
(predose)
Serum sample for SARS -CoV -2 
serology testing X
(predose)XX
(predose)X X X X X X 8.5.2
Immunogenicity assessments
Serum sample for ChAdOx1 nAbs 
assessmentX
(predose)X
(predose)X X X X
8.5.2
Serum sample for seasonal CoV 
serology testingX
(predose)X
(predose)X X X
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 23of 130Table 3 Schedule of Activities: Treatment and Follow -up Period –Substudy and Immunogenicity Cohort ([LOCATION_003]
Participants Only)
Procedure Treatment and Follow -up Period
For details 
see SectionDay 1 8 a15 29 36 a43 57 90 180 360 730
Window (days) NA ± 3 ± 1 -3 to +7 ± 3 ± 3 ± 3 ± 5 ± 10 ± 15 ± 30
PBMCs for assessment of B -cell and 
T-cell responses fX
(predose)X X X
8.5.2Serum sample for SARS -CoV -2 nAbs 
assessmentX
(predose)XX
(predose)X X X X
Nasal adsorption for SARS -CoV -2 
mucosal responses (optional)X
(predose)XX
(predose)X X X X
Serum sample for ACE2 competition 
serologyX
(predose)X
(predose)X X
Safety assessments
Local and systemic predefined 
solicited AEs (recorded daily by 
[CONTACT_859760] e -Diary) –
Substudy onlyX
(through 
Day 8)X
(through 
Day 36)8.3.[ADDRESS_1198116] for safety 
monitoringX X
aNot a study site visit; participants will be contact[CONTACT_859759] .
bIf urine tests positive or indeterminate, a quantitative serum β-hCG will be performed for confirmation. 
cVaccin ations, other than AZD1222, for prevention of SARS -CoV-[ADDRESS_1198117] study sites , 
as outlined in the laboratory manual .
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 24of 130Table 3 Schedule of Activities: Treatment and Follow -up Period –Substudy and Immunogenicity Cohort ([LOCATION_003]
Participants Only)
Procedure Treatment and Follow -up Period
For details 
see SectionDay 1 8 a15 29 36 a43 57 90 180 360 730
Window (days) NA ± 3 ± 1 -3 to +7 ± 3 ± 3 ± 3 ± 5 ± 10 ± 15 ± 30
ACE2 = angiotensin -converting enzyme 2; AE = adverse event ( treatment -emergent ); AESI = adverse event of special interest; β -hCG = beta -human chorionic 
gonadotropin; CoV = coronavirus; COVID -19 = c oronavirus disease 2019; MAAE = medically attended adverse event; NA = not applicable; 
nAb =neutralizing antibody; PBMC = peripheral blood mononuclear cell; SAE = serious adverse event; SARS -CoV -2 = severe acute respi[INVESTIGATOR_7686] -
coronavirus -2; [LOCATION_003] = [LOCATION_002] of America; WOCBP = women of childbearing pote ntial.
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD12 22 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 25of 130Table 4 Schedule of Activities: Illness Visits (Participants with Qualifying Clinical Symptoms )
ProcedureaSite Visit Home Collection by [CONTACT_670069] -CoV -2 
Positive Participants OnlyFor details 
see Section Day 1 3 5 8 11 14 21 28
Window (days) NA ± 1 ± 1 ± 2 ± 2 ± 2 ± 2 ± 2
Medical history X X X X 8.1
Brief phy sical examination X X X X 8.2.1
Vital signs (including pulse oximetry) X X X X 8.2.2
Concomitant medication 6.5
Efficacy assessments
Digital health device [IP_ADDRESS]
Symptoms associated with COVID -19
(recorded daily by [CONTACT_670070] e -Diary )[IP_ADDRESS]
Virology assessments
Nasal swab for SARS -CoV -2 RT -PCR 
(local laboratory)X [IP_ADDRESS]
Nasophary ngeal swab 
SARS -CoV -2 RT -PCR (central laboratory) X X X X
[IP_ADDRESS]
SARS -CoV -2 sequencing (central laboratory) X X
Respi[INVESTIGATOR_859726] X [IP_ADDRESS]
Saliva sample for viral sheddingbX X X X X X X X [IP_ADDRESS]
Immunogenicity assessments
PBMCs for B -cell and T -cell responses XcX
8.5.2Serum sample for SARS -CoV -2 nAbs assessment X X X
Nasal adsorption for SARS -CoV -2 mucosal 
responses (optional)X X X
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 26of 130Table 4 Schedule of Activities: Illness Visits (Participants with Qualifying Clinical Symptoms )
ProcedureaSite Visit Home Collection by [CONTACT_670069] -CoV -2 
Positive Participants OnlyFor details 
see Section Day 1 3 5 8 11 14 21 28
Window (days) NA ± 1 ± 1 ± 2 ± 2 ± 2 ± 2 ± [ADDRESS_1198118] negative for SARS -CoV -2 will be instructed to stop all illness visit assessments and return the digital health 
device (see Section [IP_ADDRESS] ). 
bCollection of saliva sample for viral shedding is optional in non -[LOCATION_003] sites and may occur after a feasibility assessment has been completed.
cPBMCs will be collected from up to approximately the first [ADDRESS_1198119] (see Section [IP_ADDRESS] ).
ACE2 = angiotensin -converting enzyme 2; AESI = adverse events of special interest; CoV = coronavirus; COVID -19 = c oronavirus disease 2019; 
MAAE =medically attended adverse event; NA = not applicable; nAb = neutr alizing antibody; PBMC = peripheral blood mononuclear cell; RT -PCR = reverse 
transcriptase polymerase chain reaction; SAE = serious adverse event; SARS -CoV -2 = severe acute respi[INVESTIGATOR_7686] -coronavirus -2. 
Clinical Study Protocol -Amendment [ADDRESS_1198120].
2.2 Background
In December 2019, a cluster of pat ients with pneumo nia of unknown cause was linked to a 
seafood wholesale market in Wuhan, China and were later confirmed to be infected with a 
novel coronavirus, known as 2019 -nCoV (Zhu et al 2020 ). The virus was subsequent ly 
renamed to SARS -CoV -2 because it is s imilar to the coronavirus responsible for SARS- CoV, 
a lineage B Betacoronavirus . SARS -CoV -2 shares more than 79% of its sequence with 
SARS -CoV, and 50% wi th the coronavirus responsible for MERS -CoV, a m ember of the 
lineage C Betacoronavirus (Lu et al  2020 ). COVID -[ADDRESS_1198121] been more than 40millio n 
confirmed cases and > 1.1 millio ndeaths globally (WHO 2020 ). It is believed that evolut ion 
of the pandemic will vary  across countri es, affected in part by  [CONTACT_859761]. As a result, there may be regional waves 
of the di sease and pockets of vulnerable populat ions. Globally, governments have 
acknowledged that an effect ive vaccine against COVID -[ADDRESS_1198122] cells during CoVs infec tion via 
different receptors (Li 2016 ). SARS -CoV -2 belongs to the phylogenet ic lineage B of the 
genus Betacoronavirus and i t recogni zes the ACE2 as the entry  receptor (Zhou et al 2020) . It 
Clinical Study Protocol -Amendment [ADDRESS_1198123] wi th subsequent transfer of 
development activit ies to the Sponsor. Nonclinical studies found AZD1222 to be 
immunogenic in BALB/c and CD -[ADDRESS_1198124] a single 
dose of AZD1222 induced ant igen-specific ant ibody  and T -cell responses, a booster 
immuni zation enhanced antibody  responses, parti cularly in pi[INVESTIGATOR_14107], wi th significant increases in 
SARS -CoV -2 neutralising ant ibody  titres (Graham et al 2020 ). Further, in a SARS -CoV -[ADDRESS_1198125] fo llowing SARS -CoV -2 
challenge in vaccinated rhesus macaques was observed ( van Doremalen et al 2020 ).
The clinical development program for AZD1222 was init iated by  [CONTACT_859762], 
and current ly has4 ongoing studi esbeing conducted in the [LOCATION_006] (FIH COV001 
[[STUDY_ID_REMOVED]], COV002 [[STUDY_ID_REMOVED]]), Brazil (COV003 [ISRCTN89951424], and 
South Africa ( COV005 [[STUDY_ID_REMOVED]]). The Sponsor, in addit ion to thi s study , has 
2ongoing studies in Russia (D8111C00001 [[STUDY_ID_REMOVED]]) and Japan (D8111C00002).
Preliminary unblinded data are available for the FIH Study  COV001 and Study  COV002.
Study COV001 enro lled the first participant on [ADDRESS_1198126] one dose of 5 × 1010vp AZD1222 and 10 participants 
who received a second dose of 5 × 1010vp AZD1222 [ADDRESS_1198127] SARS -CoV -2 were detected in 32 (91%) of 
35participants after a single dose when measured in microneutrali zation assay  (MNA 80) and 
in 35 (100%) participants when measured in plaque reduction neutrali zation test (PRNT 50). 
Clinical Study Protocol -Amendment [ADDRESS_1198128] ivity (9 of  9 in MNA 80at Day  42 
and 10 of 10 in Marburg virus neutraliz ation assay  on Day  56). Neutrali zing ant ibody  
responses correlated strongly with ant ibody  levels measured by [CONTACT_6428] (Folegatti et al 2020b ).
As of [ADDRESS_1198129] one dose of AZD1222 ranging fro m 2.2 × 1010vp to 
5× 1010vp. Based on preliminary data as of 24 July 2020, the local and systemic so licited -AE
profile following a single dose of 5 × 1010vp in parti cipants 18 to 55 y ears of age was 
generally comparable to resul ts in Study COV001. In general, a decline in the incidence and 
severit y of solici ted AEs was observed across the age groups (18 -55, 56- 69, and ≥ 70 years).
Another ChAdOx1 -vectored vaccine expressing the full -length S protein fro m a related 
betacoronavirus, MERS -CoV, has been given to 53participants as part of 2 ongoing 
dose-escalat ion Phase I studies (MERS001 [[STUDY_ID_REMOVED]] and MERS002 [[STUDY_ID_REMOVED]], 
sponsor ed by  [CONTACT_859762]) at doses ranging from  5 × 109vp to 5 × 1010vp. 
Preliminary immunogenicit y data fro m MERS001 suggested that a single dose of ChAdOx1 
MERS can elicit both humoral and cellular responses. Overall, the vaccine was safe and 
generally  well  tolerated, wi th no seri ous adverse reactions reported in either study . 
The ChAdOx1 plat form has been used in 14clinical studies sponsored by  [CONTACT_859763], tuberculosis, mal aria, 
chikungunya, Zika, MERS -CoV, and Meningit is B. Over [ADDRESS_1198130]
immunogenicit y after a single dose and favorable safet y profiles, with no vaccine -related 
SAEs .
See the AZD1222 IB, Sections 4 and 5 for addit ional informat ion on nonclinical and clinical 
studi es, respectively, of AZD1222 and related ChAdOx1 -vectored vaccines. Detail on the 
development and chemistry  of AZD1222 is provided in the IB, Secti on 3.
Overall, the preliminary  data f rom the AZD1222 clinical and nonclinical studies, and the 
acceptable safet y and efficacy  data f or the MERS -CoV vaccine and other ChAdOx1 -vectored 
vaccines, support further development of AZD1222 for the preven tion of  COVID -19.
2.3 Benefit/Risk Assessment
More detailed informat ion about the known and expected benefits and potential risks of 
AZD1222 can be found in the AZD1222 IB.
Clinical Study Protocol -Amendment [ADDRESS_1198131] 
commo n local solicited AEs were vaccinat ion site pain and tenderness . Comm on systemic 
solicited AEs across the 2 studies included chills, feverishness, fever, fatigue, headache, joint 
pain, malaise, and myalgia. The majorit y of events were mild or moderate in severit y and 
resolved wit hin 1 to 7 day s (Secti on 2.2and AZD1222 IB ).
There are no ident ified risks for AZD1222. Important pot ential risks are immuno logic 
reacti ons: serious hypersensi tivity (anaphylact ic reactions )and vasculit ides; neuro logic 
reacti ons: demyelinat ing diseases; and vaccine -associ ated enhanced respi[INVESTIGATOR_23715]. A 
summary of risks associated with AZD1222 and sa fety informat ion reported across the 
AZD1222 clinical studies are provided in the current versio n of the AZD1222 IB.
2.3.[ADDRESS_1198132] any guaranteed benefit, however, AZD1222 may be 
efficacious and offer participants protection from COVID- 19. The informat ion gained fro m 
this study  will inform development decisio ns. 
2.3.3 Overall Benefit: Risk Conclusion
For the safet y of parti cipants, t he protocol has incorporated various ri sk mit igation measures 
including appropriate inclusio n and exclusio n criteria, close m onitoring of partici pants, and 
stoppi[INVESTIGATOR_3418]. An independent DSMB will provide study  oversight, evaluat ing cumulat ive 
safet y and other clinical data at regular interv als.Taking these measures into account ,the 
potenti al risks i dentified in associat ion with AZD1222 are j ustified by [CONTACT_859764] n of COVID-19.
3 OBJECTIVES AND ENDPO INTS
Table 5 Objectives and Endpoints
Objective aEstimand bDescription/Endpoint
PRIMARY
1 To estimate the efficacy of 2 IM doses of 
AZD1222 compared to saline placebo 
for the prevention of COVID -19 Population: Fully vaccinated analy sis set
Endpoint: A binary response, whereby a participant with 
negative serostatus at baseline is defined as a COVID -[ADDRESS_1198133] case of SARS -CoV -2 RT -PCR -positive 
symptomatic illness occurs ≥ [ADDRESS_1198134] second dose of 
study intervention. Otherwise, a partici pant is not defined as 
a COVID -19 case.
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 31of 130Table 5 Objectives and Endpoints
Objective aEstimand bDescription/Endpoint
Intercurrent events : For participants who withdraw from 
the study  prior to having met the criteria for the primary 
efficacy endpoint, absence of data following these 
participants’ withdrawal will be treated as missing (ie, 
counted as not having met the criteria); participants who 
withdraw before [ADDRESS_1198135] second dose will be excluded from 
primary endpoint analy sis.Participants unblinded to 
treatment assign ment prior to having met the criteria for the 
primary  efficacy  endpoint will be censored at the date of 
unblinding.
Summary measure: VE, calculated as 1 -relative risk.  
(Relative risk is the incidence in the vaccine group relative to 
the incidence in the control group.)
2 To assess the safety and tolerability of 
2IM doses of AZD1222 compared to 
saline placeboa) Incidence of AEs for [ADDRESS_1198136] each dose of study 
interventio n
b) Incidence of SAEs, MAAEs, and AESIs from Day [ADDRESS_1198137] 
treatment through Day 730
3 To assess the reactogenicity of 2 IM 
doses of AZD1222 compared to saline 
placebo
(Substud yonly)Incidence of local and systemic solicited AEs for [ADDRESS_1198138]-treatment response (negative 
at baseline to positive post treatment with study intervention) 
for SARS -CoV -2 Nucleocapsid antibodies occurring 
≥ [ADDRESS_1198139] case of SARS -CoV -2 RT -PCR -
positive symptomatic illness occurring ≥ [ADDRESS_1198140] case of SARS -CoV -2 RT -PCR -
positive symptomatic illness occurring ≥ [ADDRESS_1198141] case of SARS -CoV -2 RT -PCR -
positive symptomatic illness occurring ≥ [ADDRESS_1198142] second 
dose of study intervention regardless of evidence of prior 
SARS -CoV -2 infection c
5 To estimate the efficacy of 2 IM doses of 
AZD1222 compared to saline placebo 
for the prevention of severe or critical 
symptomatic COVID -19 a)The incidence of SARS -CoV -2 RT -PCR -positive severe 
or critical sy mptomatic illness occurring ≥ [ADDRESS_1198143] 
secon d dose of study intervention c
b)The incidence of SARS -CoV -[ADDRESS_1198144] dose of 
study intervention
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 32of 130Table 5 Objectives and Endpoints
Objective aEstimand bDescription/Endpoint
6 To estimate the efficacy of 2 IM doses of 
AZD1222 compared to saline placebo 
for the prevention of COVID -19-related 
Emergency Department visitsThe incidence of COVID -19-related Emergency Department 
visits occurring ≥15days post second dose of study 
interventio nc
7 To assess antibody responses to 
AZD1222 S antigen following 2 IM 
doses of AZD1222 or saline placebo
(Substud yand Illness Visits only)a) Post-treatment GMTs and GMFRs from day of dosing 
baseline value to [ADDRESS_1198145] each dose in SARS -CoV -2 
S, RBD antibo dies (MSD serology assay)
b) The proportion of participants who have a post -treatment 
seroresponse ( ≥ 4-fold rise in titers from day of dosing 
baseline value to [ADDRESS_1198146] each dose) to the S, RBD 
antigens of AZD1222 (MSD serology assay)
8 To determine anti -SARS -CoV -2 
neutralizing antibody levels in serum 
following 2 IM doses of AZD1222 or 
saline placebo
(Substud yand Illness Visits only)a) Post-treatment GMTs and GMFRs from day of dosing 
baseline value to [ADDRESS_1198147] each dose in SARS -CoV-2 
neutralizing antibodies (wild -type assay  or 
pseudo -neutralization assay)
b) Proportio n of participants w ho have a post -treatment 
seroresponse ( ≥ 4-fold rise in titers from day of dosing 
baseline value to [ADDRESS_1198148] each dose) to AZD1222 as 
measured by [CONTACT_7544] -CoV -2neutralizing antibodies 
(wild -typeassay  or pseudo-neutralization assay)
[ADDRESS_1198149] dose of study 
interventio n
EXPLORATORY
1 To estimate the efficacy of 2 IM doses of
AZD1222 compared to saline placebo 
for the all -cause mortalityThe incidence of all -cause mortality from Day 1 through 
Day 730
2 To estimate the efficacy of 2 IM doses of 
AZD1222 compared to saline placebo 
for COVID -19-related deathsThe incidence of COVID -19-related deaths occurring from 
Day 1 through Day  730
3 To estimate the efficacy of 2 IM doses of
AZD1222 compared to saline placebo 
for the prevention of COVID -19-related 
hospi[INVESTIGATOR_859727])The incidence of COVID -19-related hospi[INVESTIGATOR_859728] ≥ [ADDRESS_1198150] second dose of study 
interventio n
b)The incidence of COVID -19-related hospi[INVESTIGATOR_859729]
4 To estimate the efficacy of 2 IM doses of
AZD1222 compared to saline placebo 
for the prevention of COVID -19-related 
ICU admissionsa)The incidence of COVID -19-related ICU admissions
occurring ≥ [ADDRESS_1198151] second dose of study 
interventio n
b)The incidence of COVID -19-related ICU admissions
occurring post first dose of study intervention
5 To quantify SARS -Cov -2 viral loads in 
infected participants treated with 2 IM 
doses of AZD1222 or saline placebo
(Illness Visits only)Viral genome copi[INVESTIGATOR_859730] -PCR
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 33of 130Table 5 Objectives and Endpoints
Objective aEstimand bDescription/Endpoint
6 To characterize sequence variations in 
SARS -CoV -2 through genotypic 
analy ses in participants treated with 2 IM 
doses of AZD1222 or saline placebo
(Illness Visits only)Genoty pic analy sis of SARS -CoV -2 from NP swabs 
collected on Day 1 illness visit  
7 To quantify duration of viral shedding i n 
symptomatic SARS -CoV -2 infected 
participants treated with 2 IM doses of 
AZD1222 or saline placebo
(Illness Visits only)Duration of SARS -CoV -2 shedding in saliva over time 
8 To assess the biometric profiles 
associated with COVID -19 using a 
biosensor in p articipants treated with 
2IM doses of AZD1222 or saline 
placebo
(Illness Visits only)Bioph ysical parameters, including but not limited to serial 
measurements of skin temperature, heart rate, respi[INVESTIGATOR_862], blood oxygen saturation, and physical activit y, recorded 
using a biosensor from illness visits Day 1 through Day 28 
9 To assess symptoms associated with 
COVID -19 using an e -Diary  in 
participants treated with 2 IM doses of 
AZD1222 or saline placebo
(Illness Visits only)Symptoms recorded by [CONTACT_670076] e -Diary  
from illness visits Day 2 through Day 28 
10 To assess SARS -CoV -2 specific 
antibodies in an ACE2 competition assay 
following 2 IM doses of AZD1222 or 
saline placebo
(Substud yonly)a)Post-treatment GMTs and GMFRs from Day [ADDRESS_1198152] each dose in ACE2 competing 
antibodies from serum samples
b)Proportio n of participant s who have a post -treatment 
seroresponse ( ≥ 4-fold rise in titers from day of dosing 
baseline value to [ADDRESS_1198153] each dose) in ACE2 
competing antibodies
11 To assess B -and T -cell responses 
following 2 IM doses of AZD1222 or 
saline placebo
(Substud yonly)a)Quantification of (IFN -γ) ELISpot responses to 
SARS -CoV -[ADDRESS_1198154] each dose
b)Intracellular cytokine staining and flow cytometry for 
B-and T -cell responses from day of dosing baseline to 
14days post each dose
12 To assess SARS -CoV -2 antibodies in 
nasal secretions following 2 IM doses of 
AZD1222 or saline placebo
(Substud yonly)a)Post-treatment GMTs and GMFRs from Day [ADDRESS_1198155] each dose in SARS -CoV -2 S, RBD, 
and Nucleocapsid antibodies (MSD serology assay) 
b)Proportio n of participants w ho have a post -treatment 
seroresponse ( ≥ 4-fold rise in titers from Day [ADDRESS_1198156] each dose ) to SARS -CoV -2 S, 
RBD, and Nucleocapsid antigens (MSD serology assay)
13 To assess anti -vector responses to the 
ChAdOx -1 adenovirus vector following 
2 IM doses of AZD1222 or saline 
placebo
(Substud yonly)Proportio n of participants w ho have a post -treatment 
seroresponse ( ≥ 4-fold rise in titers from Day [ADDRESS_1198157] each dose ) to AZD1222 as measured 
by [CONTACT_859765]1 neutralizing antibodies
Clinical Study Protocol -Amend ment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 34of 130Table 5 Objectives and Endpoints
Objective aEstimand bDescription/Endpoint
14 To assess additional immune responses 
following 2 IM doses of AZD1222 or 
saline placeboOther exploratory assays for humoral and cellular immune 
responses may be performed based upon emerging safety, 
efficacy, and immunogenicity data
aSubstudy: The substudy will be conducted only in the [LOCATION_003]. The first participants randomized in each 
age group in the [LOCATION_003], including 1 500 participants 18 to 55 years of age, 750 participants 56 to 6 9years 
of age, and 750 participants ≥ 70 years of age ,will also participate in a substudy assessing the 
reactogenicity and immunogenicity of AZD1222 .
Illness Visits: Participants w ho present with qualifying symptoms will be tested for SARS -CoV -[ADDRESS_1198158], the variable (or endpoint) of 
interest, the specification of how intercurrent events are reflected in the scientific question of interest, and 
the population-level summary for the variable.
cKey secondary  endpoint.
ACE2 = angiotensin -converting enzyme 2; AE = adverse event; AESI = adverse event of special interest; 
CDC = Centers for Disease Control and Prevention; COVID -19 = coronavirus disease 2019; ELISpot = 
enzyme-linked immunospot; GMFR = geometric mean fold rise; GMT = geometric mean titer; ICU = 
intensive care unit; IFN -γ = interferon -gamma ; IM = intramuscular; MAAE = medically attended adverse 
event; MSD =Meso Scale Discover y; NP = nasopharyngeal; RT -PCR = reverse transcriptase polymerase 
chain reaction; qRT -PCR = quantitative reverse transcriptase polymerase chain reaction, RBD = receptor
binding domain; S = Spi[INVESTIGATOR_2531]; SAE = serious adverse event; SARS -CoV -2 = severe acute respi[INVESTIGATOR_7686] -
coronavirus -2; [LOCATION_003] = [LOCATION_002] of America; VE = vaccine efficacy.
[ADDRESS_1198159] acebo -controlled, mult icenter study  
assessing the safet y, efficacy, and immunogenicit y of AZD1222 co mpared to saline placebo 
for the prevent ion of COVID- 19. Participants will be adults ≥[ADDRESS_1198160] m edically -stable chronic diseases, and are at increased risk for SARS- CoV -2 
acquisit ion and COVID -19. Approximately [ZIP_CODE] participants will be rando mized in a 
2:1ratio to receive 2 IM doses of either 5 × 1010vp(nominal , ± 1.5 × 1010vp)AZD1222 
(n=approximately  [ZIP_CODE]) or saline placebo (n = approximately  10 000) 4 weeks apart, on 
Days 1 and 29. Rando mizat ion will be stratified by [CONTACT_654] ( ≥ 18 and < 65 years, and ≥ 65years) , 
with at least 25% of participants to be enro lled in the o lder age stratum . Participants who 
received their first dose of study  intervent ion between 28August [ADDRESS_1198161] be present for 2 or more day s. Parti cipants wi th a 
COVID -19 qualifying symptom (s) will  be tested for SARS -CoV -2, and if posit ive will 
Clinical Study Protocol -Amendment [ADDRESS_1198162] be present for ≥ 2 
consecutive daysChills
Cough
Fatigue
Muscle aches
Body aches
Headache
New loss of taste 
New loss of smell
Sore throat
Congestion
Runny nose
Nausea
Vomiting
Diarrhea
Adapted f rom (CDC 2020 ).
Safety will be assessed for the duration of the study . AEs will be recorded for [ADDRESS_1198163] 
each dose of study  intervent ion (ie, unt il Day [ADDRESS_1198164] second dose), 
and SAEs, MAAEs, and AESIs will be recorded through Day 730. See Secti ons8.3, 8.3.[ADDRESS_1198165] participants rando mized in eac h age group in the [LOCATION_003] , incl uding 1 500 participants 
18 to 55 years of age, 750 participants 56 to 69 years of age, and 750 participants ≥ [ADDRESS_1198166] igate cell -mediated immunogenicity , in parti cular Th1/Th2 responses, after 
AZD1222 or saline placebo administration, a n immunogenicit y cohort of approximately  
300participants will be added. Participants will fo llow the SoA in Table 3except they will not 
record reactogenicit y.
All participants will remain on study  for [ADDRESS_1198167] dose of study  
intervent ion (Day  730). If AZD1222 is proven to be safe and efficacious based on the primary  
endpo int analysis (see Sect ion [IP_ADDRESS] ), following discussio n at that time with the US FDA, 
other Regul ators if appropriate, and the COVID -[ADDRESS_1198168] about t he 
diagnosis and causalit y assessment of selected neurol ogical  AESIs occurring in the AZD1222 
clinical development program. See Appendix A 5for addit ional detail.
4.2 Scientific Rationale for Study Design
4.2.1 Rationale for Study Design and Participant Population
The participant population is male and female adults ≥ [ADDRESS_1198169]- sponsored studies. Study  COV001 ([STUDY_ID_REMOVED]) enrolled 
adults 18 to 55 years of age. Study  COV002 ([STUDY_ID_REMOVED]) enrolled adults18 years of age 
and o lder.
Adults wit h medically -stable chronic diseases may participate if, according to the judgement 
of the invest igator, hospi[INVESTIGATOR_859731] -specified 
follow-up. 
The study  will exclude females who are pregnant or breast- feeding and individuals less than
18years of age. Wo men who are pregnant or breast -feeding are excluded at this po int as 
nonclinical devel opmental  and reproductive t oxicity studi es to support vaccinat ing these 
individuals have yet to be performed. Addit ionally, i t is pl anned that children and adolescents 
Clinical Study Protocol -Amendment [ADDRESS_1198170] ion are not excluded. Participant’s baseline serostatus will be determined 
but baseline serostatus will not be used as a basis for exclusio n from the study . Parti cipants 
who are seroposit ive at baseline are enrolled in order to gather safety data in this group as it is 
anticipated that, if proven to be efficacious, the vaccine will rapi[INVESTIGATOR_859732]. Participant’s baseline serostatus will be determined so that 
subgroup analyses for both safet y and efficacy can be performed by  [CONTACT_169944]. 
The study  popul ation represents the init ial target populat ion for AZD1222. If AZD1222 
demonstrates efficacy for the prevent ion of COVID -19, the safet y and immunogenicit y of the 
vaccine in addit ional groups such as the immunosuppressed, pregnant women, and children 
and ado lescents may be assessed in future studies . 
4.2.[ADDRESS_1198171] 4 components: (1) a definit ion of 
clinical illness; (2) a method of respi[INVESTIGATOR_859733]; (3) an assay method for laboratory  conf irmation; and (4) a 
defined surveillance period. Assessment of AZD1222 efficacy will begin ≥ [ADDRESS_1198172] each do se of 
study  interventi on. SAEs, MAAEs, and AESIs and will be collected from Day 1 through end 
of the study . AESIs include terms ident ified by [CONTACT_859766] (SPEAC 2020 ).
4.3 Justification for Dose
The AZD1222 dose of 5 × 1010vp was selected based on accumulated clinical experience with 
this vaccine in ongo ing clinical studies sponsored by [CONTACT_385864] y of Oxford (see 
Secti on2.2). Safet y and immunogenicit y data from an addit ional clinical study , MERS001
([STUDY_ID_REMOVED]) , using the same ChAdOx1 vector, also helped inform dose select ion. 
Clinical Study Protocol -Amendment [ADDRESS_1198173] clinical study  of a ChAdOx1 -vectored vaccine expressing the 
full-length S protein fro m a separate, but related, betacoronavirus. ChAdOx1 MERS has been 
given to 31 participants to date at doses ranging from 5 × 109vp to 5 × 1010vp. Despi[INVESTIGATOR_859734] y observed at the 5 × 1010vp, this dose was safe, with self -limit ing AEs and no 
serious adverse reactions recorded. The 5 × 1010vp was the most immunogenic, in terms o f 
inducing neutralizing ant ibodies against MERS -CoV using a live virus assay (Folegatti et al  
2020a ). Given the immunogenicit y findings and safet y profile observed wit h the 
ChAdOx1 -vectored vaccine against MERS -CoV, the 5 × 1010vp dose was chosen for 
AZD1222. See the AZD1222 IB.
Based on accumulating nonclinical and clinical data gathered for AZD1222 as well as for 
other SARS -CoV -2 vaccines in development, a 2 -dose regimen was selected for the study  in 
order to enhance the immune responses to the virus (AZD1222 IB).
In an NHP challenge study , [ADDRESS_1198174] co mpleted the study  if he/she has co mpleted all phases of 
the study  including the last scheduled procedure shown in the SoA (Section 1.3).
The end o f the study  is defined as the date of the last scheduled procedure shown in the SoA 
(Secti on 1.3) for the l ast parti cipant in the study  globally .
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 39of 1305 STUDY POPULATION
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known 
as protocol waivers or exemptions, is not permitted .
5.1 Inclusion Criteria
Parti cipants are eligible to be included in the study only if all o f the following criteria apply:
Age
1Adult, ≥ [ADDRESS_1198175] ion
Defined as adults whose locations or circumstances put them at appreciable risk of 
exposure to SARS -CoV -2 and COVID -19, based on available risk assessment 
contem poraneous to enrollment (believed to be at risk/exposure)
3Medically  stable such that, accordi ng to the j udgment of the invest igator, hospi[INVESTIGATOR_859735] -specified follow-up
A stable medical condit ion is defined as disease not requiring significant change in 
therapy  or hospi [INVESTIGATOR_859736] 3 months prior to
enrollment
4Able to understand and co mply with study  requi rements/procedures (if applicable, w ith 
assistance by [CONTACT_84452], surrogate, or legally  authori zed representative) based on the 
assessment of the invest igator
Reproduction
5Contraceptive use by [CONTACT_601070] d be consistent with local regulat ions regarding the 
methods of contraception for those participat ing in clinical studies 
6Female participants
(a)Women of childbearing potential must:
Have a negat ive pregnancy test on the day of screening and on Day  1
Use one highly  effect ive form of birth control  for at l east [ADDRESS_1198176] ive method of contraception is defined as one that can achieve a 
failure rate of less than 1% per y ear when used consistent ly and correctly (see 
Table 6). Peri odic abstinence, the rhy thm method, and wit hdrawal are NOT 
acceptable methods of contracepti on.
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 40of 130(b)Women are considered of childbearing potential unless they  meet ei ther of the 
following criteria:
Surgically sterilized (including bilateral tubal ligat ion, bilateral oophorectomy, or 
hysterectomy), or 
Post-menopausal
For wom en aged < [ADDRESS_1198177] -menopausal  is defined as having both:
o A history  of ≥[ADDRESS_1198178] -menopausal range
Until follicle -stimulating hormone is documented to be within menopausal 
range, the participant is to be considered of childbearing potential
For wom en aged ≥[ADDRESS_1198179]- menopausal is defined as having a history  
of ≥12 m onths amenorrhea prior to rando mizat ion, wi thout an al ternat ive 
cause, fo llowing cessat ion of exogenous sex -hormonal  treatm ent
Table 6 Highly Effective Methods of Contraception
Barrier Methods Hormonal Methods
• Intrauterine device
• Intrauterine hormone -releasing system 
(IUS) a
• Bilateral tubal occlusion
• Vasectomized partner b
• Sexual abstinence c• Combined (estrogen -and progestogen -containing 
hormonal contraception)
Oral (combined pi[INVESTIGATOR_4382])
Intravaginal
Transdermal (patch)
• Progestogen -only hormonal contraception
Oral 
Injectable
Implantable
aThis is also considered a hormonal method 
bProvided that partner is the sole sexual partner of the woman of childbearing potential study participant 
and that the vasectomized partner has received medical assessment of the surgical success 
cSexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse from 28 days prior to Day 1 through 60 days fol lowing administration of the second dose of 
study intervention, and if it is the preferred and usual lifestyle of the participant
Informed Consent
7Capable of giving signed informed consent as described in Appendix A,which includes 
compliance wi th the requi rements and restri ctions listed in the ICF and in this protocol
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 41of 1305.2 Exclusion Criteria 
Parti cipants are excl uded from  the study  if any of t he following cri teria apply:
Medical Conditions
1History  of allergy  to any  com ponent of the vaccine
2History  of Guillain -Barré syndrom eor any  other demyelinat ing condit ion
3Significant infect ion or other acute illness, including fever > 100 °F(> 37.8 °C) on the 
day prior to or day  of randomizati on 
4History  of laboratory -confirmed SARS -CoV -[ADDRESS_1198180] 
6months (≥ 20 mg per day of prednisone or i ts equivalent, given daily  or on al ternate 
days for ≥ [ADDRESS_1198181] ration of study  intervent ion)
The fo llowing exceptions are permitted: 
 Topi[INVESTIGATOR_2855]/inhaled ste roids or short -term oral steroi ds (course l asting ≤14 days)
 Hum an immunodeficiency virus -positive stable participants on stable antiretrovi ral 
therapy , eg, (NIH 2020 , Waldrop et al 2016)
7History  of primary  malignancy  except for:
(a)Malignancy  with low potenti al risk for recurrence after curative treatment (for 
example, history  of childhood leukaemia) or metastasis (for example, indo lent 
prostate cancer) in the opi[INVESTIGATOR_3078] n of the site investigator.
(b)Adequately treated non -melanoma skin cancer or lent igo maligna wit hout evidence of 
disease
(c)Adequately treated uterine cervical carcino ma in situ witho ut evi dence of disease
(d)Localized prostate cancer
8 Clinically significant bleeding disorder (eg, factor deficiency, coagulopathy, or platelet 
disorder), or pri or history  of significant bl eeding or brui sing fo llowing IM inject ions or 
venepuncture
9Severe and/o r uncontrolled cardio vascular disease, respi[INVESTIGATOR_23715], gastrointestinal 
disease, liver disease, renal disease, endocrine disorder, and neurological illness, as 
judged by  [CONTACT_24342] (mild/moderate well -controll ed com orbidi ties are all owed)
10Any ot her significant disease, disorder, or finding that may significant ly increase the risk 
to the parti cipant because o f participat ion in the study , affect the abilit y of the participant 
to parti cipate in the study , or impair interpretation of the study  data
Note: The AESIs as outlined in Appendix E(including Table 14) shoul d be considered 
when evaluat ing a participant for ExclusionCriterion 10, as the presence of these AESIs, 
Clinical Study Protocol -Amendment [ADDRESS_1198182] igator is asked to utilize his /her 
clinical judgment in determining the participant’s eligibilit y for the study . Shoul d the 
participant have condit ions as outlined in Appendix Eand the participant is enro lled, the 
Invest igator is asked to document notes on site regarding the final rat ionale for 
enrollment.
Prior/Concomitant Therapy
11Receipt of, or planned receipt of invest igational products indicated for the treatment or 
prevent ion of SARS -CoV -2 or COVID -19 
Note: For participants who beco me hospi[INVESTIGATOR_215444] h COVID- 19, receipt of licensed 
treatm ent opti ons and/or participat ion in invest igatio nal treatment studies is permitted
12Receipt of any  vaccine (licensed or invest igational) other than licensed influenza vaccines 
within 30 days prior to and after administration of study  interventi on
13Receipt of immunoglobulins and/or any  blood products wi thin 3 m onths prior to 
administration of study  intervent ion or expected receipt during the perio d of study  
follow-up
Other Exclusions
14Involvement in the planning and/or conduct of this study (applies to both Sponsor staff 
and/or staff at the study  site)
15For wom en only -current ly pregnant (confirmed wit h posi tive pregnancy test) or 
breast -feeding 
16Has donated ≥ [ADDRESS_1198183] ion 6.5
3Agree to wear digital healt h device if diagnosed with COVID -19as described in 
Secti on8.1.2.2
5.4 Screen Failures
Screen failures are defined as part icipants who consent to participate in the clinical study  but 
are not subsequent ly rando mly assigned to study  intervent ion. A minimal set of scr een failure 
inform ation is required to ensure transparent reporting of screen failure participants to meet 
the Consolidated Standards of Reporting Trials publishing requirements and to respond to 
Clinical Study Protocol -Amen dment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 43of 130queri es fro m regul atory  authori ties. Minimal informat ion includes demography, screen failure 
details, eligibilit y criteria, and any  SAE s.
Individuals who do not meet the criteria for participation in this study  (screen failure) m ay be 
rescreened. Only  a single rescreening is allo wed in the study . Rescreened parti cipants are 
requi red to si gn a new ICF (Appendix A 3), and will be assigned a new participant number.
6 STUDY INTERVENTION
In general, study  intervent ionis defined as any investigational intervent ion(s), marketed 
product(s) ,or placebo intended to be administered to or medical device(s) utilized by a study  
participant according to the study  protocol . For this study , study  intervent ion is defined as 
AZD122 2 or saline placebo ( Table 7). The thi rd party  medical device used for assessment of 
COVID -19 symptom s (ie, digital heal th device [Secti on8.1.2.2 ])isnot considered a study  
intervent ion.
6.1 Study Interventions Administered
6.1.1 Investigational Products
Table 7 Investigational Products
Intervention Name [CONTACT_99213]1222 Placebo
Type Vaccine Placebo
Dose Formulation10 mM histidine, 7.5% (w/v) sucrose, 
35mM sodium chloride, 1 mM magnesium 
chloride, 0.1%  (w/v) polysorbate 80, 
0.1mM edetate disodium, 0.5% (w/v) 
ethanol, at pH [IP_ADDRESS]% (w/v) saline
Unit Dose Strength(s) ≥0.7× 1011vp/mL
Dosage Level(s) 5 × 1010vp(nominal , ±1.5 × 1010vp)
Route of Administration Intramuscular Intramuscular
Use Experimental Placebo
IMP and NIMP IMP IMP
Sourcing Provided centrally by [CONTACT_859767] a carton. 
Each carton and vial will be labelled as 
required per country requirementNot applicable
Current/Former Name [CONTACT_859807]1 nCoV -19 Not applicable
IMP = investigational medicinal product; NIMP = non -investigational medical product; vp = viral particles ; 
w/v = weight/volume .
Clinical Study Protocol -Amendment [ADDRESS_1198184] be stored at 2 -8°C (36 -46°F) for the duration of 
assigned shelf -lifeandmust not be frozen. AZD1222 must be kept i n original packaging unt il 
use to prevent prolonged light exposure.
Placebo
Commercially available 0.9% (w/v) saline for injection will be sourced locally for placebo.
6.1.[ADDRESS_1198185] dose will be 
administered on Day  1 and the second dose on Day  29 (seeTable 2and Table 3). 
It is recommended that t he study intervent ions be administered as an IM i nject ion into the 
deltoid of the non -dominant arm .Other inject ion sites m ay be used if necessary .
All study  parti cipants will be observed in the clinic for at least [ADDRESS_1198186] be trained to recognize and treat anaphylaxis. 
6.2 Preparation/Handling/Storage/Accountability
1The invest igator or designee must confirm appropriate temperature condit ions have been 
maintained during transit for all study  intervent ion received and any discrepancies are 
reported and resolved before use of the study  intervent ion.
2Only participants enro lled in the study  may receive st udy intervent ion and only 
authori zed si te staff may  supply  or administer study  intervent ion. All study  intervent ion 
must be stored in a secure, environmentally controlled, and mo nitored (m anual  or 
autom ated) area in accordance wit h the l abelled storage con ditions wi th access limited to 
the invest igator and authorized site staff.
3The invest igator, institution, or the head of the medical inst itution (where applicable) is 
responsible for study  interventi on accountabilit y, reconciliat ion, and record maintenance
(ie, recei pt, reconciliat ion, and final disposit ion records).
4Further gui dance and information for the final disposit ion of unused study  interventi ons 
are provided in the Pharm acy Manual  or specified handling ins tructi ons.
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 45of 1306.2.1 Dose Preparation and Administration
[IP_ADDRESS] AZD1222
Doses of AZD1222 must be prepared by [CONTACT_93305] (or designee in accordance 
with local and inst itutional regulat ions) using aseptic technique. Each dose is prepared by 
[CONTACT_261858] 0.[ADDRESS_1198187] be prepared from a new 
vial. 
Each vial o f AZD1222 has a labe l-claim  volume of 5 mL and can provide up to ten 
0.5mLdoses.
[IP_ADDRESS] Placebo
Doses of saline placebo m ust be prepared by  [CONTACT_794210] (or desi gnee in 
accordance with local and inst itutional regulat ions) using asept ic technique. Each saline 
placebo do se is prepared by [CONTACT_859768] 0.5 mL from a 0.9% (w/v) saline vial or IV bag in a 
sterile syringe. If 0.9% (w/v) saline is extracted from IV bags, the manufacturers ’
recommendat ion for maximum  number of needle punctures of the IV bag port must not be 
excee ded.
Saline (0.9% [w/v]) does not contain preservatives. Each vial or IV bag must be assigned a 
beyo nd-use-date of  [ADDRESS_1198188] be 
administered within the bey ond-use-date of the vial/IV bag. If saline placebo dose 
administration is not completed within the 6-hour vial/IV bag beyo nd-use-date, a new dose 
must be prepared fro m a new vial or IV bag.
6.3 Measu res to Minimize Bias: Randomization and Blinding
6.3.[ADDRESS_1198189] ions for the IRT 
will be provi ded to each study  site. Rando mization will be stratified by [CONTACT_654] ( ≥ 18 to 
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 46of 130< 65 years, and ≥ 65 years), with at least 25% of participants to be enro lled in the older age 
stratum .
Where a participant does not meet all the eligibilit y criteria but incorrectly received study  
intervent ion, the investigator should inform the Study Physician immediately, and a discussio n 
shoul d occur between the Study  Physician and the investigator regarding whether to continue 
or discontinue the participant .
6.3.[ADDRESS_1198190] pri or to dose 
preparati on (due to differences in container closure), IMP will be handled by  [CONTACT_29646] (or designee in accordance wit h local and inst itutional regulat ions) at the study  
site. Once drawn into sy ringes for administrati on, AZD1222 and saline placebo are not 
visually dist inct fro m each other.
The IRT will provide the invest igator(s) or pharmacists a dose tracking number to be allocated 
to the parti cipant at the dispensing visit. Routines for this will be described in the IRT user 
manual that will be provided to each study  site.
The rando mizat ion code should not be broken except in medical emergencies when the 
appropriate management of the participant requires knowledge of the treatment 
rando mizat ion. The invest igator docum ents and reports the action to the Sponsor, without 
revealing the treatment given to participant to the Sponsor staff.
The Sponsor retains the right to break the code for SAEs that are unexpected and are 
suspected to be causally  related to an invest igational medicinal product and that poten tially 
requi re expedited reporting to regulatory  authori ties. Randomizat ion codes will not be broken 
for the pl anned analyses of data until all decisio ns on the evaluabilit y of the data from each 
individual part icipant ha ve been made and documented.
6.3.[ADDRESS_1198191] the immediate 
management of the parti cipant’s condit ion (eg, antidote available), the invest igator has the 
sole responsibilit y for determining if unblinding of a participants’ intervent ion assignment is 
warranted. Participant safet y must al ways be the first considerat ion in making such a 
determinat ion. If a participant’s intervent ion assignment is unblinded for safet y, the Sponsor 
must be notified within 24 hours after breaking the blind. 
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 47of 130In the event that a study  parti cipant i s contact[CONTACT_859769] a licensed and/or authorized
COVID -[ADDRESS_1198192] igator or designee, under medical supervisio n. The date, and time if applicable, 
of dose administered will be recorded in the source documents and recorded in the eCRF. The 
dose of study  intervent ion and study  parti cipant i dentificat ion will be confirmed at the time of 
dosing by  a member of the study  site staff other than the person administering the study  
intervent ion.
6.5 Concomitant Therapy
Any medicat ion or vaccine (including over -the-counter or prescript ion medicines) that the 
participant is receiving at the time of enro llment or receives during the period specified in the 
SoA (Section 1.3), must be recorded in the eCRF along with the informati on listed bel ow. 
Vitamins and/or herbal supplements are not to be recorded.
Reason for use
Dates of administration including start and end dates
Dosage information including dose and frequency
The Study  Physician shoul d be con tacted if there are any  questi ons regarding concomitant or 
prior therapy .
6.5.1 Perm itted Concomitant Medications
Parti cipants may  take concomi tant medicat ions prescribed by [CONTACT_859770]/or for heal th maintenance. Primary care 
provi ders, or where appropriate invest igators, should prescribe appropriate concomitant 
medicat ions or treatments deemed necessary  to provide full supportive care and comfort 
during the study . Partici pants who devel op COVID -[ADDRESS_1198193] of care. 
All routine vaccinat ions other than influenza are permitted beginning > 30days after l ast dose 
of study  intervent ion. Licensed influenza vaccines are permitted at any  time.
6.5.[ADDRESS_1198194] be notified if a participant 
receives any o f these prohibited medications. The use of the following conco mitant 
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 48of 130medicat ions and/or vaccines, however, will not definit ively  requi re wi thdrawal of the 
participant from the study , but m ay determine a parti cipant’s eligibilit y to receive a second 
dose or evaluabilit y in the per -protocol  analysis set.
If a participant receives a prohibited conco mitant medicat ion, the invest igator in consultat ion 
with the Sponsor will evaluate any  potenti al impact on recei pt of study  intervent ionbased on 
time the medicat ion was administered, the medicatio n’spharm acology and pharmacokine tics, 
and whether the medicat ion will co mpromi se the parti cipant’s safet y orinterpretati on of the 
data (see Section 7.1).
Invest igational products indicated for the treatment of SARS -CoV -2 or COVID -19 
Note: For participants who beco me hospi[INVESTIGATOR_215444] h COVID- 19, receipt of licensed 
treatm ent opti ons and/or parti cipat ion in invest igatio nal treatment studies is permitted . 
Experimental v accinat ions, o ther than AZD1222, for prevent ion of SARS -CoV -2 or 
COVID -19.
Note : Parti cipants choosing to receive a licenced and/or authorized COVID- [ADDRESS_1198195] igator so it can be properly documented. Participants, who 
receive a licenced and/or a uthorized COVID- [ADDRESS_1198196] to be fo llowed for safet y reporting and all 
assessments .
Receipt of any  vaccine (licensed or invest igational) other than licensed influenza vaccines 
within 30 days prior to and after administration of study  interventi on(eg, Dose 1 and 
Dose 2). Thirty (30)days after the second vaccinatio n, other routine vaccinat ions are 
permitted as clinically indicated.
Glucocorti coids at a dose ≥ 20 mg/day o f prednisone or equiva lent given daily or on
alternate day s for ≥ 14 consecut ive days between rando mizat ion and the participant’s
scheduled final visit
Other sy stemically administered drugs with significant immunosuppressive activit y, such
as azathioprine, tacrolimus, cyclosporine, m ethotrexate, or cy totoxi c chem otherapy
between rando mizat ion and the participant’s scheduled final visit
Immunoglobulins and/or any  blood product
6.6 Dose Modification
Study  intervent ion will be administered as described in Section 6.1.2 . Dose modificat ion is not 
permitted. 
6.7 Intervention After the End of the Study
There i s no intervent ion after the end of the study  (see definit ion in Sect ion 4.4).
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 49of 1307 DISCONTINUATION OF S TUDY INTERVENTION AN D 
PARTICIPANT DISCONTI NUATION/WITHDR AWAL
7.1 Discontinuation of Study Intervention
Each participant will receive 2 doses of study intervent ion (see Section 6). An individual 
participant will not receive the firstorsecond dose of study  intervent ion if any o f the 
following occur in the participant in question:
1Withdrawal o f consent after signing informed consent
2Parti cipant m eets one or m ore of the exclusio n criteria or f ails to m eet all inclusio n 
criteria for study  parti cipati on 
3Laboratory -confirmed SARS -CoV -[ADDRESS_1198197] not received study  intervent ion, 
regardl ess of reason, will not be fo llowed. 
7.1.1 Study Suspension or Term ination
The Sponsor reserves the right to temporarily suspend or permanent ly terminate this study  or a 
component of the study  at any  time. The reasons for temporarily suspending the study  may 
include, but are not limited, to the fo llowing:
Any death, SAE, or other safet y finding assessed as related to study intervent ion that in 
the opi [INVESTIGATOR_859737] m ay precl ude further administrati on of  study  intervent ion
No addi tional parti cipants will be randomized or treated with study  intervent ion until review 
by [CONTACT_25963] -19 Vaccine DSMB is co mplete (see Appendix A 5for COVID -19 Vaccine 
DSMB informat ion).
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 50of 1307.2 Participant Withdrawal from the Study
A participant may withdraw fro m the study  at any  time at hi s/her own request, or may  be 
withdrawn at any  time at t he discretion of the investigator for safet y, behavioral, 
compliance, or administrative reasons. This is expected to be unco mmo n.
A participant who considers wit hdrawing fro m the study  must be informed by  [CONTACT_122610]-up opti ons ( eg, tel ephone contact, a contact [CONTACT_4490] a 
relative or treating physician, or information fro m medical records).
If the participant withdraws consent for disclosure of future informat ion, the Sponsor may 
retain and cont inue to use any data collected before su ch a withdrawal o f consent.
If a participant withdraws fro m the study , it shoul d be confirmed if he/she st ill agrees for 
exist ing samples to be used in line with the original consent. If he/she requests withdrawal 
of consent for use of samples, destruction of any sam ples taken shoul d be carri ed out in 
line with what was stated in the informed consent and local regulat ion. The invest igator 
must docum ent the decisio n on use of exist ing samples in the site study records and 
inform  the Sponsor Study  Team .
7.[ADDRESS_1198198] be taken if a participant fails to return to the clini c for a requi red 
study  visit:
The study  site must attem pt to contact [CONTACT_859771] t he participant wishes to and/or 
shoul d cont inue in the study .
Before a participant is deemed lost to fo llow-up, the invest igator or designee must make 
every effort to regain contact [CONTACT_6635] (where possible, 3 telephone calls and, 
if necessary ,a certified letter to the participant’s last known mailing address or local 
equivalent m ethods). These contact [CONTACT_13140]’s 
medical record.
Shoul d the participant continue to be unreachable, he/she will be considered to have 
withdrawn from  the study . 
Discontinuati on of  specific sites or of the study  as a who le are handled as part of Appendix A.
8 STUDY ASSESSMENTS AND PROCEDURES
Study  procedures and their timing are summarized in the SoA (Section 1.3). Protocol
waivers or exempt ions are not allowed.
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 51of 130Immediate safet y concerns should be discussed wit h the Sponsor immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue 
study  interventi on.
Adherence to the study  design requi rements, including those specified in the So A
(Secti on 1.3)is essent ial and requi red for study  conduct.
All screening evaluat ions must be com pleted and reviewed to confirm that potential 
participants m eet all eligibilit y criteria. The invest igator will maint ain a screening log to 
record details o f all participants screened and to confirm eligibilit y or record reasons for 
screening failure, as applicable.
Procedures conducted as part of the part icipant’s routine clinical management (eg, blood 
count) and obtained before signing of the ICF may be utilized for screening or baseline 
purposes provided the procedures met the protocol -specified criteria and were performed 
within the t ime frame defined i n the SoA.
8.[ADDRESS_1198199] participants weekly  (telephone/em ail/text) through Day  [ADDRESS_1198200] ion with SARS -CoV -2.
If a parti cipant presents with a COVID -19 qualifying symptom(s) on Day s 1-3, the nasal swab 
collected on Day  1 will be tested locally  for SARS -CoV -2 (see Section [IP_ADDRESS] ). If posit ive, 
the participant will be instructed to init iate illness visit s. If negat ive, the participant will 
continue wit h scheduled assessments per their assigned study  (ie,main study  [Table 2]or 
substudy  [Table 3]).
Parti cipants who present wi th a COVID -19 qualifying symptom(s) after Day  [ADDRESS_1198201] be present for ≥ 2 
consecutive daysChills
Cough
Fatigue
Muscle aches
Body aches
Headache
New loss of taste 
New loss of smell
Sore throat
Congestion
Runny nose
Nausea
Vomiting
Diarrhea
Adapted f rom(CDC 2020 ).
8.1.2 Illness Visits
Symptom atic parti cipants (as defined in Section 8.1.1 ) will be instructed to visit the study  site 
for initiation of  illness assessments ( Table 4); where supported, home or mobile visits may be 
subst ituted for the sitevisits .Symptom aticparticipants will co mplete the Day  [ADDRESS_1198202] ion requirements (eg,digital healt h 
device andIllness e-Diary recordings, and saliva samples) . SARS -CoV -2 RT -PCR results will 
be available during the ho me co llection peri od and parti cipants will be informed of their 
status. The results of the COVID -19 RT-PCR testing should also be reported to the 
participants’ primary  care provi ders. Only  parti cipants who test posit ive will be instructed to 
continue wit h the illness visits, including ho me collect ion of saliva samples and di gital health 
device and Illnes s e-Diary  recordings . Parti cipants who test negative for SARS -CoV -[ADDRESS_1198203] result, Investigators should provide appropri ate 
clinical fo llow-up of  participants , as clinically  indicated . Once Illness visits are discontinued, 
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 53of 130participants will cont inue with fo llow-up visits per their assigned study  (ie,main study  [Table 
2]or substudy  [Table 3]). 
[IP_ADDRESS] SARS -CoV -2 Testing and Other Virology Assessments
At the Day 1 illness visit, mid -turbinate nasal swabs and nasopharyngeal swabs will be 
collected and tested for SARS -COV -2 by [CONTACT_670088] R T-PCR assays (see Section [IP_ADDRESS] ). 
Saliva will be collected during site illness visits and by  [CONTACT_6270]-collection at hom e throughout the 
illness visit s to quantify duration o f viral shedding (see Section [IP_ADDRESS] ). Other virology  
assessments are described in Sect ion 8.6.
Genoty pic evaluat ion of SARS -CoV -[ADDRESS_1198204] viral variants.
[IP_ADDRESS] Digital Health Device
At the Day  1 illness visit, participants will receive a wearable, digital health device 
(eg,Current Health Monitoring System) and be trained on use of the biosensor . The digital 
healt h device will cont inuously track biophysical parameters, including but not limited to, 
serial measurements of skin temperature, heart rate, respi[INVESTIGATOR_2842], blood oxygen saturation, 
and physical act ivity. 
Data will be obtained from the biosensor and transmitted via a wireless hub from the 
participant to the vendor platform. The vendor platform will be mo nitored remotely 24hours a 
dayby a team which includes registered nurses . The m onitoring team willreceive technical
alerts if there are dat aor devi ce issues, andphysi ologi c alerts if participants’ vi tal signsmeet 
prespecified criteria .The physi ologic alerts are i ntended to provide an early indication o f 
worsening healt h status that would allow the monit oring team and inves tigator to provi de 
appropriate fo llow-up. Allalerts will be triaged and fo llowedupby [CONTACT_941] m onitoring team
according to agreed -upon monitoring protocols .A registered nurse will review thealerts 
requi ring clinical attention and will apply  clinical  judgem ent (based on the Schmitt -Thom pson 
COVID -19 - Diagnosed or Suspected After Hours Telephone Triage Protocols) (Schmitt -
Thom pson 2020 )to determine which alerts can be addressed directly wit h the participant via 
telephone, and which alerts shoul d be escalated to the on -call clinician at the site .If escalat ion 
is required, the nurse will contact [CONTACT_21639] -call clinician by  [CONTACT_859772]-up. For alltechnical and physio logic alerts, details
regarding the nature of the alert and action taken will be documented within the Current 
Health Moni toring System and an inform ational email will be sent to the invest igator within 
2hours for further fo llow-up if required . If local regul ations prohibit the m onitoring team  
from collecting ident ifying informat ionabout partici pants, or from contact[CONTACT_859773], the Investigator and site staff will be responsible for monitoring the 
transmitted data and responding to both technical and physio logic alerts [ADDRESS_1198205] negative and stop the illness visits will be instructed to
return the digital healt h device .
[IP_ADDRESS] Illness e-Diary
An Illness e-Diary  will be used to collect self -reported inform ation abo ut COVID -19-
associ ated symptom s(listed below per CDC (CDC 2020 ).At the Day 1 illness visit, 
participants (or,if applicable, their caregiver, surrogate, or legally authori zed representative )
will be given access to the Illness e -Diary  and trained by [CONTACT_859774] y of the symptoms.
Parti cipants who test posit ive for SARS -CoV -[ADDRESS_1198206] 
negat ive will be instructed to stop Illness e -Diary  recording.
Study sites will mo nitor the health status of participants via Illness e-Diary  responses after the 
Day 1 illness visit , and will c all parti cipants as needed based on theseresponses. 
COVID -19 Symptoms
Fever New l oss of taste 
Shortness o f breath New l oss of smell
Difficult y breathing Sore throat
Chills Congest ion
Cough Runny nose
Fatigue Nausea
Muscle aches Vomit ing
Body  aches Diarrhea
Headache
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 55of 1308.1.3 Severe COVID-19
The severit y of COVID -19 will be evaluated in participants with symptoms of COVID-19. A 
diagnosis of severe or critical COVID -19 will include laboratory -confirmed COVID -19 
(SARS -CoV -2 RT -PCR -positive symptom atic illness) plus any of the following:
Clinical signs at rest indicat ive o f severe systemic illness (respi[INVESTIGATOR_2842] ≥ 30 breaths per 
minute, heart rate ≥125 beats per minute,  oxygen saturation ≤ 93% on room  air at sea 
level, or partial pressure of oxygen to fraction of  inspi[INVESTIGATOR_218687] <300 mm Hg)
Respi[INVESTIGATOR_33078] (defined as needing high -flow oxy gen, noninvasive vent ilation, 
mechanical vent ilation or extracorporeal membrane oxygenat ion)
Evidence of shock (systolic bl ood pressure < 90 mm Hg, diastolic blood pressure 
< 60 mm Hg, or requiring vasopressors)
Significant acute renal, hepat ic, or neurologic dysfunct ion
Admissio n to an intensive care unit
Death
8.1.4 Medical Notes Review
With the parti cipant’s consent, the study  team  will request access to medical notes or submit a 
data collection form for com pletion by [CONTACT_859775] -attended 
COVID -19 epi [INVESTIGATOR_1841]. Any  data rel evant for assessment of the efficacy endpo ints or 
vaccine -associated enhance drespi [INVESTIGATOR_23715] (see Section 8.3.9 ) will be collected. These 
are likely to include, but not limited to, informat ion on intensive care unit admissio ns, clinical 
param eters such as oxy gen saturati on, respi [INVESTIGATOR_859738], need for oxy gen 
therapy , need for vent ilatory support, imaging , blood tests results, and overall outcome 
(survival or death) .
8.1.5 Monitoring for Asymptomatic Infection
Blood sam ples will be collected according to the SoA (Section 1.3)for SARS -CoV -[ADDRESS_1198207] ion. See descript ion of assessment in 
Secti on [IP_ADDRESS] . 
8.2 Safety Assessments
Planned time po ints for all safet y assessments are provided in the SoA (Section 1.3).
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 56of 1308.2.1 Physical Exa minations
A co mplete physical examinat ion will be performed at screening fo llowed by [CONTACT_670091] (Section 1.3). 
A co mplete physical examinat ion will include, but not be limited to, assessment of height, 
weight,general appearance, head, ears, eyes, nose, throat, neck, skin, as well as 
cardi ovascu lar, respi[INVESTIGATOR_696] , abdo minal, and nervous systems. Each clinically  significant 
abnorm al finding at screening will be recorded in the medical history .
A targeted physical examinat ion will include areas suggested by  [CONTACT_941] m edical  history . Each
clinically signif icant abnorm al finding following vaccination will be recorded as an AE.
All physical examinat ions will be performed by a licensed healt hcare provider 
(eg,physician, physician assistant, or licensed nurse practitioner). 
8.2.2 Vital Signs
Vital signs, including heart rate, pulse oximetry, blood pressure, and body temperature, will be 
perform ed as specified in the SoA (Section 1.3). The participant should be rest ing prior to the 
collect ion of vital signs.
Data collected through the digital healt h device on heart rate, respi[INVESTIGATOR_2842], tem perature, 
and oxygen saturati on level will be recorded as exploratory  efficacy  measurements and should 
not be re ported as AEs unless result ing in anMAAE or SAE.
Situations in which vital sign results should be reported as AEs are described in Sect ion 8.3.[ADDRESS_1198208] information, 
specific to this clinical study .
For wom enparticipants of childbearing potential, a urine sample for pregnancy  testing will be 
collected according to the SoA (Section 1.3). Urine pregnancy te sts for -hCG may be 
perform ed at the si te using a licensed test (dipst ick). If urine tests posit ive or indeterminate, a 
quant itative serum β-hCG will be performed for confirmat ion.  
Addit ional safet y samples may  be collected if clinically indicated at the discret ion of the 
investigator
Clinical Study Protocol -Amendment [ADDRESS_1198209] ion.
The definit ions of an AE or SAE can be f ound in Appendix B. 
All AEs are considered to be unso licited AEs (collected by  ‘open quest ion’ at study  visits) 
unless categorized as so licited AEs recorded in the substudy only. 
Solicited AEs are local or sy stemic predefined events for assessment of reactogenicit y. 
Solicited AEs will be co llected in a Solicited AE e-Diary only  for parti cipants in the substudy
(Secti on8.3.7 ), and will be assessed separately from the (unso licited) AEs co llected during 
the study .
General informat ion for AEs in this protocol excludes solicit ed AEs. 
AEs will be reported by  [CONTACT_17071] (or, when appropriate, by a caregiver, surrogate, or the 
participant's legally  authori zed representative). 
The invest igator and any designees are responsible for detecting, document ing, and recording 
events that mee t the defini tion of  an AE.
8.3.[ADDRESS_1198210]. 
See the SoA (Se ction1.3) for the scheduled timepoints. 
If the invest igator becomes aware of an SAE with a suspected causal relat ionship to the study  
intervent ion that occurs after the end of the clinical study  in a parti cipant treated by  [CONTACT_531427], the invest igator shall, without undue delay, report the SAE to the Sponsor.
8.3.2 Follow- up of AEs and SAEs
Any AEs that are unresolved at the participant’s last AE assessmen t in the study  are f ollowed 
up by  [CONTACT_83764], but without further recording in the 
Clinical Study Protocol -Amendment [ADDRESS_1198211] addit ional inform ation for any  parti cipant wi th 
ongoing AE(s)/SAE(s) at the end of th e study , if judged necessary .
AE variables
The fo llowing variables will be collected for each AE:
AE (verbat im)
Date when the AE started and stopped
Severit y grade/max imum severit y grade/changes in severit y grade
Whether the AE is serious or not
Invest igator causalit y rating against the study  intervent ion (yes or no)
Action taken with regard to study  intervent ion
AE caused participant’s withdrawal fro m study  (yes or no)
Outcom e
In addit ion, the fo llowing vari ables will be collected for SAEs:
Date AE met criteria for SAE
Date invest igator became aware of SAE
AE is seri ous due to
Date of hospi[INVESTIGATOR_059]
Date of discharge
Probable cause of death
Date of death
Autopsy  performed
Causalit y assessment in relat ion to study  procedure(s)
Causalit y assessment to other medicat ion
The grading scales from US FDA guidance for healt hy vo lunteers enro lled in a prevent ive 
vaccine clinical study (FDA 2007 )will be utilized for all unsolici ted events with an assigned 
severit y grading. 
8.3.[ADDRESS_1198212] igator should assess causal relationship between study intervention and each AE, 
andanswer ‘yes’ or ‘no’ to the question ‘Do y ou consi der that there is a reasonable possibilit y 
that the event may have been caused by  [CONTACT_33159]?’
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 59of 130For SAEs, causal relat ionship should also be assessed for other medicat ion and study  
procedures. Note that for SAEs that could be associated with any study  procedure the causal 
relationship is implied as ‘yes .’
A guide to the interpretation of the causalit y quest ion is found in Appendix B. 
8.3.4 Adverse Events Based on Signs and Symptoms
All AEs spontaneously reported by  [CONTACT_670778]: ‘Have y ou had any heal th probl ems since the previous visit/y ou were 
last asked?’, or revealed by [CONTACT_859776]. When 
collect ing AEs, the recording of diagnoses is preferred (when possible) to recording a list of 
signs and symptoms. However, if a diagnosis is known and there are other signs or symptoms 
that are no t generally part of the diagnosis, the diagnosis and each sign or symptom will be 
recorded separately.
8.3.[ADDRESS_1198213] igator (which may include but not limi ted to 
consideration as to whether treatment or non -planned visits were required).
If deteri oration in a vi tal sign is associ ated wi th clinical signs and symptoms, the sign or 
symptom  will be reported as a nSAE or MAAE , and the associated vital sign will be 
considered as addit ional informat ion. 
8.3.6 Hy’s Law
Cases where a participant shows elevations in liver biochemistry  may requi re further 
evaluat ion. Any occurrences o f AST or ALT ≥ 3 × ULN together with total bilirubin 
≥ 2 × ULN and confirmed as a Hy's Law case should be reported as an SAE.
Hy’s Law
AST or ALT ≥ 3 × ULN together with TBL ≥ 2 × ULN, where no other reason, other than the 
study  interventi on, can be found to explain the combinat ion of increases, eg, elevated ALP 
indicat ing cholestasis, viral hepat itis, another drug. The elevat ion in transaminases must 
precede or be coincident with (ie, on the same day) the elevation in TBL, but there is no 
specified t imeframe wit hin which the elevat ions in transaminases and TBL must occur.
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 60of 1308.3.7 Solicited Adverse Events (Only for Substudy)
Local  and systemic predefined so licited AEs for reactogenicit y assessment ( Table 8) will be 
collected in a Solicited AE e-Diary for 7days following administration of each dose of study  
intervent iononly from parti cipants in the substudy. 
Solicited AEs shoul d not be reported as unsolicited AEs (see Section 8.3). However, solicited 
AEs shoul d be reported as SAEs or MAAEs if they fulfil the criteria (see Sections 8.3and 
8.3.8 , respecti vely).
Table [ADDRESS_1198214] of Predefined Solicited Adverse Events for Reactogenicity 
Assessment
Local Systemic 
Pain at the site of injection Fever ( > 100 °F [> 37.8 °C])a
Erythema/ redness at the site of injectionb Chills
Tenderness Muscle pains
Induration/swelling at the site of the injection b Fatigue
Headache
Malaise
Nausea
Vomiting
aFever measured by [CONTACT_28414]. Investigators who consider a temperature lower than this cutoff as a fever 
or a ‘fever ’reported by [CONTACT_859777] a thermometer should record the event as 
‘elevated body temperature. ’
bSwelling and redne ss must be ≥ 0.25 inches ( ≥0.6 centimeters) in diameter.
Solicited AE e-Diary
On Day  1, parti cipants in the substudy  (or, if applicable, their caregiver, surrogate, or legally  
authori zed representative) will be given an oral thermometer, tape measure, and access to the 
Solicited AE e-Diary, wi th instructions on use, al ong wi th the emergency  24-hour telephone 
number to contact [CONTACT_21639] -call study  physician if needed. 
Parti cipants will be instructed to recor d for 7 days fo llowing administration of each dose of 
study  interventi on, the timing and severit y of local and systemic solicit ed AEs, if applicable, 
and whether medication was taken to relieve the symptoms. 
Severity Assessment of Solicited AEs
Severit y will be assessed for solicited AEs by [CONTACT_2299] (or, if applicable, their caregiver, 
surrogate, or legally authorized representative) according to toxicit y grading scales modified 
and abridged from the US FDA guidance (FDA 2007 )as defined in Appendix D. Because 
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 61of 130solicited AEs are expected to occur after vaccinat ion, they will not be assessed for relat ionship 
to study  intervent ion.
8.3.8 Medically Attended Adverse Events
MAAEs will be collected acc ording to the timepo ints specified in the SoA (Section 1.3).
MAAEs are defined as AEs leading to medically- attended visits that were not routine visi ts 
for physical  examinat ion or vaccinat ion, such as an emergency  room  visit, or an otherwi se 
unscheduled visit to or from medical personnel (medical doctor) for any reason .AEs, 
including abnormal vital signs, ident ified on a routine study  visit or during the scheduled 
illness visit s will not be considered MAAEs.
8.3.[ADDRESS_1198215]
AESIs will be co llected according to the timepo ints specified in the SoA (Section 1.3). 
AESIs are events of scientific and medical interest specific to the further understanding of 
study  interventi on saf ety profile and require close mo nitoring and rapid co mmunicat ion by [CONTACT_859778]. AESIs for AZD1222 are based on Brighton Collaboration case 
definit ions (SPEAC 2020 ), clinical experience, and scient ific interest . SeeAppendix Efor a 
listing and description of AZD1222 AESIs . 
An AESI can be serious or non -serious. All AESIs will be recorded in the eCRF. If any AESI 
occurs in the course of the study , invest igators or other site personnel will inform the 
appropriate Sponsor representatives wit hin one day ie, immediately but no later than 
24hours of when he or she beco mes aware of it. Serious AESIs will be recorded and reported 
as per Secti on 8.3.10 .
[IP_ADDRESS] Potential N eurolog ical AESIs
If a participant experiences new onset (acute or subacute) motor and sensory disturbances 
(eg,weakness, numbness, paresthesia s, hypoesthesia, hyperesthesia, dysesthesias) , 
bowel /bladder dysfunct ion, gai t impairment, visual disturbance, or any  event of myelit is, 
encephalo myelit is, transverse myelit is, or other sudden neurological defici t, there shoul d be 
prom pt neurol ogical evaluati on, incl uding referral to a neurology  specialist for further 
evaluat ion and testing, asclinically indicated. Testing can include evaluat ion for peri pheral 
demyelinat ing condit ions (eg, EMG). In cases o fconcern for spi[INVESTIGATOR_854951], s ee Figure 2
for a recommended testing algorithm . 
An independent Neurological AESI Expert Committee will review and provi de advice on the 
diagnosis and causalit y assessment of selected neurol ogical  AESIsoccurring in the AZD1222 
clinical development program (see Appendix A 5). 
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 62of 130Figure 2 Neurology Testing Algorithm
aAdapted from (Rovira et al 2015 )
Ab = antibody ; ACE = angiotensin converting enzyme; ADC = apparent diffusion coefficient ;ANA =antinuclear antibody ; ANCA = antineutrophil cytoplasmic antibodies ;AQP4 
=aquaporin 4 ;CMV =cytomegalovirus ; CNS = central nervous system ; CRP = c-reactive protein ; CSF = cerebral spi[INVESTIGATOR_872]; CT = computed tomography; DWI = diffusion -
weighted im age; EBV = Epstein -Barr virus ; ED = emergency department; ENA = extractable nuclear antigen antibodies ; ESR = erythrocyte sedimentation rate ; FLAIR = fluid -
attenuated inversion recovery; GRE = gradient echo ; HIV = human immunodeficiency virus ; HSV = herpes simplex virus ; IgG=immunoglobulin G ; MOG = myelin 
oligodendrocyte glycoprotein ; MRI = magnetic resonance image ; PCR = polymerase chain reaction; RF = rheumatoid factor ; RPR = rapid plasma reagin ; STIR = short T1 
inversion recovery; SWI = susceptibility -weighted imaging ; TSH = thyroid stimulating hormone; TM = transverse myelitis ; VDRL = Venereal Disease Research Laboratories ; 
VZV = varicella -zoster virus . 

Clinical Study Protocol -Amendment [ADDRESS_1198216] to be reported, whether or not con sidered causally related to the study  
intervent ion, or to the study  procedure(s). All SAEs will be recorded in the eCRF.
If any SAE occurs in the course of the study , investi gators or other site personnel will inform 
the appropriate Sponsor representatives within one day  ie, immediately but no later than 
24hours of when he or she beco mes aware of it.
The designated Sponsor representative will work with the invest igator to ensure that all the 
necessary  informat ion is provided to the [COMPANY_008] Patient Safe ty data entry  site within 
onecalendar day of initial receipt for fatal and life -threatening events and within [ADDRESS_1198217] igator/study  site staff how to proceed.
For further guidance on the definit ion of a nSAE, see Appendix B.
The reference document for definit ion of expectedness is the AZD1222 IB , Secti on 5.6 . 
8.3.11 Pregnancy
All pregnancies and outcomes of pregnancy wit h concepti on dates fo llowing administrati on of
study  interventi onshoul d be reported to the Sponsor, except if the pregnancy is discovered 
before the participant has received any study  intervent ion.
[IP_ADDRESS] Maternal Exposure
Female participants who are pregnant or have a confirmed posit ive pregnancy test at screening 
or Day  1 will be excluded from the study  (see Sectio n 5.2). Pregnancy  itself is not regarded as 
an AE unless there is a suspi[INVESTIGATOR_24510] n that the study  intervent ion may have interfered with the 
effect iveness of a contraceptive medicat ion. Congenital a bnormalit ies/birth defects and 
spontaneous miscarriages should be reported and handled as SAEs. Elective abortions without 
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 64of 130complicat ions should not be handled as AEs. The outcome of all pregnancies (spontaneous 
miscarri age, el ective terminat ion, ectopic pr egnancy , norm al birth or congeni tal abnorm ality) 
shoul d be f ollowed up and docum ented even if the participant was discont inued fro m the 
study .
If any pregnancy  occurs in the course of the study , then the investigator or other site personnel 
informs the app ropri ate Sponsor representatives within [ADDRESS_1198218] igator to ensure that all relevant 
inform ation is provided to the [COMPANY_008] Patient Safet y data entry  site within 1 or 
5calendar days for SAEs ( see Section 8.3.10 ) and within [ADDRESS_1198219] igator to ensure that all relevant 
inform ation is completed within 1(Initial Fatal/Life -Threatening or fo llow up
Fatal /Life -Threatening) or 5(other serious init ial and fo llow up) calendar days if there is an 
SAE associated with the medicat ion error (see Sectio n 8.3.10 ) and within 30 days for all other 
medicat ion errors.
The definit ion of a Medicat ion Error can be found in Appendix B 4. 
8.3.13 Medical Device Deficiencies
Any deficiency  observed wi th the di gital heal th device (third-party  medical device) will be 
collected and reported to the manufacturer by  [CONTACT_670094], immediately but no l ater than [ADDRESS_1198220] ions, use errors, and informat ion supplied by [CONTACT_941] m anufacturer.
The m anufacturer ’s medical  device com plaint report will be used to collect the deficiency . 
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 65of 1308.4 Overdose
For thi s study , any dose of study  interventi on exceeding that specified in the protocol will be 
considered an overdose.
There i s no specific treatment for an overdose with AZD1222. If overdose occurs, the 
participant shoul d be treated supportively wit h appropriate monitoring as necessary.
An overdose with associated AEs is recorded as the AE diagnosis/symptoms on the 
relevant AE m odules in the eCRF and on the Overdose eCRF module
An overdose without associated symptoms is only  reported on the Overdose eCRF 
module
If an overdose occurs in the course of the study , the invest igator or other site personnel inform 
appropriate Sponsor representatives immediately, but no later than [ADDRESS_1198221] igator to ensure that all relevant 
inform ation is provided to the [COMPANY_008] Patient Safet y data entry  site within one or 
5calendar days for overdoses associated with an SAE (see Section 8.3.10 ) and within 
30days for all other overdoses.
8.[ADDRESS_1198222] confident iality. Further details on Handling of Human Bio logical 
Samples are provi ded in Appendix C.
Samples will  be stored for a m aximum  of 15 y ears fro m the date of the issue of the CSR in 
line with consent and local requirements, after which they will be destroyed/repatriated. 
Remaining bio logical  sample aliquots will be retained at the Sponsor or its designee for a 
maximum o f 15 years fo llowing issue of the CSR. Addit ional use excludes genet ic analysis 
and includes but is not limited to, analysis o f COVID -19 and other coronavirus -related 
diseases or vaccine- related responses, eg, exploratory  immuno logy, such as systems sero logy 
and profiling of B -and T -cell repertoire . The results from further analysis will not be reported 
in the CSR.
8.5.1 Pharmacokinetics
Pharmacokinet ic parameters are not evaluated in this study .
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 66of 1308.5.2 Immunogenicity Assessments
Serum  samples for immunogenicit y assessments will be co llected according to the SoA 
(Secti on 1.3). Samples will be collected, labelled, stored, and s hipped as detailed in the 
Laboratory  Manual. Result s for expl oratory  immunogenicit y analyses may be reported 
separately  from the CSR.
[IP_ADDRESS] SARS -CoV -2 Serology Assessments
Serum  samples will be co llected to assess SARS -CoV -2 antigen -specific ant ibody  levels fro m 
all participants according to the SoA (Section 1.3). Authorized laboratories will assess 
serol ogic responses to AZD1222 by [CONTACT_859779] m negat ive to 
positive as defined by a validated immunoassay directed at the SARS -CoV -2 S antigen. The 
rate of asymptomat ic SARS -CoV -2 infection in participants receiving AZD1222 vs saline 
placebo will  be determined by [CONTACT_859780] a SARS -CoV -2 Nucleocapsid assay operated 
by [CONTACT_859781] . Serol ogic assessment to S, RBD, and N ucleocapsid antigens will 
also be assessed quant itatively using a validated mult iplexed MSD immunoassay.
[IP_ADDRESS] SARS -CoV -2 Neutralizing Antibody Assessments
Serum  samples to m easure SARS -CoV -2 neutralizing antibody  levels will be co llected fro m 
participants in the substudy  according to the timepoints specified in the SoA (Section 1.3). 
Authori zed l aboratori es will  measure neutralizing ant ibodies to SARS -CoV -2 using validated 
wild-type neutralizat ion assay  or pseudo -neutralization assays.
[IP_ADDRESS] Assessment of Mucosal Responses 
Nasal samples to evaluate SARS -CoV -2 antigen -specific antibody  responses in nasal 
secretions will be collected from part icipants in the substudy ,from participants enrolled in the 
immunogenicit y cohort ,and during illness visits according to the SoA (Section 1.3). Nasal  
adsorpti on specimens will be collected by  [CONTACT_859782] . Antibody  response s to SARS -CoV -2 S, RBD, and N ucleocapsid
antigens may be assessed in a qualified mult iplexed MSD immunoassay and stratified by 
[CONTACT_859783] (IgA, IgG, IgM).  
[IP_ADDRESS] Assessment of Cell-mediated Immune Responses
Cell-mediated immune responses (ie, B -cell and T -cell responses) will be assessed by 
[CONTACT_859784] T -cell ELISpot assays to 
SARS -CoV -2 antigens, flow cy tometry after intracellular cy tokine staining, single- cell RNA 
sequencing, B -cell and T -cell receptor sequencing, andother m ethodol ogy as determined by 
[CONTACT_1052]/or authorized laboratories. Data on Th1/Th2 po larization after AZD1222 
vaccination will be provided and may be reported separately fro m the CSR . Sam ples will  be 
collected from up to 300participants in the substudy , from approximately [ADDRESS_1198223] a 
positive SARS -CoV -2 RT -PCR result at timepoints specified in the SoA (Secti on1.3).
Addit ionally ,plasma will be iso lated fro m the whole blood samples co llected to iso late 
PBMCs ,which may be utilized for exploratory  immunogenicit y and bio marker analyses as 
outlined in Section 8.6.2 .
[IP_ADDRESS] Additional Serum Immunogenicity
Addit ional serum  samples for expl oratory  immunogenicit y evaluat ion will be obtained 
according to the SoA (Section 1.3). Serologic assessment to seasonal coronavirus ant igens 
will also be assessed quant itatively using a qualified mult iplexed MSD immunoassay , while 
anti-vector immune responses (ie ,ChAdOx1 neutralizing ant ibodyresponses) will 
characterize the induction of antibodies to the ChAdOx1 vector and the persistence of these 
antibodies over time .Exploratory  sera samples may  be utilized to investi gate addi tional 
humoral and cellular immune responses as well as potential correlates of protection as 
determined by [CONTACT_941] S ponsor and/or authorized laboratories based upon emerging safet y, 
efficacy ,and immunogenicit y data.
8.5.3 Pharmacodynamics
Pharmacodynamics are not evaluated in this study .
8.6 Human  Biological Sample Biomarkers
8.6.1 Collection of Mandatory Samples for Biomarker Analysi s
By [CONTACT_670100] , the parti cipant consents to participate in the 
mandatory  research components of the study .
Samples for bi omarker research are required and will be co llected fro m participants during 
illness visit s as specified i n the SoA (Section 1.3). Mi d-turbinate nasal and nasopharyngeal 
swabs will be co llected at site illness visits for virologic assessments. Saliva samples will be 
collected at site illness visits and by [CONTACT_859785] -collection period. These 
biomarker m easurements will support our understanding of potential correlates of protection, 
durati on of  immune responses, and correlat ions between immunogenicit y and reactogeni city. 
Details for sample co llection, processing, and testing will be provided in the Laboratory  
Manual.
Any results fro m such analyses may be reported separately fro m the CSR.
[IP_ADDRESS] Viro logic Assessments
Instructi ons for obtaining and processing mid -turbinate nasal swabs and nasopharyngeal swab 
samples are provided in the Laboratory  Manual . Mid -turbinate nasal and nasopharyngeal 
swabs will be assessed by  [CONTACT_859786] -PCR assays for the det ection of  SARS -CoV -2 by 
[CONTACT_155871] -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 68of 130local and central laboratories, respectively. Genotypic analysis o f the viral S protein will be 
perform ed by  [CONTACT_859787]. Addit ionally, a validated mult iplexed 
respi [INVESTIGATOR_859739] a central laboratory  operated on behalf of the Sponsor.
[IP_ADDRESS] Assessment of Viral Shedding
Viral shedding will be assessed in saliva samples collected using a Spectrum DNA 
(SDNA -1000) col lection kitor other saliva co llection devices at site illness visits or 
self-collected at home , by [CONTACT_859788]- PCR assay for the measurement of SARS -CoV -2. 
Collect ion of saliva sample for viral shedding is optional in non-[LOCATION_003] sites and may  occur 
after a feasibilit y assessment has been completed.
8.6.2 Other Stud y-related Biomarker Research
Already co llected samples may be analy zed for different bio markers thought to play a role in 
COVID -19 severit y or outcom es including, but not limited to serum , plasma or mucosal 
cytokines, quant ificat ion of RNA, micro -RNA, and/or non -coding RNA using quant itative 
RT-PCR , microarray , sequencing, or other technology  in blood , PBMCs, or mucosal  
specimens to evaluate their association wit h observed clinical responses to AZD1222. Other 
study -related bi omarker research excludes genet ic analysis.
For storage, re -use,and destruction of bio marker samples see Section 8.5. 
8.[ADDRESS_1198224] cas e of SARS -CoV -2 RT -PCR -positive symptom atic illness 
occurs ≥ [ADDRESS_1198225] second dose of study intervent ion.Otherwi se, a parti cipant is not 
defined as a COVID -19 case .VE will be calculated as 1 -relative risk, which is the incidence 
in the vaccine group r elative to the incidence in the control group. The null hypothesis is: VE 
is equal to 30%. Whereas, the alternat ive hypothesis is: VE is not equal to 30%. That is:
Null hypothesis: VE = 30%
Alternat ive hypothesis: VE ≠ 30%
Clinical Study Protocol -Amendment [ADDRESS_1198226] ion has 
been used to con trol the overall t ype I error at 5% with 0.31% alpha at the interim and 4.9% at 
the primary analysis . Atthe interim analysis ,the VE will be presented with a 2- sided 99.69% 
CI, and statist ical significance will be achieved if the 2 -sided 99.69% CI is >30%. The 
success criterion for the interim analysis will be stati stical significance wit h an observed VE 
point estimate of at least 50%. At the primary analysis VE will be presented with a 2 -sided 
95.10 % CI, and statist ical significance will be achiev ed if the 2-sided 9 5.10% CI is > 30%.
The success criterion for the primary analysis o f the study  will be statistical significance with 
anobserved VE point estimate of at least 50% .  
In the event that the results of the interim or primary  analysis are statist ically significant for 
the primary  efficacy endpoint, an addit ional analysis with 5% al pha will be performed once all 
participants have co mpleted their first year of fo llow up. 
9.2 Sample Size Determination
Approximately  [ZIP_CODE] parti cipants will be screened such that approximately  
30 000 participants will be rando mized in a 2:1 ratio to receive 2 IM doses of either 
5 × 1010vp (nominal , ± 1.5 × 1010vp) AZD1222 (the act ive group, n = approximately [ZIP_CODE]) 
or saline placebo (the con trol group, n = approximately 10 000) 4 weeks apart .
Note: ‘Enrolled ’ means a participant’s, or their legally acceptable representative’s, agreement 
to parti cipate in a clinical study  following com pletion of the informed consent process. 
Potenti al parti cipants who are screened for the purpose of determining eligibilit y for the study , 
but are not randomly assigned/assigned in the study, are considered ‘screen failures ’, unless 
otherwise specified by  [CONTACT_760] .
The sample size calculat ions are based on the primary  efficacy endpo int and were derived 
following a m odified Poisson regressio n approach (Zou 2004 ). The calculat ions account for an 
interim and primary  analysis, and the timing of these analyses will be driven by [CONTACT_859758] . The interim analysis will be carried out when approximately 
50% of the total amount of statistica l inform ation is available. A Lan-DeMets al pha-spending 
funct ion has been used to account for mult iplicit y, where the Ty pe I error at the interim and 
primary  analyses is with 0.31% al pha at the interim analysis and 4.9% at the primary analysis 
such that th e overall Type I error is controlled at 5%. The calculat ions assume minimal loss to 
follow-up as i t is ant icipated that participants will remain engaged in the study . All 
participant s will be fo llowed for the enti re durati on of  the study .
For the primary  efficacy analysis, approximately  [ADDRESS_1198227] a VE of 60% with > 90% power. The se 
Clinical Study Protocol - Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 70of 130calculat ions assume an observed attack rate of approximately  0.8% and are based on a [ADDRESS_1198228], where the lower bound of the 2 -sided 95.10% CI for VE is required to be greater than 
30% wi th an observed point estimate of at least 50%.
An interim effic acy analysis will be conducted when approximately [ADDRESS_1198229] been reported across the active and control groups 
within the popul ation of participants who are sero negative at baseline, which will give > 70% 
power to detect a VE of 70% and > 90% power to detect a VE of 75%. These calculat ions 
assume an observed attack rate of approximately 0.4% and are based on a [ADDRESS_1198230], where 
the lower bound of the 2 -sided 99.69% CI for VE is required to be greater t han 30% withan 
observed po int estimate of at least 50%. A statist ically significant finding at the interim 
analysis will not be considered a reason to stop the study , but instead will be interpreted as 
early  assessment of efficacy.
9.3 Populations for Analyse s
The fo llowing popul ations are defined:
Table [ADDRESS_1198231] 
one dose of s tudy interventio n.
Erroneously -treated participants (eg, those randomized to treatment A but were 
actually  given treatment B) are accounted for in this analysis set by [CONTACT_859789].
A participant who has on one or several occasions received active s tudy 
interventio nis classif ied as active for all summaries, including summaries by 
[CONTACT_2715].
Immunogenicity analysis setThe immunogenicity analysis population will include all participants in the 
safety analysis set who have no protocol deviations judged to have the 
potential to interfere with the generation or interpretation of an immune 
response. Examples of protocol viol ations will be documented in the Statistical 
Analy sis Plan.  
COVID -19 = coronavirus disease 2019 ; RT-PCR = reverse transcriptase polymerase chain reaction ; SARS -
CoV-2 = severe acute respi[INVESTIGATOR_7686] -coronavirus [ADDRESS_1198232] been observed for the 
primary  endpoint (see Section 9.2)within the populat ion ofparticipants who are seronegative
at baseline . All partici pants in the study  will be assessed for efficacy  and safet y for 2years 
following the first dose of study  intervent ion (Day  730). The final  DBL will occur when all 
participants have co mpleted the study .
This sect ion is a summary of the planned statist ical analyses of the most important endpoints, 
including primary  and key  secondary endpoints. A more technical and detailed descript ion of 
the stati stical analyses will be described in the SAP, and an approved versio n will be finalized
prior to the interim analyses (see Section 9.5).
All personnel invo lved in the analyses of the study will remain blinded until the primary  DBL 
and protocol deviat ions are ident ified, unless the DSMB determines that the efficacy  and 
safet y have been definit ively established during interim analysis . In this case, the DSMB will 
notify the Oversight Group who will then d etermine the course of act ion for the study , which 
may include unblinding personnel from the Sponsor or i ts representatives associated with the 
analyses and regulatory  submissi on of interim results .
Analyses will be performed by [CONTACT_859790].
Categorical variables will be summarized using frequency and percentages, where the 
deno minator for calculat ion is the underlying analysis set populat ion unless otherwise stated.
Clinical Study Protocol -Amendment [ADDRESS_1198233] deviat ion, median, minimum and maximum, and quartiles where 
more appropri ate.
All po int estimates will be presented together with a 95% CI, unless otherwise stated. 
P-values, corresponding to a [ADDRESS_1198234], will be presented for comparisons between 
treatm ents. Methods for controlling mult iplicit y across endpoints are discussed in 
Secti on9.4.4 .
9.4.1 General Considerations
The primary  efficacy  analysis will be based on the double -blind, placebo -controlled phase of 
the study , and will co mpare participants rando mized to receive 2 nominal doses of 5× 1010vp 
(± 1.5 × 1010vp) AZD1222 against participants rando mized to saline placebo.
The primary  estimand will  be used for the analysis of the primary  efficacy  endpoint. It will be 
based on participants in the fully vaccinated analysis set, defined as all rando mized 
participants who are seronegative at baseli ne, receive 2doses of study  interventi on, and who 
remain on -study  [ADDRESS_1198235] imand consists of 
participants who withdraw fro m the study  or are unblinded to treatment assignment prior to 
havin g met the primary  efficacy endpoint. The intercurrent event of early  study  withdrawal  
will be handled using the treatment policy strategy and the absence of data fo llowing these 
participants’ withdrawal will be treated as missing (ie, counted as not having met the criteria). 
Parti cipants unblinded to treatment assignment prior to having met the criteria for the primary  
efficacy  endpoint will be censored at the date of unblinding. Participants who wi thdraw before 
[ADDRESS_1198236] eristics will be summarized by [CONTACT_859791] , safet y analysis set ,and immunogenicit y analysis set . 
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 73of 1309.4.2 Efficacy 
An overview of the primary and secondary efficacy objectives, endpo ints,and the associated 
case definit ions is presented in Appendix F.
A blinded independent efficacy  adjudicati on commi ttee will review relevant data of potential  
cases for the COVID -19-related efficacy endpo intevaluat ions. More detail on this process 
will be provided in the SAP and the Efficacy Adjudicat ion Co mmittee Charter ( see also 
Appendix A 5).
[IP_ADDRESS] Primary Endpoint
The primary  endpoint is the first case of SARS -CoV -2 RT -PCR -posit ive symptomat ic illness 
occurring ≥ [ADDRESS_1198237] 
RT-PCR -confirmed SARS -CoV -2 and meet the fo llowing cri teria at any  point from  their 
initial illness visit at the site (Day  1) through thei r second illness visit (Day 14):
1One or m ore Category  A findings
OR
2Two or more Category  B findings
Category A:
Pneumo nia diagnosed by  [CONTACT_13190] x -ray, or computed tomography scan
Oxygen saturation of ≤ 94% on room  airor requi ring ei ther new init iation or escal ation in 
supplemental  O2
New or worsening dyspnea/shortness of breath
Category B:
Fever > 100 °F(> 37.8 °C) or feverishness
New or worsening cough
Myalgia/muscle pain
Fatigue that interferes with activities of daily living
Vomit ing and/or diarrhea (only one finding to be counted toward endpoint definit ion)
Anosmia and/or ageusia (only one finding to be counted toward endpoint definit ion)
The primary  efficacy  endpoint will be assessed at 2 milestones during the study , giving an 
interim analysis (see Section 9.5) and a primary analysis. The timing of these analyses will be 
driven by [CONTACT_859792] . The interim analysis will be carried out when approximately  
Clinical Study Protocol -Amendment [ADDRESS_1198238] been observed (see Section 9.2). A final analysis will also be 
carried out when all participants have co mpleted the 2-year study . However, the final analysis 
will not be con trolled for mult iplicit y and statisti cal hypotheses will  be tested at a nominal 
5% s ignificance l evel (based on a [ADDRESS_1198239]).
As the primary  efficacy analysis, the plan is to use the primary  estimand and a Poisson 
regression model with robust variance (Zou 2004 )to analyze the primary  efficacy  endpoint, 
includ ingstudy  arm and age as covariates as well as the log of the follow-up time as an offset . 
The VE will be est imated fro m the model, which will give the RRR in the incidence o f 
SARS -CoV -2 RT -PCR -posit ive symptomat ic illness. VE is calculated as 
RRR =100*(1 -relative risk), which is the incidence in the vaccine group r elative to the 
incidence in the control group expressed as a percentage. For the interim analysis the VE will 
be presented with a 2- sided 99.69% CI, and statistical significance will be achieved if the 
2-sided 99.69% CI i s > 30% . The success criterion for the interim analysis will be statist ical 
significance wi th an observed VE point estimate of at least 50%. At the primary analysis VE 
will be presented with a 2 -sided 95.10% CI, and statist ical significance will be achieved if the 
2-sided 95.10% CI i s > 30% . The success criterion for the primary analysis o f the study  will 
be stati stical significance wi th an observed VE point estimate of at least 50%.  The CI sare
based on a Lan-DeMets al pha-spending funct ion for [ADDRESS_1198240] y ear of fo llow up. For this analysis, VE will be prese nted wi th a 2-
sided 95% CI, and statistical significance will be achieved if the 2 -sided 95% CI is > 0%. 
Model  assumpt ions will be checked and the robustness of the primary analysis will be 
assessed. The Poisson regressio n model with robust vari ance has t he flexibilit y for expl oring 
multiple imputation approaches using, eg, the observed placebo attack rate to impute missing 
data. If the Poisson regressio n model with robust vari ance fails to converge, an alternative 
approach will be implemented. Full detail s will be docum ented in the SAP.
To support the primary  analysis, a Cox proporti onal hazard m odel will be fitted to the data as 
well as Kaplan -Meier curves presented for the active and control groups, showing the 
cumulative incidence of the first case of SARS -CoV -2 RT -PCR -posit ive symptomat ic illness 
occurring ≥ [ADDRESS_1198241] ics 
for the vaccine and control groups will also be produced. Full details will be documented in 
the SAP.
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 75of 1309.4.2.2 Secondary En dpoints
The set of secondary endpo ints include the fo llowing summary  measures, derived from binary  
outcom es:
Incidence of the first post-treatment response (negative at baseline to posit ive post 
treatm ent wi th study  intervent ion) for SARS -CoV -2 Nucl eocapsi d ant ibodies occurring 
≥ [ADDRESS_1198242] second dose of study  interventi on(key secondary  endpoint)
Incidence of the first case of SARS -CoV -2 RT -PCR-positive symptom atic illness 
occurring ≥ [ADDRESS_1198243] second dose of study  intervent ion using CDC criteria (see 
Secti on 8.1.1 for definit ion)
Incidence of the first case of SARS -CoV -2 RT -PCR-positive symptom atic illness
occurring ≥ [ADDRESS_1198244] one of the fo llowing symptom s
1 N ew onset of fever (> 100 °F [ > 37.8 °C]), OR 
2 C ough, OR 
3 S hortness o f breath, OR 
4 A nosmia/ageusia
Incidence of the first case of SARS -CoV -2 RT -PCR-positive symptom atic illness 
occurring ≥ [ADDRESS_1198245] ion (key secondary  endpoint)
Incidence of SARS -CoV -2 RT -PCR -posit ive severe or critical symptomat ic COVID -19 
occurring ≥ [ADDRESS_1198246] second dose of study  intervent ion (see Section 8.1.3 for 
definition)(key secondary  endpoint)
Incidence of SARS -CoV -[ADDRESS_1198247] dose of study  intervent ion
Incidence of COVID -19-related Emergency  Departm ent visi ts occurring ≥ [ADDRESS_1198248] 
second dose of study  intervent ion (key  secondary  endpoint)
Post-treatm ent GMTs and GMFRs fro m day of dosing baseline value to [ADDRESS_1198249] each 
dose in SARS -CoV -2 S, RBD antibodies (MSD serology  assay)
The proporti on of  parti cipants who have a post -treatment seroresponse ( ≥ 4-fold rise in 
titers from  day of dosing baseline value to [ADDRESS_1198250] each dose) to the S, RBD ant igens 
of AZD1222 (MSD serology  assay )
Post-treatm ent GMTs and GMFRs fro m day of dosing baseline value to [ADDRESS_1198251] each 
dose in SARS -CoV -2 neutralizing ant ibodies (wild -type assay  or pseudo -neutralizat ion 
assay)
Proporti on of  parti cipants who have a post -treatm ent seroresponse ( ≥ 4-fold rise in titers 
from day of dosing baseline value to [ADDRESS_1198252] each dose) to AZD1222 as measured by 
[CONTACT_7544] -CoV -2neutralizing ant ibodies ( wild-typeassay  or pseudo -neutralization assay)
The incidence of SARS -CoV -[ADDRESS_1198253] variance (Zou 
2004 ), includ ingstudy  arm and age as covariate s according to the hierarchical approach for 
multiplicit y protecti on (refer to Section 9.4.4 ). 
For non -key secondary  endpoints, the same methodology  outlined for the primary  endpoint 
will be applied however the RRR will be est imated fro m each m odel, with a corresponding 
95% CI. A p- value, corresponding to a [ADDRESS_1198254] ics will be produced 
for the vaccine and control groups. Full details wil l be documented in the SAP.
To assess immune response, the set of secondary  endpoints al so includes:
Post-treatm ent GMTs and GMFRs fro m dayof dosing baseline valu es to [ADDRESS_1198255] 
each dose in SARS -CoV -2 S, RBD antibodies (MSD serology  assay)
Proporti on of  parti cipants who have a post -treatm ent seroresponse ( ≥ 4-fold rise in titers 
from day of dosing baseline value sto [ADDRESS_1198256] each dose ) to the S, RBD antigens of 
AZD1222 (MSD serology  assay )
Post-treatm ent GMTs and GMFRs fro m day of dosing baseline value sto [ADDRESS_1198257] 
each dose in SARS -CoV -2 neutralizing ant ibodies (wild -type assay or 
pseudo -neutralizat ion assay)
Proporti on of  parti cipants who have a post -treatm ent seroresponse ( ≥ 4-fold rise in titers 
from day of dosing baseline value to [ADDRESS_1198258] each dose ) to AZD1222 as measured by 
[CONTACT_7544] -CoV -2 neutralizing ant ibodies (wild -type assay  or pseudo -neutralization assay)
The proporti on of  parti cipants who have a post -treatment seroresponse to the S and RBD 
antigens of AZD1222 will be deri ved for the vaccine and control groups, with corresponding 
95% Cl opper -Pearson exact CIs. Similarly, the proportion of participants who have a 
post-treatm ent seroresponse to AZD1222 as measured by  [CONTACT_7544] -CoV -2 neutralizing 
antibodies will be derived for the vaccine and control groups, with corresponding 
95%Clopper-Pearson exact CIs.  
The GMT and GMFR endpo ints will be analysed on the log (base 2) scale by [CONTACT_859793] (ANOVA) models, and will include study  arm and age as categorical covaria tes.  
On the l og scal e, the m odels will  be used to estimate a mean response for the vaccine and 
control  groups and the difference (vaccine -control), wi th corresponding 95% confidence 
limits. These values will then be back -transform ed to give geom etric me ans f or the vaccine 
and control groups and a ratio of geometric means (vaccine/control), with corresponding 
95%confidence limit s. A p- value, corresponding to a [ADDRESS_1198259] the control. The p -value will be no minal as secondary endpo ints 
are not controlled for mult iplicity.
To support these analyses, descriptive statistics will be produced for the vaccine and control 
groups. Full details will be documented in the SAP.
[IP_ADDRESS] Exploratory Endpoints
Full details o f the analyses for the exploratory  endpoints will be specified in the SAP. 
9.4.3 Safety
[IP_ADDRESS] Primary Endpoints
Overview
The safet y of AZD1222 will primarily  be assessed by:
Incidence of AEs for28 day s post each dose of study  intervent ion
Incidence of SAEs from Day [ADDRESS_1198260] treatment through Day 730
Incidence of MAAE (defined in Sect ion 8.3.8 ) and AESIs (defined in Sect ion 8.3.9 ) from 
Day [ADDRESS_1198261] treatm ent through Day  730
Incidence of local and systemic so licited AEs for [ADDRESS_1198262] each dose of study  
intervent ion
AEseverit ywill be graded according to the US FDA guidance (FDA 2007 )andcoded using 
the most recent versi on of  the Medical Dict ionary for Regul atory  Activit ies. AEs will be 
presented for each treatment group by  [CONTACT_103467]. Summaries will 
include the number and percentage of participants reporting at least one event, number of 
events and exposure adjusted rates, where appropriate.
An overview of AEs will be presented for each treatment group, including the number and 
percentage of participants with any AE and SAEs . Summari es will present the relat ionship to 
study  interventi on as assessed by  [CONTACT_17062], maximum intensit y, seriousness, and death.
A listing will cover details for each individual AE. Full details of all AE analyses will be 
provi ded in the SAP , including intercurrent events for safet y due to potenti al unblinding of 
participants for administration of licensed and/or approved SARS -CoV -2 or COVID -19 
vaccine .
[IP_ADDRESS] Other Safety Endpoints
Vital Signs
For SARS -CoV -2-positive participants , vital sign measur ements will be performed as 
specified in the SoA (Section 1.3). The set of assessments will include pulse oximetry , blood 
pressure, and body  temperatu re.  
Clinical Study Protocol -Amendment [ADDRESS_1198263] ion has been used to account for mult iplicity of the primary  endpoint across the 
2 time po ints, with 0.31% alpha at the interim analysis and 4.9% at the primary analysis. Thus, 
the interim and primary  analyses will  present estimates with 2- sided 99.69 %and 95.10% CIs, 
respectively , and stati stical significance will be achieved if the 2 -sided CIs are > 30%. At the 
interim or primary  analysis, the success criterion for the study  will be stati stical significance 
with an observed VE point estimate of at lea st 50%. If the primary  endpoint achieves 
statist ical significance at the 0.31% level at the interim (or at the 4.9% level at the primary ), a 
hierarchical approach will be used to control for mult iplicity of the primary  and key  secondary  
efficacy  endpoints. That i s, the null hypotheses for these efficacy  endpoints will  be tested in a 
hierarchical order, and the subsequent null hypothesis will be tested at a significance level o f 
0.31% or 4.9% (2 -sided), at the interim and primary analysis, respect ively, only if the pri or 
null hypothesis is rejected.
A formal assessment of the key  secondary efficacy endpo ints at the interim or primary will 
only be conducted if the statist ical significance of the primary  efficacy endpoint is 
demonstrated at 2 -sided al pha of 0.3 1% at the interim or 4.9% at the primary  analysis. Wit h 
that, the overall Ty pe I error i s controlled at 0.05. Therefore, no further mult iplicit y 
adjustm ent is necessary.
The testing strategy  at the interim analysis or primary  analysis will be as fo llows:
Step 1 :
1Interim analysis: Perform the test of primary  endpoint wi th 0.31% al pha l evel. If the 
2-sided 99.69% CI i s > 30% wi th VE point estimate ≥ 50%, then proceed to Step 2. 
Otherwi se no null hypothesis is rejected for the interim analysis.
2Primary analysi s: Perform  the test of primary endpoint with 4.9% alpha level. If the 
2-sided 95.10% CI i s > 30% wi th VE point estimate ≥ 50%, then proceed to Step 2. 
Otherwi se no null hypothesis is rejected for the primary  analysis.
Step 2: 
1Interim analysis: Test the 4 key secondary endpo intsat the significance level of 0.31% 
using hierarchical fixed -sequence testing in the order below. If the 2-sided 99.69% CI i s 
> 0%, then proceed to the next endpoint. 
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 79of 1302Primary analysis: Test the 4 key  secondary  endpoint sat the significance l evel of 4.9% 
using hierarchical fixed -sequence testing in the order below. If the two -sided 95.10% CI 
is > 0%, then proceed to the next endpoint. 
(a)Key Secondary  Endpoint 1: Inci dence of the first case of SARS -CoV -2 RT -PCR -
positive symptom atic illness occurring ≥ [ADDRESS_1198264] ion.
(b)Key Secondary  Endpoint 2: Inci dence of the first case of SARS -CoV -2 RT -PCR -
positive severe or crit ical symptom atic COVID -19 occurring ≥ [ADDRESS_1198265] second 
dose of study  intervent ion.
(c)Key Secondary  Endpoint 3: Inci dence of COVID -19-related E mergency Departm ent 
visits occurring ≥ [ADDRESS_1198266] second dose of study  intervent ion.
(d)Key Secondary  Endpoint 4: Inci dence of the first post -treatm ent response (negative at 
baseline to posit ive post treatment with study intervent ion) for SARS -CoV -2 
Nucleocapsid ant ibodies occurring ≥ [ADDRESS_1198267] y ear of  follow up. This analysis 
will use the same testing strategy  described above for primary and key  secondary  endpoints, 
with a 5% al pha level.
9.4.[ADDRESS_1198268] of subgroups includes, but may not be limited to: gender ,age,and serostatus at baseline . 
Full details o f all subgroup analyses will be described in the SAP, including hypotheses that 
will be tested and the covariates and interaction terms to be included in the statist ical models.
9.[ADDRESS_1198269] ion [IP_ADDRESS] will be carried out by  
[CONTACT_25963] -[ADDRESS_1198270] been reported across the 
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 80of 130active and control groups (ie, when approximately 50% of the total amo unt of statistical 
inform ation is available) within the popul ationof parti cipants who are seronegative at 
baseline . A stati stically significant finding at the interim analysis (ie, 2-sided 99.69 % CI is 
> 30% ) will not be considered a reason to stop the st udy, but instead will be interpreted as 
early assessment of efficacy. The SAP will describe the planned interim analyses in greater 
detail.
9.[ADDRESS_1198271] of the study . During the study , the benefit/ri sk assessment will be continuously 
monitored by  [CONTACT_25963] -19 Vaccine DSMB to ensure that the balance remains favorable. 
Further details, composit ion, and operati on of  the COVID -19 Vaccine DSMB will be 
described in a separate COVID -19 Vaccine DSMB charter.
For details on the COVID -19 Vaccine DSMB, refer to Appendix A 5.
10 SUPPORTING DOCUMENTA TION AND OPERATIONAL
CONSIDERATIONS
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 81of 130Appendix ARegulatory, Ethical, and Study Oversight Considerations
A 1 Regulatory and Ethical Considerations
This study  will be conducted in accordance wit h the protocol and with the fo llowing:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizat ions of Medical 
Sciences Internat ional Ethical Guidelines
Applicable ICH GCP Guidelines
Applicable laws a nd regulations
The protocol, protocol amendments, ICF, IB, and other relevant documents 
(eg,advertisements) must be submitted to an IRB/IEC by [CONTACT_317791]/IEC before the study  is initiated.
Any amendments to the protocol will require IRB/IEC and applicable Regulatory  
Authori ty approval  before implementati on of  changes m ade to the study  design, except 
for changes necessary  to eliminate an immediate hazard to study  parti cipants.
The Sponsor will be responsible for o btaining the required authorizat ions to conduct the 
study  from the concerned Regulatory  Authori ty. This responsibilit y may be delegated to a 
CRO but the accountabilit y remains wi th the Sponsor.
The invest igator will be responsible for providing oversight o f the conduct of the study  at 
the site and adherence to requirements of 21 CFR, ICH guidelines, the IRB/IEC, 
European Regulation 536/2014 for clinical studies (if applicable), European Medical 
Device Regulation 2017/745 for clinical device research (if app licable), and all Food and 
Drug Administration (FDA) Regulat ions, as applicable and all other applicable local 
regul ations
Regulatory Reporting Requirements for SAEs
Prom pt notificat ion by [CONTACT_859794] l egal 
obligat ions and ethical responsibilit ies towards the safet y of parti cipants and the safet y of 
a study  intervent ion under clinical invest igation are m et.
The Sponsor has a legal responsibilit y to notify  both the l ocal regulatory  authori ty and 
other regul atory  agencies about the safet y of a study  intervent ion under clinical 
investigat ion. The Sponsor will co mply wi th country -specific regulatory  requi rements 
relating to safet y reporting to the regulatory  authorit y, IRBs/IECs, and investigators.
For all stud ies except those utilizing medical devices, invest igator safet y reports must be 
prepared for suspected unexpected serious adverse reactions (S[LOCATION_003]R) according to local 
regul atory  requi rements and Sponsor policy and forwarded to invest igators as necessary.
European Medical Device Regulat ion 2017/745 for clinical device research (if 
applicable), and all other applicable local regulat ions
An invest igator who receives an invest igator safety report describing an SAE or other 
specific safet y informat ion (eg, summa ry or list ing of SAEs) fro m the Sponsor will 
Clinical Study Protocol -Amendment [ADDRESS_1198272] igator’s Brochure andwill notify  the IRB/IEC, 
if appropriate according to local requirements.
A [ADDRESS_1198273] igator or his/her representative will explain the nature of the study to the participant 
or his/her l egally authori zed representative and answer all questions regarding the study .
Parti cipants m ust be inform ed that thei r parti cipat ion is vo luntary and they  are f ree to 
refuse to participate and may wit hdraw their consent at any  time and for any  reason 
during the study . Partici pants or thei r legally  authori zed representative will be required to 
sign a statem ent of  inform ed consent that meets the requirements of [ADDRESS_1198274] 
requi rements, where applicable, and the IRB/IEC or study  center.
Thestudy medical record must include a statement that written informed consent was 
obtained before the participant was enro lled in the study and the date the written consent 
was obtained. Th e authori zed person obtaining the informed consent must also sign the 
ICF.
Parti cipants m ust be re -consented to the most current version of the ICF(s) during their 
participat ion in the study if required by [CONTACT_1201] .
A copy  of the ICF(s) m ust be provi ded to the participant or the participant’s legally 
authori zed representative.
Parti cipants who are rescreened are required to sign a new ICF.
The ICF will contain a separate section that addresses and documents the collect ion and use of 
any mandatory  and/or opt ional human bio logical  sam ples. The invest igator or authorized 
designee will explain to each participant the objectives of the analysis to be done on the 
samples and any potential future use. Participants will be told that they  are free to refuse to 
participate in any optional samples or the future use and may wit hdraw their consent at any  
time and for any  reason during the retention period. 
A 4 Data Protection
Parti cipants will be assigned a unique ident ifier by [CONTACT_1034]. Any participant records 
or datasets that are transferred to the Sponsor will contain the ident ifier only; part icipant 
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C0000 1
CONFIDENTIAL AND PROPRIETARY 83of 130names or any  information which would make the participant ident ifiable will not be 
transferred.
The parti cipant must be inform ed that hi s/her personal  study -related data will be used by  
[CONTACT_9324]. The level of disclo sure and use 
of their data m ust al so be explained to the participant in the informed consent. 
The parti cipant must be inform ed that hi s/her m edical  records m ay be examined by 
[CONTACT_17080] y Assurance auditors or other authorized personnel appo inted by  [CONTACT_429], by  [CONTACT_17081]/IEC m embers, and by  [CONTACT_720487].
A 5 Committee Structure
The safet y of all Sponsor clinical studies is closely m onitored on an ongoing basis by [CONTACT_325410] y. Issues ident ified will be addressed; for 
instance, this could invo lve amendments to the Clinical Study Protocol and letters to 
investigators. 
A PSRT com prised of Sponsor, COVID- [ADDRESS_1198275] 
the responsibilit y of evaluat ing cumulat ive safet y and other clinical stu dy data at regular 
intervals and m aking appropri ate recommendat ions based on the available data. During the 
study , the benefi t/risk assessment will be cont inuously mo nitored by  [CONTACT_25963] -19 Vaccine 
DSMB to ensure that the balance remains favorable. For exa mple, events of potential 
vaccine -associated enhanced respi[INVESTIGATOR_859740] -19 cases by [CONTACT_4318] . Harm  for severe COVID -19 cases is any VE ≤0 for which 
Fisher’s exact test (1 -sided) is statist ically significant at the 5% level . This assessment will 
begin after [ADDRESS_1198276] accrued in the study and will be performed in 
real time as events occur . Harm monitoring will include all COVID -19 cases and all severe 
COVID -19 cases fro m Day 1 for parti cipants in the full analysis set. Harm monitoring for 
overall COVID -19 cases will use the same boundary  as severe COVID- 19 cases (ie, VE ≤0 
for which Fisher’s exact test [1-sided]is statist ically significant at the 5% l evel) but will  be 
perform ed on a week ly basis. Full details of the COVID- [ADDRESS_1198277] about t he diagnosis and 
causalit y assessment of selected neurological AESIs occurring in the AZD1222 clinical 
development program. Details on the composit ion and operati on of  this committee are 
described in the Neurological AESI Exp ert Committee Charter. 
A blinded independent efficacy adjudication co mmittee will review rel evant data of potential 
cases for the COVID -19-related efficacy endpo int evaluat ions. More detail on this process 
will be provided in the SAP and the Efficacy Adju dication Co mmittee Charter .
A 6 Dissemination of Clinical Study Data
A descript ion of this clinical study  will be available on 
http://astrazenecagrouptrials.pharmacm.com and http://www.clinicaltrials.gov as will the 
summary of the study  resul ts when they  are a vailable. The clinical study  and/or summary of 
study  resul ts may  also be available on other websit es according to the regulations of the 
countri es in which the study  is conducted.
A 7 Data Quality Assurance
All participant data relat ing to the study  will be re corded on eCRF unless transmitted to 
the Sponsor or designee electronically  (eg, l aboratory  data). The invest igator is 
responsible for verifying that data entries are accurate and correct by  [CONTACT_122642].
The invest igator must maintain a ccurate docum entati on (source data) that supports the 
inform ation entered in the eCRF.
The invest igator must permit study -related m onitoring, audi ts, IRB/IEC review, and 
regul atory  agency inspecti ons and provi de di rect access to source data documents.
Moni toring details describing strategy  (eg, risk -based init iatives in operations and qualit y 
such as Risk Management and Mit igation Strategies and Analyt ical Risk-Based 
Moni toring), m ethods, responsibilit ies and requirements, including handling of 
nonco mpliance issues and m onitoring techniques (central, remote, or on -site monitoring) 
are provided in the relevant study  plans.
The Sponsor or designee is responsible for the data management of this study  including 
qualit y checking of the data.
The Sponsor assumes a ccountabilit y for acti ons delegated to other individuals 
(eg,Contract Research Organizat ions).
Study  monitors will perform  ongoing source data verification to confirm that data entered 
into the eCRF by [CONTACT_1191], complete, and verifiable fro m 
source documents; that the safet y and ri ghts of  participants are being protected; and that 
the study  is being conducted in accordance with the currently approved protocol and any 
other study  agreem ents, ICH GCP, and all applicable regulato ry requi rements.
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 85of 130Records and documents, including signed ICFs, pertaining to the conduct of this study  
must be retained by [CONTACT_41176] [ADDRESS_1198278] itutional policies requi re a l onger retenti on pe riod. No records m ay be 
destroy ed during the retention period without the written approval of the Sponsor. No 
records m ay be transferred to another location or party  without wri tten notificat ion to the 
sponsor.
A 8 Source Documents
Source documents provide evidence for the existence of the participant and substantiate 
the integrit y of the data collected. Source documents are filed at the invest igator’s site.
Data entered in the eCRF that are transcribed from source documents must be consistent 
with the sourc e documents or the discrepancies must be explained. The investigator may 
need to request previous medical records or transfer records, depending on the study. 
Also, current medical records must be available.
A [ADDRESS_1198279] igator may include but are 
not limited to:
Failure of the invest igator to comply wit h the pr otocol , the requi rements of the IRB/IEC 
or local health authori ties, the Sponsor's procedures, or GCP guidelines
Inadequate recruit ment of parti cipants by  [CONTACT_17062]
Discontinuati on of  further study  intervent ion developm ent
If the study  is prem ature ly terminated or suspended, the Sponsor shall prompt ly inform the 
investigators, the IECs/IRBs, the regulatory  authorit ies, and any contract research 
organi zation(s) used in the study  of the reason for terminat ion or suspensio n, as specified by 
[CONTACT_859795]. The invest igator shall pro mptly inform the participant 
and should assure appropr iate parti cipant therapy  and/or foll ow-up.
Clinical Study Protocol -Amendment [ADDRESS_1198280] the opportuni ty to be transferred to another site to 
continu e the study .
A 10 Publication Policy
The results of this study  may be published or presented at scient ific meet ings. If this is 
foreseen, the invest igator agrees to submit all manuscripts or abstracts to the Sponsor 
before submissio n. This allows the Sponsor to protect proprietary information and to 
provi de comments.
The Sponsor will co mply with the requi rements for publicat ion of study  resul ts. In 
accordance with standard editorial and ethical practice, the Sponsor will generally support 
publicat ion of mult icenter studi es only  in thei r entirety  and not as individual site data. In 
this case, a coordinat ing invest igator will be designated by [CONTACT_11402].
Authorship will be determined by  [CONTACT_73008] h Internat ional 
Committee of Medical Journal  Editors authorship requirements.
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 87of 130Appendix BAdverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
B [ADDRESS_1198281] a causal 
relationship with this treatment. An AE can therefore be any unfavorable and unintended sign 
(eg, an abnormal laboratory  finding), symptom (for example nausea, chest pain), or disease 
temporally  associ ated wi th the use of a m edicinal product, whether or not considered related 
to the m edicinal product. 
The term  AE is used to include both SAEs and non -SAEs and can include a deterioration of a 
pre-exist ing medical occur rence. An AE may occur at any  time, including run -in or washout 
periods, even if no study  intervent ion has been administered.
B 2 Definition of Serious Adverse Events
An SAE is an AE occurring during any study  phase (i e, run -in, treatment, washout, 
follow-up),that fulfils one or more of the following criteria:
Results in death
Is immediately life -threatening
Requi res in -partici pant hospi [INVESTIGATOR_325352] 
Results in persistent or significant disabilit y or incapaci ty 
Is a c ongeni tal abnorm ality or bi rth defect
Is an important medical event that may jeopardize the participant or may require medical 
treatm ent to prevent one of the outcomes listed above.
AEs for malignant tumors reported during a study  should generally be asse ssed as SAEs . If 
no other seriousness criteria apply, the ‘Important Medical Event’ criterion should be used. In 
certain situat ions, however, medical judgement on an individual event basis should be applied 
to clarify  that the m alignant tum or event shoul d be assessed and reported as a non-SAE . For 
example, if the tumor is included as medical history and progression occurs during the study , 
but the progression does not change treatment and/or prognosis of the malignant tumor, the 
AE m ay not fulfil the attrib utes for being assessed as serious, although reporting o f the 
progression of the malignant tumor as an AE is valid and should occur. Also, some types of 
malignant tumors, which do not spread remotely after a routine treatment that does not require 
hospi [INVESTIGATOR_059], m ay be assessed as non -serious; exam ples in adul ts include Stage 1 basal cell 
carcino ma and S tage 1A1 cervical cancer removed via cone biopsy.
Clinical Study Protoco l -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 88of 130Life Threatening
‘Life -threatening’ means that the participant was at immediate risk of death from the A E as i t 
occurred or it is suspected that use or continued use of the study  intervent ion would result in 
the participant’s death. ‘Life -threatening’ does not mean that had an AE occurred in a more 
severe form it might have caused death (eg, hepatitis that r esolved wi thout hepat ic failure).
Hospi[INVESTIGATOR_33093], although the reasons for it 
may be (eg, bronchospasm, laryngeal oedema). Hospi[INVESTIGATOR_33094]/or surgical operations 
planned before or d uring a study are not considered AEs if the illness or disease existed before 
the participant was enro lled in the study , provi ded that i t did not deteriorate in an unexpected 
way during the study .
Important Medical Event or Medical Treatment
Medical and sc ientific judgement should be exercised in deciding whether a case is serious in 
situations where important m edical events may  not be immediately life threatening or result in 
death, hospi [INVESTIGATOR_3094], disabilit y, or incapacit y but may jeopardize the particip ant or m ay 
requi re medical treatm ent to prevent one or more outcomes listed in the definit ion of seri ous. 
These should usually be considered as serious.
Simply stoppi[INVESTIGATOR_33095]; medical 
judgement must be used. 
Examples of important medical events include such events as listed below:
Angioedema not severe enough to require intubation but requiring iv hydrocortisone 
treatm ent
Hepatotoxicit y caused by [CONTACT_475140] 
N-acetylcysteine
Intensive treatment in an emergency room or at home for allergic bronchospasm
Blood dy scrasias (eg, neutropenia or anaemia requiring blood transfusion, etc.) or 
convulsio ns that do not result in hospi[INVESTIGATOR_72913]
Development of drug dependency or drug abuse
Intensity Rating Scale
The grading scales found in the US FDA guidance for healt hy vo lunteers enro lled in a 
prevent ive vaccine clinical study  (FDA 2007 )will be utilized for all events with an assigned 
severit y grading. 
It is important to dist inguish between serious and severe AEs. Severit y is a measur e of 
intensity whereas seri ousness is defined by [CONTACT_73010] B 2. An AE of severe 
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 89of 130intensity need not necessarily be considered serious . For example, nausea that persists for 
several hours may  be consi dered severe nausea, but not a nSAE unless it meets the criteria 
shown in Appendix B 2. On the other hand, a stroke that results in only a limited degree of 
disabili ty may be considered a mild stroke but would be a nSAE when i t satisfies the cri teria 
shown in Appendix B 2.
B 3 A Guide to Interpreting the Causality Question
When making an assessment of causalit y consi der the foll owing f actors when deciding if there 
is a ‘reasonable possibilit y’that an AE m ay have been caused by [CONTACT_2203].
Time Course. Exposure to suspect drug. Has the participant actually received the suspect 
drug? Did the AE occur in a reasonable temporal relat ionship to the administration of the 
suspect IMP?
Consistency wit h known IMP profile. Was the AE consistent with the previous 
knowl edge of the suspect IMP (pharmaco logy and toxi cology) or drugs of the same 
pharmaco logical class? Or could the AE be ant icipated from its pharmaco logical 
properties?
De-challenge experience. Did the AE resolve or improve on stoppi[INVESTIGATOR_33096] r educing the dose 
of the suspect IMP?
No al ternative cause. The AE cannot be reasonably explained by [CONTACT_73011], other drugs, other host or environmental factors.
Re-challenge experi ence. Di d the AE reoccur if the suspe cted IMP was reintroduced after 
having been stopped? [COMPANY_008] would not normally reco mmend or support a 
re-challenge .
Laboratory  tests. A specific laboratory  invest igation (if performed) has confirmed the 
relationship .
In difficult cases, other factors could be considered such as:
Is this a recogni zedfeature of overdose of the IMP?
Is there a known mechanism?
Causalit y of ‘related’ is m ade if fo llowing a review of the relevant data, there is evidence for a 
‘reasonable possibilit y’of a causal relation ship for the individual case. The expressio n 
‘reasonable possibilit y’ of acausal relationship is meant to convey, in general, that there are 
facts (evidence) or arguments to suggest a causal relat ionship.
The causalit y assessment i s perform ed based on the available data including enough 
inform ation to m ake an informed judgment. With no available facts or arguments to suggest a 
causal relat ionship, the event(s) will be assessed as ‘not related’.
Clinical Study Protocol -Amendment [ADDRESS_1198282] shoul d be classified as no reasonable possibilit y.
B 4 Medication Error
For the purposes of this clinical study  a medicat ion error is an unintended failure or mistake in 
the treatment process for an [COMPANY_008] study  intervention that either causes harm to the 
participant or has the potential to cause harm to the participant. 
A medicat ion error is not lack of efficacy o f the IMP, but rather a human or process related 
failure while the IMP is in control of the study  site staf f or parti cipant.
Medicat ion error includes situat ions where an error. 
Occurred
Was i dentified and intercepted before the participant received the IMP
Did not occur, but circumstances were recognised that could have led to an error
Examples of events to be reported in clinical studies as medication errors:
IMP name [CONTACT_33165] n
Dispensing error eg, medication prepared incorrectly , even if i t was not actually  given to 
the participant
IMP  not administered as indicated, for example, wrong route or wrong site o f 
administration
IMP not taken as indicated eg, tablet disso lved in water when it should be taken as a solid 
tablet 
IMP not stored as instructed eg, kept in the fridge when it should be at room temperature 
Wrong participant received the medicat ion (exclu ding IRT errors)
Wrong IMP administered to participant (excluding IRT errors)
Examples of events that do not require reporting as medicat ion errors in clinical studies:
Errors related to or resulting fro m IRT -including those which lead to one of the abo ve 
listed events that would otherwise have been a medicat ion error 
Parti cipant acci dentally  missed IMP dose(s) eg, forgot to take medicat ion
Accidental  overdose (will be captured as an overdose)
Errors related to background and rescue medicat ion, or stand ard of care m edicat ion in 
open l abel studi es, even if an [COMPANY_008] product 
Medicat ion errors are not regarded as AEs but AEs may  occur as a consequence of the 
medicat ion error.
Clinical Study Protocol -Amendment [ADDRESS_1198283] igator at each study  site keeps full traceabilit y of collected bi ological samples from 
the participants while in storage at the study  site unt il shipment or di sposal  (where 
appropriate) and records relevant processing informat ion related to the sam ples whilst at si te.
The sample receiver keeps full traceabilit y of the sam ples while in storage and during use unt il 
used or disposed of or until further shipment and keeps record of receipt o f arrival and onward 
shipment or disposal.
The Sponsor or delegated representatives will keep oversight of the ent ire life cycle through 
internal  procedures, m onitoring of study  sites, auditing or process checks, and contractual 
requi rements of external la boratory  provi ders
Samples retained for further use will be stored in the [COMPANY_008]- assigned biobanks or other 
sample archive facilit ies and will be tracked by  [CONTACT_670784].
C 2 Withdrawal of Informed Consent for Donated Biological Samples 
The Sponsor ensures that bio logical samples are destroy ed at the end of a specified period as 
described in the informed consent.
If a participant withdraws consent to the use of donated bio logical  samples, the samples will 
be disposed of/destroy ed/repatriated, and the action documented. If samples are already  
analyzed ,the Sponsor is not obliged to destroy  the resul ts of this research.
Following wi thdrawal  of consent for bio logical samples, further study  partici pation shoul d be 
considered in relat ion to the wi thdrawal  processes .
The invest igator:
Ensures participant’s withdrawal of informed consent to the use of donated samples is 
highlighted immediately to the Sponsor or delegate.
Ensures that relev ant human bio logical samples from  that parti cipant, if stored at the 
study  site, are immediately  identified, disposed of as appropriate, and the action 
docum ented.
Ensures that the participant and the Sponsor are informed about the sample disposal.
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C000 01
CONFIDENTIAL AND PROPRIETARY 92of 130The Sponsor ensures the organization(s) ho lding the samples is/are informed about the 
withdrawn consent immediately and that samples are disposed of or repatri ated as appropriate, 
and the action is documented and study  site is notified.
C [ADDRESS_1198284] SAMPLES
International Airline Transportation Associat ion (IATA) 
(https://www.iata.org/whatwedo/cargo/dgr/Pages/download.aspx ) classifies infect ious 
substances into 3 categori es: Category  A, Category B or Exempt
Category A Infectious Substances are infect ious substances in a form that, when exposure to 
it occurs, i s capable of causing permanent disabilit y, life-threatening or fatal  disease in 
otherwi se healt hy humans or animals . 
Category A Pathogens are, eg, Ebola, Lassa fever virus. Infect ious substances meet ing these 
criteria which cause disease in humans or both in humans and animals must be assigned to 
UN2814. Infect ious substances which cause disease only in animals must be assigned to 
UN2900.
Category B Infectious Substances are infect ious Substances that do not meet the criteria for 
inclusio n in Category  A. Category  B pathogens are, eg, Hepatitis A, C, D, and E viruses. They  
are assigned the fo llowing UN number and proper shippi[INVESTIGATOR_72919]:
UN 33 73 – Biological Substance, Category  B
are to be packed in accordance with UN [ADDRESS_1198285] to these R egulati ons unless they  
meet the criteria for inclusio n in another class.
Clinical study samples will fall into Category  B or exempt under IATA regulat ions
Clinical study  samples will routinely  be packed and transported at ambient temperature in 
IATA 650 co mpliant packaging 
(https://www.iata.org/whatwedo/cargo/dgr/Documents/DGR -60-EN-PI650.pdf).
Biological samples transported in dry  ice requi re addi tional dangerous goods specificat ion 
for the dry -ice content
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 93of 130Appendix DToxicity Grading Scales for Solicited Adverse Eve nts
The toxi city grading scales for the solicited AEs were modified and abridged from the 
USFDA Guidance on Toxicit y Grading Scale for Healthy Adult and Adolescent Volunteers 
Enrolled in Prevent ive Vaccine Clinical Trials (FDA 2007 ).
Table 10: Clinical Abnormalit ies, Local React ions to Inj ectable Product
Table 11: Clinical Abnormalit ies, Vital Signs
Table 12: Clinical Abnormalit ies, Sy stemic (Genera l or Illness)
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 94of 130Table 10 Tables for Clinical Abnormalities: Local Reactions to Injectable 
Product
Local Reaction to 
Injectable ProductReaction Grade
Mild 
(Grade 1)Moderate
(Grade 2)Severe 
(Grade 3)Life Threatening 
(Grade 4)
PainDoes not interfere 
with activityRepeated use of 
non-narcotic pain 
reliever > 24 hours 
or interferes with 
activityAny use of narcotic 
pain reliever or 
prevents daily 
activityER visit or 
hospi[INVESTIGATOR_859741]/redness a, b 1-2 inches
(2.5–5 cm)> 2-4 inches
(5.1–10 cm)> 4 inches
(> 10 cm)Necrosis or 
exfoliative 
dermatitis
Induration/swelling a, b 1-2 inches
(2.5–5 cm)>2-4 inches
(5.1–10 cm)> 4 inches
(> 10 cm)Necrosis
aIn addition to grading the measured local reaction at the greatest single diameter, the measurement should 
be recorded as a continuous variable. Reactions < 0.25 inches(< 0.6 c entimeters ) in diame ter will not be 
recorded.
bGrade 4 erythema or induration is determined by [CONTACT_859796] e-Diary .
ER = emergency room.
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 95of 130Table 11 Tables for Clinical Abnormalities: Vital Signs 
Vital Sign aVital Signs Grade
Mild 
(Grade 1)Moderate
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening (Grade 4)
Fever ( °C)b
(°F) b37.9-38.4
100.1 -101.138.5-38.9
101.2 -102.039.0-40
102.1 -104> 40
> 104
Tachycardia 
(beats/minute)101-115 116- 130 > 130ER visit or 
hospi[INVESTIGATOR_859742] 
(beats/minute) c 50-54 45-49 < 45ER visit or 
hospi[INVESTIGATOR_859743];  systolic 
(mm Hg)141-150 151-155 > 155ER visit or 
hospi[INVESTIGATOR_624647]; diastolic 
(mm Hg)91-95 96-100 > 100ER visit or 
hospi[INVESTIGATOR_624648]; systolic 
(mm Hg)85-89 80-84 < 80ER visit or 
hospi[INVESTIGATOR_859744] 
(breaths/minute)17-20 21-25 > 25 Intubatio n
Note: Record vital signs as adverse events only if clinically relevant and changed from baseline.
aParticipant should be at rest for vital signs measurements
bNo recent hot or cold beverages or smoking
cUse clinical judgment when characterizing bradycardia among some healthy participant populations, for 
example, conditioned athletes
ER = emergency room; Hg = mercury.
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 96of 130Table 12 Tables for Clinical Abnormalities: Systemic (General or Illness)
Systemic (General)Systemic Grade
Mild 
(Grade 1)Moderate
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening 
(Grade 4)
Nausea/vomitingNo interference 
with activity or 
1-2 epi[INVESTIGATOR_1841]/24 hrsSome interference 
with activity or 
> 2epi[INVESTIGATOR_1841]/24 hrsPrevents daily 
activity, required 
outpatient IV 
hydrationER visit or 
hospi[INVESTIGATOR_859745]; prevents 
daily  activityER visit or 
hospi[INVESTIGATOR_859746]-narcotic pain 
reliever > 24 hrs or 
some interference 
with activitySignificant; any use 
of narcotic pain 
reliever o r prevents 
daily  activityER visit or 
hospi[INVESTIGATOR_859747]; prevents 
daily  activityER visit or 
hospi[INVESTIGATOR_859748]; prevents 
daily  activityER visit or 
hospi[INVESTIGATOR_859749] (as 
defined according to 
applicable regulations)No interference 
with activitySome interference 
with activity not 
requiring 
interventio nPrevents daily 
activity  and required 
medical interventionERvisit or 
hospi[INVESTIGATOR_93278] = emergency room; hrs = hours; IV = intravenous.
Clinical Study Protoc ol-Amendment [ADDRESS_1198286]
AZD1222 AESIs are based on Brighton Collaboratio n case definit ions (SPEAC 2020 ),
clinical experience, and scient ific interest . There is no current evidence to suggest that 
AZD1222 is associate d with these AESIs. 
Table [ADDRESS_1198287]
AESI Medical Concept
NeurologicGeneralized convulsion : Seizures are epi[INVESTIGATOR_859750], involuntary muscular contractions. They may also 
manifest as sensory disturbances, autonomic dysfunction and behavioral abnormalities, 
and impairment or loss of consciousn ess. 
Guillain -Barré syndrome : GBS is a peripheral nerve demyelinating disease, which can 
present as temporary ascending paralysis.
Acute disseminated encephalomyelitis : ADEM is defined as a uniphasic syndrome of 
brain inflammation and demyelination occurring in temporal association with an 
antecedent immunologic challenge, such as infection or an immunization. ADEM most 
commonly occurs in the pediatric population.
Other neurologic events : These events would include new onset event (acute or 
subacut e)motor and sensory disturbances (eg,weakness, numbness, paresthesia s, 
hypoesthesia, hy peresthesia, dysesthesias ), bowel/bladder dysfunction, gait 
impairment, or visual disturbance , or any event of myelitis, encephalomyelitis, myelitis 
transverse ,or other sudden neurological deficit .
VascularThrombotic, thromboembolic, and neurovascular events : These are events that can 
manifest as transient or permanent vision problems, dizziness, trouble understanding, 
facial droop, slurred speech, unilateral weakness, deep vein thrombosis with swollen, 
warm or painful leg, pulmonary embolism with shortness of breath, chest pain or 
irregular heart rate.
HematologicThrombocytopenia : Thrombocytopenia is a disorder in which there is an abnormally 
low platelet co unt; a normal platelet count ranges from 150 000 to 450 000 platelets 
per μL.
ImmunologicVasculitides : Vasculitides are a group of related disorders characterized by 
[CONTACT_859797] (vasculitis) leading to tissue or end -organ injury.
Anaphy laxis : Anaphylaxis an acute hypersensitivity reaction with multi -organ-system 
involvement that can present as, or rapi[INVESTIGATOR_14274], a severe life -threatening 
reaction requiring immediate medical attention.
Vaccine -associated enhanced respi[INVESTIGATOR_3765] : The pathogenicity of VAERD has 
been linked to a vaccine immune response characterized by [CONTACT_859798]-neutralizing antibodies, and a T -cell response of the Th2 type with 
hypereosinophilia (Lambert et al 2020 ). VAERD may manifest as a severe form of 
respir atory  disease with prolonged fever, and diverse clinical manifestations of disease 
severity  and pathological changes marked by [CONTACT_859799], 
broncho -interstitial pneumonia, and necrotizing bronchiolitis (Rajão et al 2016 ).
Clinical Study Protocol -Amendment [ADDRESS_1198288]
AESI Medical Concept
Potential immune -mediated conditions : These conditions are a group of autoimmune 
inflammatory disorders characterized by [CONTACT_859800], which 
may or may  not have an autoimmune aetiology. A list of events is provided in 
Table 14. 
ADEM = acute disseminated encephalomyelitis; AESI = adverse event of special interest; GBS = Guillain -
Barré syndrome; VAERD = vaccine -associated enhanced respi[INVESTIGATOR_3765].
Table [ADDRESS_1198289] of Potential Immune -mediated Medical Conditions
Category Condition
Gastrointestinal disordersCeliac disease
Crohn’s disease
Ulcerative colitis
Ulcerative proctitis
Liver disordersAutoimmune cholangitis
Autoimmune hepatitis
Primary  biliary  cirrhosis
Primary  sclerosing cholangitis
Metabolic diseasesAddison’s disease
Autoimmune thyroiditis (including Hashimoto thyroiditis)
Diabetes mellitus type I
Grave's or Basedow’s disease
Musculoskeletal disordersAntisynthetase syndrome
Dermatomyositis
Juvenile chronic arthritis (including Still’s disease)
Mixed connective tissue disorder
Polymya lgia rheumatic
Polymyositis
Psoriatic arthropathy
Relapsing polychondritis
Rheumatoid arthritis
Scleroderma, including diffuse systemic form and CREST syndrome
Spondyloarthritis, including ankylosing spondylitis, reactive arthritis 
(Reiter's Syndrome) and undifferentiated spondyloarthritis
Systemic lupus erythematosus
Systemic sclerosis
Clinical Study Protocol -Amendment [ADDRESS_1198290] of Potential Immune -mediated Medical Conditions
Category Condition
Neuroinflammatory disordersAcute disseminated encephalomyelitis, including site specific variants 
(eg,non-infectious encephalitis, encephalomyelitis, myelitis, 
radiculomyelitis)
Cranial nerve disorders, including paralyses/paresis (eg, Bell’s palsy)
Guillain -Barré syndrome, including Miller Fisher syndrome and other 
variants
Immune -mediated peripheral neuropathies and plexopathies, including 
chronic inflammatory demyelinating polyneuropathy, multifocal motor 
neuropathy  and polyneuropathies associated with monoclonal 
gammopathy
Multiple sclerosis
Neuromyelitis optica spectrum disorder
Narcolepsy
Optic neuritis
Transverse myelitis
Myasthenia gravis, including Eaton -Lambert syndrome
Skin disordersAlopecia areata
Autoimmune bullous skin diseases, including pemphigus, pemphigoid and 
dermatitis herpetiformis
Cutaneous lupus erythematosus
Erythema nodosum
Morphoea
Lichen planus
Psoriasis
Rosacea
Sweet’s syndrome
Vitiligo
VasculitidesLarge vessels vasculitis including: giant cell arteritis such as Takayasu's 
arteritis and temporal arteritis
Medium sized and/or small vessels vasculitis including: polyarteritis 
nodosa, Kawasaki's disease, microscopic polyangiitis, Wegener's 
granulomatosis, Churg –Strauss syndr ome (allergic granulomatous 
angiitis), Buerger’s disease, thromboangiitis obliterans, necrotizing 
vasculitis and anti -neutrophil cytoplasmic antibody (ANCA) positive 
vasculitis (type unspecified), Henoch -Schonlein purpura, Behcet's 
syndrome, leukocytoclast ic vasculitis
Clinical Study Protocol -Amendment [ADDRESS_1198291] of Potential Immune -mediated Medical Conditions
Category Condition
OtherAntiphospholipid syndrome
Autoimmune hemolytic anemia
Autoimmune glomerulonephritis (including IgA nephropathy, 
glomerulonephritis rapi[INVESTIGATOR_10480], membranous glomerulonephritis, 
membranoproliferative glomerulonephritis, and mesangioproliferative 
glomerulonephritis)
Autoimmune myocarditis/cardiomyopathy
Autoimmune thrombocytopenia
Goodpasture syndrome
Idiopathic pulmonary fibrosis
Pernicious anemia
Raynaud’s phenomenon
Sarcoidosis
Sjögren’s sy ndrome
Stevens -Johnson syndrome
Uveitis
Clinical Study Protocol -Amendment [ADDRESS_1198292] case of SARS -CoV -2 
RT-PCR -positive sy mptomatic illness 
occurs ≥ [ADDRESS_1198293] RT -PCR -confirmed SARS -CoV -2 and meet 
the following criteria at any point from their initial illness visit at the 
site (Day  1) through their second illness visit (Day 14):
1 One or more Category A findings 
OR
2 Two or more Category B findings
Category A:
• Pneumo nia diagnosed by [CONTACT_13190] x -ray, or computed tomography
scan
• Oxygen saturation of ≤ 94% on room air or requiring either 
new initiation or escalation in supplemental O 2
• New or worsening dyspnea/shortness of breath
Category B:
• Fever > 100 °F (> 37.8 °C) or feverishness
• New or worsening cough
• Myalgia/muscle pain
• Fatigue that interferes with activities of daily living
• Vomiting and/or diarrhea (only one finding to be counted 
toward endpoint definition)
• Anosmia and/or ageusia (only one f inding to be counted toward 
endpoint definition)
Clinical Study Protocol -Amendment [ADDRESS_1198294] -
treatment response (negative at 
baseline to positive post treatment 
with study intervention) for SARS -
CoV-2 Nucleocapsid antibodies 
occurring ≥ [ADDRESS_1198295] second dose 
of study intervention (key secondary 
endpoint)The first post -treatment response (negative at baseline to positive 
post treatment w ith study  intervention) for SARS -CoV -2 
Nucleocapsid antibodies occurring ≥ [ADDRESS_1198296] case of 
SARS -CoV -2 RT -PCR -positive 
symptomatic illness occurring 
≥ [ADDRESS_1198297] case of SARS -CoV -2 RT -PCR -positive symptomatic 
illness fo r a participant occurring ≥ [ADDRESS_1198298] second dose of 
study intervention using criteria from the CDC (CDC 2020 ):
Fever
Shortness of breath
Difficulty breathing
Chills
Cough
Fatigue
Muscle aches
Body aches
Headache
New loss of taste 
New loss of smell
Sore throat
Congestion
Runny nose
Nausea
Vomiting
Diarrhea
Clinical Study Protocol -Amendment [ADDRESS_1198299] case of 
SARS -CoV -2 RT -PCR -positive 
symptomatic illness occurring 
≥ [ADDRESS_1198300] case of SARS -CoV -2 RT -PCR -positive sy mptomatic illness for 
a participant occurring ≥ [ADDRESS_1198301] one of the following symptoms:  
1 New onset of fever (> 100 °F [> 37.8 °C]), OR 
2 Cough, OR 
3 Shortness of breath, OR 
4 Anosmia/ageusia
Clinical Study Protocol -Amendment [ADDRESS_1198302] case of 
SARS -CoV -2 RT -PCR -positive 
symptomatic illness occurring 
≥ [ADDRESS_1198303] second dose of study 
interventio nregardless of evidence of 
prior SARS -CoV -2 infection (key 
secondary endpointParticipant must have RT -PCR -confirmed SARS -CoV -2 and meet 
the following criteria at any point from their initial illness visit at the 
site (Day  1) through their second illness visit (Day 14):
1 One or more Category A findings 
OR
2 Two or more Category B findings
Category A:
• Pneumo nia diagnosed by [CONTACT_13190] x -ray, or computed tomography
scan
• Oxygen saturation of ≤ 94% on room air or requiring either 
new initiation or escalation in supplemental O 2
• New or worsening dyspnea/shortness of breath
Category B:
• Fever > 100 °F (> 37.8 °C) or feverishness
• New or worsening cough
• Myalgia/muscle pain
• Fatigue that interferes with activities of daily living
• Vomiting and/or diarrhea (only one finding to be counted 
toward endpoint definition)
• Anosmia and/or ageusia (only one finding to be counted toward 
endpoint definition)
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 106of 130Table 15 Overview of Primary and Secondary Efficacy Objectives, Endpoints ,and Associated Case Definitions
Objective Endpoint Case Definition
SecondaryTo estimate the efficacy of 
2IM doses of AZD1222 
compared to saline placebo for 
the prevention of severe or 
critical symptomatic
COVID -19a)The incidence of SARS -CoV -2 
RT-PCR -positive severe or critical 
symptomatic illness occurring 
≥ [ADDRESS_1198304] second dose of 
study intervention (key secondary 
endpoint)Participant must have laboratory -confirmed COVID -19 
(SARS -CoV -2 RT -PCR -posit ive symptomatic illness) plus any of 
the following:
• Clinical signs at rest indicative of severe systemic illness 
(respi[INVESTIGATOR_31145] ≥ 30 breaths per minute, heart rate ≥ 125 beats 
per minute,  oxygen saturation ≤ 93% on room air at sea level, 
or partial pre ssure of oxygen to fraction of inspi[INVESTIGATOR_218687] 
<300 mm Hg)
• Respi[INVESTIGATOR_33078] (defined as needing high-flow oxygen, 
noninvasive ventilation, mechanical ventilation or 
extracorporeal membrane oxygenation)
• Evidence of shock (systolic blood pressure < 90 mm Hg, 
diastolic blood pressure < 60mm Hg, or requiring 
vasopressors)
• Significant acute renal, hepatic, or neurologic dysfunction
• Admission to an intensive care unit
• Deathb)The incidence of SARS -CoV -[ADDRESS_1198305] dose of study intervention
To estimate the efficacy of 
2IM doses of AZD1222 
compared to saline placebo for 
the prevention of COVID -19-
related Emergency Department 
visitsThe incidence of COVID -19-related 
Emergency Department visits
occurring ≥ [ADDRESS_1198306] second dose 
of study intervention (key secondary  
endpoint)COVID -19-related Emergency Department visits occurring 
≥ [ADDRESS_1198307] second dose of study intervention
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 107of 130Table 15 Overview of Primary and Secondary Efficacy Objectives, Endpoints ,and Associated Case Definitions
Objective Endpoint Case Definition
SecondaryTo assess antibody responses to 
AZD1222 S antigen following 
2 IM doses of AZD1222 or 
saline placebo
(Substud yand Illness Visits 
only)a) Post-treatment GMTs and GMFRs 
from day  of dosing baseline value 
to [ADDRESS_1198308] each dose in 
SARS -CoV -2 S, RBD antibo dies 
(MSD serology assay)a) Post-treatment GMTs and GMFRs from day of dosing baseline 
value to [ADDRESS_1198309] each dose in SARS -CoV -2 S, RBD
antibodies (MSD serology assay)
b) The proportion of participants who 
have a post -treatment seroresponse 
(≥ 4-fold rise in titers from day of 
dosing baseline value to [ADDRESS_1198310] each dose) to the S, RBD 
antigens of AZD1222 (MSD 
serology assay)b) Post-treatment seroresponse ( ≥ 4-fold rise in titers from day of 
dosing baseline value to [ADDRESS_1198311] each dos e) to the S, RBD 
antigens of AZD1222 (MSD serology assay)
To determine anti -SARS -CoV -
2 neutralizing antibody levels 
in serum following 2 IM doses 
of AZD1222 or saline placebo
(Substud yand Illness Visits 
only)a) Post-treatment GMTs and GMFRs 
from day  of dosing baseline value 
to [ADDRESS_1198312] each dose in 
SARS -CoV -2 neutralizing 
antibodies (wild -type assay  or 
pseudo -neutralization assay)a) Post-treatment GMTs and GMFRs from day of dosing baseline 
value to [ADDRESS_1198313] each dose in SARS -CoV -2 neutralizi ng 
antibodies (wild -type assay  or pseudo-neutralizatio n assay )
b) Proportio n of participants w ho 
have a post -treatment seroresponse 
(≥ 4-fold rise in titers from day of 
dosing baseline value to [ADDRESS_1198314] each dose) to AZD1222 as 
measured by [CONTACT_7544] -CoV -2
neutralizing antibodies ( wild-type
assay  or pseudo-neutralization 
assay )b) Post-treatment seroresponse ( ≥ 4-fold rise in titers from day of 
dosing baseline value to [ADDRESS_1198315] each dose) to AZD1222 as 
measured by [CONTACT_7544] -CoV -2neutralizing anti bodies ( wild-
type
assay  or pseudo-neutralization assay)
Clinical Study Protocol -Amendment [ADDRESS_1198316] RT -PCR -confirmed SARS -CoV -2 and meet 
the following criteria at any point from their initial illness visit at the 
site (Day  1) through their second illness visit (Day 14):
1 One or more Cat egory A findings 
OR
2 Two or more Category B findings
Category A:
• Pneumo nia diagnosed by [CONTACT_13190] x -ray, or computed tomography
scan
• Oxygen saturation of ≤ 94% on room air or requiring either 
new initiation or escalation in supplemental O 2
• New or worsening dyspnea/shortness of breath
Category B:
• Fever > 100 °F (> 37.8 °C) or feverishness
• New or worsening cough
• Myalgia/muscle pain
• Fatigue that interferes with activities of daily living
• Vomiting and/or diarrhea (only one finding to be counted 
toward endpoint definition)
• Anosmia and/or ageusia (only one finding to be counted toward 
endpoint definition)
CDC = Centers for Disease Control and Prevention; COVID -19 = coronavirus disease 2019; GMFR = geometric mean fold rise; GMT = geometric mean titer; 
IM = intramuscular ; MSD = Meso Scale Discover y; S = Spi[INVESTIGATOR_2531]; R BD = receptor binding domain ; RT-PCR = reverse transcriptase polymerase chain reaction ; 
SARS -CoV -2 = severe acute respi[INVESTIGATOR_7686] -coronavirus -2.
Clinical Study Protocol -Amendment [ADDRESS_1198317] aspartate aminotransferase
-hCG beta-human chorionic gonadotropin
CDC Centers for Disease Control and Prevention
ChAdOx1 MERS chimpanzee adenovirus Ox1 with MERS Spi[INVESTIGATOR_859751]1 nCoV -[ADDRESS_1198318]-in -human
GCP Good Clinical Practice
GMFR geometric mean fold rise
GMT geometric mean titer
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
IEC Independent Ethics Committee
IgA immunoglobulin A
IgG immunoglobulin G
IgM immunoglobulin M
IM intramuscular 
Clinical Study Protocol -Amendment [ADDRESS_1198319] upper limit of normal
US FDA [LOCATION_002] Food and Drug Administration
[LOCATION_003] [LOCATION_002] of America
VE vaccine efficacy
vp viral particles
WHO World Health Organization
w/v weight/volume
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 111of 130Appendix HProtocol Amendment History
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents.
Amendment 5 (18 January 2021)
This amendment is considered to be substant ial based on the cri teria set forth in Art icle 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council o f the European Unio n.
Overall Rationale for the Amendment:
The principal reason for this amendment was to add an extensio n to the study  to permit 
evaluat ion of safet y, immunogenicit y, and efficacy of 2 doses of AZD1222 administered 8 to 
12 weeks apart to adults and adolescents. The extended dosing interval is supported by  
[CONTACT_859801] y data, as well  as a high level of protection (VE 73%) against 
COVID -19 dem onstrated from a single dose (COVID -19 Vaccine [COMPANY_008] SmPC 2021).
Adolescents have been added to the study  popul ation to generate valuable data on safet y and 
immunogenicit y in this age group.
Note that the new addit ion to the study  was labeled as Part 2 (and included in a separate 
Appendix G ) and the exist ing main study and its corresponding substudy  and immunogenicit y 
cohort were relabelled as Part 1.
Section # and Name [CONTACT_670790]/
Non-substantial
Title Page,
1.1 SynopsisAdded “and Adolescents” to the 
titleTo generate evidence to 
lower the indication to 
persons 12 years of ageSubstantial
1.1 Synopsis,
2.1 Study RationaleAdded text to the study rationale 
regarding adolescents
1.1 Synopsis,
3 Objectives and 
Endpoints,
Appendix F Overview 
of Primary  and 
Secondary Efficacy 
Objectives, 
Endpoints, and 
Associated Case 
Definitio ns (Table 15)Rem oved “in adults ≥ 18 years 
of age” from primary objectives 
1-3 To make the objective s
applicable to both Part 1 
and the newly added 
Part 2Non-substantialSpecified that primary 
objective 3, secondary 
objectives 7 -8, and exploratory 
objectives 6 -14 apply  to both 
Part 1 and Part 2
Added a second endpoint for 
secondary objective 5 and 
exploratory objectives 3 and 4To show efficacy after 
1dose in severe 
COVID -19 illnessSubstantial
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 112of 130Section # and Name [CONTACT_670790]/
Non-substantial
1.1 Synopsis,
1.2 Schema,
1.3 Schedule of 
Activities
3 Objectives and 
Endpoints,
4.1 Overall Design,
4.2 Scientific 
Rationale for Study 
Design,
4.3 Justification for 
Dose,
5 Study  Populatio n,
6.1.2 Dosing 
Instructio ns,
6.3 Measures to 
Minimize Bias: 
Randomization and 
Blinding,
7.1 Discontinuation of 
study intervention
8 Study  Assessments 
and Procedures,
9 Statistical 
Considerations,
Appendix G Part 2 Added Appendix G to describe 
the new Part 2 and 
corresponding Part 2 Substudy. 
Added cross -references to 
Appendix G.To permit evaluation of 
safety, immunogenicity, 
and efficacy of 2 doses 
of AZD1222 
administered 8 to 12 
weeks apart in adults 
and adolescentsSubstantial
Relabelled the existing main 
study and its corresponding 
substudy and immunogenicity 
cohort as Part 1For clarity and 
consistency, given the 
addition of Part 2Non-substantial
1.1 Synopsis,
9.2 Sample Size 
Determination,
9.4 Statistical 
Analy sesChanged “not seropositive” to 
“seronegative”Clarification Non-substantial
[ADDRESS_1198320] dose given the 
extension of the dosing 
interval in Part 2Substantial
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 113of 130Section # and Name [CONTACT_670790]/
Non-substantial
Appendix E Adverse 
Events of Special 
Interest (Table 13)Added additional terms to 
“immunologic” of multisystem 
inflammatory syndr ome in 
children and adults and added a 
new category “respi[INVESTIGATOR_696]” with 
term of acute respi[INVESTIGATOR_859752]-substantial
Amendment 4 (14 December 2020)
This amendment is considered to be substant ial based on the cri teria set forth in Art icle 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council o f the European Unio n.
Overall Rationale for the Amendment:
The principal reason for this amendment was to incorporate revisio nsbased on FDA feedback 
and clarificat ions of study  processes. In addit ion, an immunogenicit y cohort was added to 
expand upon cell -mediated immunit y data.
Section # and Name [CONTACT_670790]/
Non-substantial
Title Page Corrected EudraCT number Correction Non-substantial
1.1 Synopsis,
3 Objectives and 
Endpoints,
9.4.1 General 
ConsiderationsAdded text to indicate that 
participants unblinded to 
treatment assignment prior to 
having met the criteria for the 
primary  efficacy endpoint will be 
censored at the date of 
unblinding.Clarification Non-substantial
1.1 Synopsis,
3 Objectives and 
Endpoints, 
[IP_ADDRESS] Secondary 
Endpoints,
Appendix G 
(Table 15)Revised the first secondary 
endpointTo permit formal 
statistical comparison and 
inclusion as key 
secondary endpoint Substantial
Identified the 4 key secondary 
endpoints (added footnote c)To indicate these are the 
endpoints that are 
multiplicity protected
1.1 Synopsis,
4.1 Overall Design,
[IP_ADDRESS] Assessment of 
Mucosal Responses,
[IP_ADDRESS] Assessment of 
Cell-mediated Immune 
ResponseAdded an immunogenicity cohort 
of approximately 300 participantsTo expand upon cell -
mediated immunity dataSubstantial
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 114of 130Section # and Name [CONTACT_670790]/
Non-substantial
1.[ADDRESS_1198321] 
studies, and the large 
outbreak in the United 
States has increased the 
attack rateSubstantial
1.1 Synopsis,
9.2 S ample Size 
DeterminationChanged attack rate for primary 
analy sis from 0.6% to 0.8%Given the reduction in 
sample size from 40 000 
to 30 000 Non-substantial
1.3 Schedule of 
Activities (Table 2 and 
Table 3)Revised Table 2 and Table 3 
captions to include 
“Immunogenicity Cohort”To address addition of 
immunogenicity cohort to 
study
Non-substantialAdded the collection of PBMCs 
at Day  180 for substudy and 
immunogenicity cohort 
participants to Table 3To build on data 
regarding durability of 
cell-mediated immunity
Revised footnote f of Table 3 to 
indicate that PBMCs will be 
isolated from up to (instead of 
approximately) 300 participants 
in the substudy and 
approximately 300 participants in 
the immunogenicity cohortTo include the newly 
added immunogenicity 
cohort
In Table 3, indicated that 
assessment of nasal adsorption for 
SARS -CoV -2 mucosal responses 
is optionalClarification
In Table 3, indicated that local 
and sy stemic predefined solicited 
AEs apply to the substudy onlyClarification
1.3 Schedule of 
Activities (Table 2 and 
Table 3, footnote c),
6.5.2 Pro hibited 
Concomitant 
MedicationsAdded text to indicate that 
experimental vaccinations, other 
than AZD1222, for prevention of 
SARS -CoV -2 or COVID -19 are 
prohibited. Also, noted that 
participants who choose to 
receive a licensed and/or 
autho rized COVID -[ADDRESS_1198322] of care 
given the rapi[INVESTIGATOR_859753] -19 vaccines 
landscapeNon-substantial
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 115of 130Section # and Name [CONTACT_670790]/
Non-substantial
1.3 Schedule of 
Activities,
8.5 Human Biological 
Samples,
8.6.2 Other Study -
related Biomarker 
Research,
8.7 Optio nal Ge nomics 
Initiative Sample,
Appendix DRem oved Optional Genomics 
Initiative assessmentDue to kit build issues 
during the COVID -19 
pandemic and lack of 
sample tube availabilityNon-substantial
4.1 Overall Design,
8.1.1 Mo nitoring 
COVID -19 Sy mptomsIn the CO VID-19 Qualifying 
Symptoms table, revised “must be 
present for ≥ 2 days” to “must be 
present for ≥ 2 consecutive days” Clarification Non-substantial
5.1 Inclusion Criteria 
(Table 6)Under combined hormonal 
methods, changed “injectable” to 
“intravaginal”Correction
Non-substantialRevised footnote c to specify that 
sexual abstinence is considered a 
highly  effective method only if 
defined as refraining from 
heterosexual intercourse from 28 
days prior to Day 1 through 60 
days following administration of 
the second dose of study 
interventio n… (instead of ‘during 
the entire period of the study’)Clarification
5.[ADDRESS_1198323] the ability of the 
participant to participate 
in the study, or impair 
interpretation of the study 
dataNon-substantial
6.3.3 Procedures for 
UnblindingSpecified the procedures in the 
event a study participant is 
contact[CONTACT_859769] a 
licensed and/or authorized 
COVID -19 vaccineClarification provided due 
to recent Emergency Use 
Authorizations for 
COVID -19 vaccinesNon-substantial
6.5.2 Pro hibited 
Concomitant 
MedicationsClarified that routine vaccinations 
are permitted (as clinically 
indicated) 30 days after the 
second vaccinationClarification Non-substantial
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 116of 130Section # and Name [CONTACT_670790]/
Non-substantial
8.1.[ADDRESS_1198324] is not 100% 
accurate and Investigators 
need to provide 
appropriate clinical 
follow -up of any  ill 
participantsNon-substantial
8.1.3 Severe 
COVID -19Revised statement to indicate that 
the severity of COVID -19 will be 
evaluated in participants with 
symptoms of COVID -19 (instead 
of participants who test positive 
for SARS -CoV -2 by  [CONTACT_937]-PCR)To be consistent with 
CRF completion 
guidelines asking sites to 
complete the endpoint 
CRF regardless of the 
local PCR resultNon-substantial
[IP_ADDRESS] Potential 
Neurological AESIsAdded clarification that the 
Investigator should evaluate the 
participant and refer to a 
neurologist as clinically indicatedBased on Investigator 
feedbackNon-substantial
9.1 Statistical 
Hypotheses,
[IP_ADDRESS] Primary 
Endpoint,
9.4.[ADDRESS_1198325] ically 
significant, an additional analysis 
with 5% alpha will be performed 
once all participants have 
completed the first year of 
follow -upTo evaluate long- term 
efficacy based on 1 year 
of follow -up before the 
final analysisSubstantial
9.3 Populations f or 
Analy ses (Table 9)For Per -protocol analysis set, 
specified that erroneously -treated 
participants who receive one dose 
of active study intervention and 
one dose of placebo, regardless of 
the sequence, will be excluded 
from this analysis setClarificatio n
Non-substantial
For the safety analysis set, 
specified that a participant who 
has on one or several occasions 
received active study intervention 
is classified as active for all 
summaries, including summaries 
by [CONTACT_859802] -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 117of 130Section # and Name [CONTACT_670790]/
Non-substantial
9.4 Statistical AnalysesAdded text to indicate when 
unblinding of personnel involved 
in the analy ses of the study may 
occurClarification for timing of 
Sponsor unblindingNon-substantial
[IP_ADDRESS] Primary 
Endpoint,
9.5 Interim AnalysesChanged “not seropositive” to 
“seronegative”Clarification Non-substantial
[IP_ADDRESS] Primary 
EndpointsClarified that AE analyses will 
include intercurrent events for 
safety due to potential unblinding 
of participants for administration 
of licensed and/or approved 
SARS -CoV -2 or COVID -19
vaccineClarification Non-substantial
9.4.4 Methods for 
Multiplicity ControlRevised to indicate how the 
primary  efficacy  endpoints and 4 
key secondary  endpoints will be 
assessedTo address the Agency’s 
request for having a 
secondary endpoint 
testing str ategySubstantial
Amendment 3 (26 October 2020)
This amendment is considered to be substant ial based on the cri teria set forth in Art icle 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council o f the European Unio n.
Overall Rationale for the Amendment:
The principal reason for this amendment was to expand AESI evaluation and oversight. Other 
key revisi ons included updating the AZD1222 safety  profile, increasing the sample size, 
extending the beyo nd-use-date for the study  intervent ion, and specifying that the substudy  will 
only be conducted in the [LOCATION_003].  
Section # and 
NameDescription of Change Brief RationaleSubstantial/
Non-substantial
Title PageAdded ClinicalTrials.gov and 
EudraCT numbersTo align with updated 
informationNon-substantial
1.1 SynopsisUpdated Objectives and 
Endpoints, Overall Design, 
Number of Participants, Statistical 
MethodsTo align with edits in the 
protocol bodyNon-substantial
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 118of 130Section # and 
NameDescription of Change Brief RationaleSubstantial/
Non-substantial
1.2 Schema, 
Figure 1 Study 
DesignNoted that the substudy will only 
be conducted in the [LOCATION_003]Due to logistical issues Non-substantial
1.3 Schedule of 
Activities, 
Table 2 Extended Day 29 visit window 
from ±3 days to -3 to + 7 days To provide greater 
scheduling flexibility to sites 
and participantsNon-substantial
1.3 Schedule of 
Activities, 
Table 3a) Noted that the substudy will 
only be conducted in the [LOCATION_003] 
b) Extended Day 29 visit window 
from ±3 days to -3 to + 7 days 
c) For participants who received 
the first dose between 
28August 2020 and 
06September 2020, extended 
the window for receiving the 
second dosea) Due to logistical issues 
b) To provide greater 
scheduling flexibility to 
sites and participants
c) To accommodate receipt 
of the second dose of 
study intervention for 
participants who 
received their first dose 
prior to the clinical holdNon-substantial 
1.3 Schedule of 
Activities, 
Table 4a) Broadened optional saliva 
sample collection for viral 
shedding to all non -[LOCATION_003] sites
b) Noted that PBMCs will be 
collected from participants 
where operationally feasibleClarifications due to 
logistical issuesNon-substantial
2.2 BackgroundUpdated information on the 
nonclinical and clinical AZD1222 
development programTo align with information in 
the updated AZD1222 IBNon-substantial
2.3.1 Risk 
AssessmentRevised important potential risks Substantial
3 Objectives and 
Endpoints, 
Table 5a) Revised estimand description 
for the primary efficacy 
endpoint to be conducted in the 
fully vaccinated analysis set, 
and added a secondary 
objective to estimate efficacy 
in all participants regardless of 
prior SARS -CoV -2 infection 
b)Noted that the substu dy will 
only be conducted in the [LOCATION_003]a)To align with the 
statistical plan 
b)Due to logistical issues Non-substantial
Clinical Study Protocol -Amend ment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 119of 130Section # and 
NameDescription of Change Brief RationaleSubstantial/
Non-substantial
4.1 Overall 
Designa)Increased the sample size from 
[ZIP_CODE] to 40 000 participants
b) For participants who received 
the first dose between 
28August 2020 and 
06September 2020, extended 
the window for receiving the 
second dose 
c) Noted that the substudy will be 
conducted only in the [LOCATION_003]
d)Added a description of the 
independent Neurologic al AESI 
Expert Committeea)Increased based on 
updated attack rates and 
public health emergency
b)To accommodate receipt 
of the second dose of 
study intervention for 
participants who 
received their first dose 
prior to the clinical hold
c)Due to logistica l issues
d) New committee to 
provide advice on 
selected neurological 
AESIsa)Substantial
b)Non-substantial
c)Non-substantial
d)Substantial
4.2.1 Rationale 
for Study Design 
and Participant 
PopulationRevised enrollment status for 
Study COV002Aligned with updated study 
status Non-substantial
[IP_ADDRESS] AZD1222,
[IP_ADDRESS] PlaceboExtended the beyond -use-date 
from [ADDRESS_1198326] and 
specified that AESIs will be 
reported to the Sponsor within one 
day of becoming aware of the 
eventTo permit close monitoring 
and rapid communication of 
safety information, and 
further understanding of the
AZD1222 safety profileSubstantial
[IP_ADDRESS] Potential 
Neurological 
AESIsNew section for evaluation of 
potential neurological AESIsFor additional safety 
monitoringSubstantial
[IP_ADDRESS] 
Assessment of 
Cell-mediated 
Immune 
ResponsesNoted that PBMCs will be
collected from participants where 
operatio nally  feasible Clarifications due to 
logistical issuesNon-substantial
[IP_ADDRESS] 
Assessment of 
Viral SheddingBroadened optional saliva sample 
collection for viral shedding to all 
non-[LOCATION_003] sites
9.2 Sample Size 
DeterminationUpdated to incorporate the 
increased sample size from 30 000 
to 40 000 participants as well as 
the underlying assumptionsIncreased based on updated 
attack rates and public 
health emergencySubstantial
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 120of 130Section # and 
NameDescription of Change Brief RationaleSubstantial/
Non-substantial
9.3 Populations 
for AnalysesAdded a fully vaccinated analysis 
set and revised the per -protocol 
analy sis set to be based on 
participants in the fully vaccinated 
analy sis setTo align with the revised 
statistical analyses for the 
primary  endpointNon-substantial
9.4.1 General 
Considerations
[IP_ADDRESS] Primary 
Endpoint
[IP_ADDRESS] Secondary 
EndpointsRevised analysesTo align with the current 
analy sis planNon-substantial
Appendix A5 
Committee 
StructureAdded a description of the 
independent Neurological AESI 
Expert CommitteeNew committee to provide 
advice on selected 
neurological AESIsSubstantial
Appendix F 
Adverse Events of 
Special Interest a)Expanded the AESI list and 
provided a description of the 
events
b)Added new table listing 
potential immune -mediated 
conditio ns to provide more 
detail on this new AESI To permit close monitoring 
and rapid communication of 
safety information and 
further understand the 
AZD1222 safety profileSubstantial
Appendix Ga)Primary  endpoint: Revised to 
note that the statistical analysis 
will be conducted in
participants with negative 
serostatus at baseline
b)Secondary endpoint evaluating 
symptomatic COVID -19 per 
CDC criteria: Revised the case 
definition to remove a 
minimum duration for any of 
the symptoms
c)Added a secondary objective to 
estimate efficacy in all 
participants regardless of prior 
SARS -CoV -2 infectionTo align with statistical 
analy sesNon-substantial
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 121of 130Amendment 2 (17 September 2020)
Overall Rationale for the Amendment:
The principal reason for this amendment was to address US FDA feedback to the 
Invest igational New Drug applicat ion. Addit ional changes included statist ical revisio ns per 
DSMB request and other revisio ns to provide clarity or correct inadvertent errors. All the 
changes were considered non -substant ial.   
Section # and Name [CONTACT_859808]/
Non-substantial
1.1 SynopsisUpdated Objectives and 
Endpoints, Overall Design, 
Statistical MethodsTo align with edits in the 
protocol bodyNon-substantial
1.3 Schedule of 
Activities, Table 3Rem oved ‘at least’ to clarify that 
PBMCs will be isolated from 
approximately 300 participants Clarification Non-substantial
1.3 Schedule of 
Activities, Table 4a) Added new footnote ‘b’ to 
indicate that collection of saliva 
sample for viral shedding 
assessment is optional in 
Chile/Peru and may occur after 
a feasibility assessment has 
been completed
b) Footnote ‘c’: removed the 
requirement for the RT -PCR 
test to be a rapid testa) Feasibility of collection 
of saliva samples in 
Chile/Peru is underway
b) Not a requirement per 
protocol and provides 
more flexibility to the 
sitesNon-substantial
3 Objectives and 
Endpoints, Table 5a) Revised definition of 
intercurrent event 
b)Revised secondary objective 1 
to assess for all SARS -COV -2 
infection
c) Added an exploratory objective 
to estimate the efficacy of 2 IM 
doses of AZD1222 compared 
to placebo for COVID -19-
related deaths
d) Added an exploratory objective 
to estimate the efficacy of 
AZD1222 compared to placebo 
for the prevention of COVID -
[ADDRESS_1198327] dose
e) Renumbered exploratory 
objective 12: removed ‘serum’ 
prior to B -and T -cell responsesa) To align with changes 
in the primary analysis
b)To align with analyses
c) Per US FDA request
d) Per DSMB request
e) To correct a 
misstatementNon-substantial
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 122of 130Section # and Name [CONTACT_859808]/
Non-substantial
4.[ADDRESS_1198328] 
needle puncture of the 
AZD1222 vial or placebo 
vial/IV bag to dose 
administrationNon-substantial
[IP_ADDRESS] AZD1222
(Additional change)Rem oved specification for a [ADDRESS_1198329] Non-substantial
6.5.2 Pro hibited 
Concomitant 
Medicationsa) For participants who received a 
prohibited concomitant 
medication, described the 
potential impact on 
participation in the study, 
including study w ithdrawal, 
discontinuation of study 
interventio n, or evaluability in 
analy sis data sets
b)Added immunoglobulins and/or 
blood producta)Per US FDA request
b)For alignment with 
exclusion criterion 13Non-substantial
7.1 Discontinuation of 
Study Interventio na) Added new criterion for 
laborato ry-confirmed SARS -
CoV-2 infection
b) Revised criterion that any 
allergic reaction related to 
study intervention, regardless 
of severity grade , will result in 
study discontinuationa) Clarification
b) Per US FDA request
c) Per US FDA requestNon-substantial
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 123of 130Section # and Name [CONTACT_859808]/
Non-substantial
c) Added new criterion for receipt 
of pro hibited concomitant 
medication that may jeopardize 
the safety of the participant or 
interpretation of the data
8.1.[ADDRESS_1198330] Non-substantial
[IP_ADDRESS] Digital Health 
DeviceDescribed the monitoring 
protocols for triage and follow -up 
of alerts from the digita l health 
devicePer US FDA request Non-substantial
[IP_ADDRESS] Assessment of 
Cell-mediated Immune 
ResponsesClarified the number of 
participants who will provide 
PBMC samples, ie, approximately 
[ADDRESS_1198331] 3 000 
during the Day 1 illness visitTo align with the SoA 
Table 3 and Table 4Non-substantial
[IP_ADDRESS] Virologic 
Assessments
(additio nal change)Clarified that a validated 
multiplexed respi[INVESTIGATOR_859754]-substantial
[IP_ADDRESS] Assessment of 
Viral Sheddinga)Clarifie d that saliva collection 
is performed utilizing a 
Spectrum DNA (SDNA -1000) 
collection kit
b) Rem oved ‘qualitative’ to 
describe the type of shedding 
assessment
c)  Added information that 
collection of saliva sample for 
viral shedding assessment is 
optional in Chile/Peru and may 
occur after a feasibility 
assessment has been completeda) Clarification 
b)Updated due to an 
assay  improvement
c) Feasibility of 
collection of saliva 
samples in Chile/Peru 
is underwayNon-substantial
9 Statistical 
Considerations
9.1, 9.2, 9.4, [IP_ADDRESS], 
9.4.4, and 9.5Amended the testing strategy, 
sample sizing, as well as number 
of events required for the interim 
and primary analysesPer DSMB request Non-substantial
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 124of 130Section # and Name [CONTACT_859808]/
Non-substantial
9.3 Populations for 
Analy sis, Table 9Added definition for 
immunogenicity analysis setTo describe the population 
to be used for the 
immunogenicity 
assessmentsNon-substantial
9.4.1 General 
ConsiderationsRevised definition of intercurrent 
eventTo align with changes in 
the primary analysisNon-substantial
9.4.2 Efficacya) Added reference to new 
Appendix G (see description 
for Appendix G below)
b) Added description of an 
adjudication committee that 
will review data of potential 
cases for the COVID -19-related 
efficacy endpointsa) Per US FDA request
b)To provide clarity on 
the process for 
determining cases to 
be included in the 
COVID -19-related 
efficacy evaluations Non-substantial
[IP_ADDRESS] Primary 
Endpoint
(additio nal change)Clarified a supportive analysis of 
the primary endpointIncorrect statement a bout 
censored observations 
removedNon-substantial
[IP_ADDRESS] Secondary 
Endpointsa) Bullet 1: Clarified that the 
endpoint will assess the 
proportion of participants who 
have a post -treatment response 
(negative at baseline to positive 
post treatment with study 
interventio n) for SARS -CoV -2 
Nucleocapsid antibodies over 
time
b)Bullet 2: Included the endpoint 
to assess the incidence of 
SARS -CoV -2RT-PCR positive 
symptomatic illness using the 
CDC criteria
c) Bullet 3: Clarified the 
University of Oxford sympto m 
criteria used to assess the 
incidence of SARS -CoV -2 RT-
PCR positive symptomatic 
illness
d)Specified the analyses for the 
incidence endpoints, and added 
a description of the analysis for 
participants positive for SARS -
CoV-2 Nucleocapsid antibodiesa) Toalign with analyses
b)Corrected an 
inadvertent omission
c) Per US FDA request
d)ClarificationNon-substantial
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 125of 130Section # and Name [CONTACT_859808]/
Non-substantial
Appendix A5 
Committee StructureAdded description of an 
adjudication committee that will 
review data of potential cases for 
the COVID -19-related efficacy 
endpointsTo provide clarity on the 
process for determining 
cases to be included in the 
COVID -19-related 
efficacy evaluations
Appendix G Overview 
of Primary  and 
Secondary Efficacy 
Objectives, Endpoints, 
and Associated Case 
Definitio nsNew overview table presenting the 
primary and secondary  efficacy 
objectives, endpoints, and 
associated case definitions Per US FDA request Non-substantial
Appendix I Protocol 
Amendment HistoryMoved summary of changes for 
Protocol Amendment 1 to this new
appendix  Per protocol template Non-substantial
CDC = Centers for Disease Control and Prevention ; COVID -19 = coronavirus disease 2019 ; eCRF = 
electronic case report form ; DSMB = Data Safety Monitoring Board ; e-Diary  = electronic diary ; IM = 
intramuscular ; NP = nasopharyngeal; PBMC = peripheral blood mononuclear cell; RT-PCR = reverse 
transcriptase polymerase chain reaction ; SARS -CoV -2 = severe acute respi[INVESTIGATOR_7686] -coronavirus 2; 
SoA = schedule of activities; US FDA = [LOCATION_002] Food and Drug Administration . 
Amendment 1 ([ADDRESS_1198332] 2020)
Overall Rationale for the Amendment:
Section # and Name [CONTACT_670790]/
Non-substantial
1.1 SynopsisUpdated Objectives and 
Endpoints, Overall Design, and 
Statistical Methods To align with edits in main 
bodyNon-substantial
1.2 SchemaRevised the footnote to identify 
the number of randomized 
participants in each age group to 
participate in the substudyTo identify by [CONTACT_859803] 
3 000 randomized 
participants who will 
participate in the substudyNon-substantial
1.3 Schedule of 
Activities
Table 2 Treatment and 
Follow -up Period -
Main StudyAdded assessment for recording 
any concomitant medication 
admini stered for the treatment of 
an SAE, MAAE, or AESI from 
Day 90 through Day 730To support evaluation of 
SAEs, MAAEs, or AESIsNon-substantial
1.3 Schedule of 
Activities
Table 3 Treatment and 
Follow -up Period -
Substudya)Added assessment for 
recording any concomitant 
medication administered for 
the treatment of an SAE, 
MAAE, or AESI from 
Day 90 through Day 730a)To support evaluation of 
SAEs, MAAEs, or 
AESI s
b)To help ensure PBMCs 
can be collected in Non-substantial
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 126of 130Section # and Name [CONTACT_670790]/
Non-substantial
b)Footnote d: identified that ‘at 
least 300’ participants in the 
substudy can have PBMCs 
collectedparticipants across age 
groups
2.2 Backgrounda) Corrected the study number 
for the University of Oxford 
South Af rican clinical study
b) Updated preliminary clinical 
data from Study COV001 and 
Study COV002To align with: 
a) The study  number 
correction made by [CONTACT_859804] 
b) The updated AZD1222 
IB, Edition 1.1Non-substantial
2.3.1 Risk AssessmentUpdated common solicited AE 
information To align with the updated 
AZD1222 IB, Edition 1.1Non-substantial
3 Objectives and 
Endpointsa)Clarified that secondary 
objective 6 is performed in 
substudy and illness visits 
only
b)Footnote a: identified the 
number of randomized 
participants in each age group 
to participate in the substudya)Humoral responses to 
AZD1222 are not 
required for main study 
participants
b)To identify by [CONTACT_859805] 3 000 randomized 
participants who will 
participate in the 
substudyNon-substantial
4.1 Overall Designa) Clarified that enrollment will 
begin with participants 18 to 
55 years of age, followed by 
[CONTACT_859806]
b) Identified the number of 
randomized participants in 
each age group to participate 
in the substudya)To provide for review of 
immunogenicity data in 
older subjects prior to 
enrollment’
b)To identify by [CONTACT_859805] 3 000 randomized 
participants who will 
participate in the 
substudyNon-substantial
4.2.1 Rationale for 
Study Design and 
Participant PopulationUpdated the number of
participants 56 to 69 and 
≥ [ADDRESS_1198333] received AZD1222 at time 
of study initiationTo align with updated study 
statusNon-substantial
5.1 Inclusion CriteriaCorrected number formatting to 
separate Criteria 3 and 4Inclusion crit erion 4 was 
erroneously included under 
inclusion criterion 3Non-substantial
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 127of 130Section # and Name [CONTACT_670790]/
Non-substantial
5.2 Exclusion Criteriaa) Clarified Criterion 2 to 
include participants with any 
other demyelinating condition
b) Clarified Criterion 6 to state 
≥20 mg per day vs 
≥ 20 mg/kg/day of prednisonePer NIH request
Correct typographical errorNon-substantial
6.1.2 Dosing 
Instructio nsDeleted instructions to cover the 
injection site with a sterile 
dressingErroneously included in 
original protocolNon-substantial
6.2.1 Do se Preparation 
and Administration; 
[IP_ADDRESS] AZD1222
[IP_ADDRESS] PlaceboClarified that AZD1222 and 
placebo doses drawn into 
syringes for administration must 
be administered according to the 
beyond -use-date of the vial or IV 
bagTo align with the beyond -
use-date of the vial or IV 
bag as AZD1222 and 
placebo do not contain 
preservativesNon-substantial
7.2 Participant 
Withdrawal from the 
StudyClarified that all collected 
samples will be destroyed if the 
participant withdraws consent 
for use of existing samplesTo align with current 
processNon-substantial
8.1.1 Mo nitoring 
COVID -19 Sy mptomsClarified that investigator 
judgement should be used when 
determining which participants 
should initiate illness visits 
during the 7 days following 
administr ation of each dose of 
study interventionTo help ensure that 
qualify ing sy mptoms for 
illness visits are due to 
potential infection with 
SARS -CoV -2 and not to 
reactogenicity of the study 
interventio n Non-substantial
[IP_ADDRESS] Digital Health 
DeviceClarified that the monitoring 
team will receive and triage 
alerts associated with 
participants’ digital health 
device data rather than the 
investigatorTo align with current 
processNon-substantial
9.1 Statistical 
Hypotheses
[IP_ADDRESS] Primary 
Endpoint
9.4.[ADDRESS_1198334] practice Non-substantial
Clinical Study Pro tocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 128of 130Section # and Name [CONTACT_670790]/
Non-substantial
Appendix A 5 
Committee StructureAdded criteria for pausing the 
study for DSMB review To ensure safety oversight Non-substantial
Appendix E Toxicity Grading Scales for Solicited Adverse Events 
Table 11 Clinical 
Abnormalities: Vital 
SignsRevised the temperature range 
for feverTo align with definition of 
fever throughout the main 
body Non-substantial
Table 12 Clinical 
Abnormalities: 
SystemicAdded information for assessing 
severity  grade of chills and 
deleted diarrheaTo align with solicited 
adverse events being 
collected, which includes 
chills but not diarrheaNon-substantial
AESI = adverse event of special interest; MAAE = medically attended adverse event; NIH = National 
Institutes of Health; SAE = serious adverse event; SAP = Statistical Analysis Plan. 
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 129of [ZIP_CODE] REFERENCES
CDC. (Centers for Disease Control and Prevent ion). Coronavirus Disease 2019 (COVID -19), 
Symptom s of Coronavrus. https://www.cdc.gov/coronavirus/2019 -ncov/symptom s-
testing/symptoms.ht ml. Published 2020. Accessed 01 July  2020.
FDA. (Food and Drug Administrat ion). Guidance for Industry . Toxi city grading scale for 
healt hy adult and ado lescent volunteers enro lled in preventive vaccine clinical trials. . 
https://www.fda.gov/media/[ZIP_CODE]/download . Published 2007. Accessed [ADDRESS_1198335] respi[INVESTIGATOR_82326] e coronavi rus viral -vectored 
vaccine: a dose -escalat ion, open -label, non -randomised, uncontrolled, Phase 1 trial. Lancet 
Infecti Dis. 2020a;2 0(7):[ADDRESS_1198336] SARS -CoV -2: a preliminary 
report of a phase 1/2, single -blind, randomised controlled trial. Lancet . 2020b;S0140 -
6736(20):[ZIP_CODE]- 4.
Graham SP, McLean RK, Spencer AJ, Belij- Rammerstorfer S, Wright D, Ulaszewska M et al. 
Evaluat ion of the immunogenicit y of prime -boost vaccination wit h the replicat ion-deficient 
viral vectored COVID -19 vaccine candidate ChAd Ox1 nCoV -19. npj  Vaccines. 2020;5(1):69.
Lambert P -H, Ambrosino DM, Andersen SR, Baric RS, Black SB, Chen RT et al. Consensus 
summary report for CEPI/BC March 12–13, 2020 meet ing: Assessment of risk of disease 
enhancement with COVID -19 vaccines. Vaccine. 2020;38(31):[ADDRESS_1198337] ion, and Evo lution of Coronavirus Spi[INVESTIGATOR_103184]. Annu Rev Viro l. 
2016;3(1):237 -61.
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H et al. Geno mic characterisat ion and epi[INVESTIGATOR_859755] 2019 novel coronavirus: implications f or virus ori gins and receptor binding. Lancet. 
2020;395([ZIP_CODE]):565-74.
NIH. (Nati onal Institutes of Health). Guidelines for the use of ant iretrovi ral agents in adul ts 
and ado lescents with HIV. https://aidsinfo.nih.gov/guidelines . Published 2020. Accessed [ADDRESS_1198338] ivated influenza virus vaccines. The Journal o f general  virology. 2016;97(7):1489-
99.
Clinical Study Protocol -Amendment 6 [COMPANY_008]
AZD1222 -D8110C00001
CONFIDENTIAL AND PROPRIETARY 130of 130Rovi ra À, Wattj es MP, Tintoré M, Tur C, Yousry  TA, Sorm ani MP et al . MAGNIMS 
consensus guidelines on the use of MRI in mult iple scl erosis —clinical implementation in the 
diagnosti c process. Nature Reviews Neurology . 2015;11(8):471 -82.
Schmitt -Thom pson. Clinical Content. COVID -19 Resources. 2020. https://www.stcc -
triage.com /covid -19-resources . Published 2020. Accessed 01 September 2020.
SPEAC. (Safet y Platform for Em ergency Vaccines) D2.[ADDRESS_1198339]: COVID -19. Work Package: WP2 Standards and Tools. v1.1. 05 March 2020. 
https://m edia.tghn.org/articles/COVID -19_AESIs_SPEAC_V1.1_5Mar2020.pdf . Published 
2020. Accessed 14 June 2020.
van Dorem alen N, Lambe T, Spencer A, Belij -Rammerstorfer S, Purush otham  JN, Port JR et 
al. ChAdOx1 nCoV -19 vaccine prevents SARS -CoV -2 pneumonia in rhesus macaques. 
Nature [Internet]. 2020 30 July  2020 [ci ted Access Date]. Available from: 
https://doi .org/10.1038/s41586-020-2608-y.
Waldrop G, Doherty  M, Vi toria M, Ford N. Stable patients and pat ients with advanced 
disease: consensus definit ions to support sustained scale up of ant iretrovi ral therapy . Tropi [INVESTIGATOR_859756] & internat ional health : TM & IH. 2016;21(9):1124- 30.
WHO. (Worl d Heal th Organizat ion) COVID -19 weekly epi[INVESTIGATOR_859757]. 18 October 
2020. https://www.who.int/docs/default -source/coronaviruse/situation -reports/20201020 -
weekly -epi-update -10.pdf?sfvrsn=58786643_26&download=true . Published 2020. Accessed 
23October 2020.
Zhou P, Yang X -L, Wang X -G, Hu B, Zhang L, Zhang W et al. A pneumo nia outbreak 
associ ated wi th a new coronavirus of probable bat origin. Nature. 2020.
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J et al. A novel coronavirus from pat ients 
withpneum onia in China, 2019. N Engl J Med. 2020;382(8):727 -33.
Zou G. A m odified po isson regression approach to prospective studies wit h binary data. Am J 
Epi[INVESTIGATOR_176310]. 2004;159(7):702-6.
6,*1$785(3$*(
7KLVLVDUHSUHVHQWDWLRQRIDQHOHFWURQLFUHFRUGWKDWZDVVLJQH G
HOHFWURQLFDOO\DQGWKLVSDJHLVWKHPDQLIHVWDWLRQRIWKHHOHFWU RQLFVLJQDWXUH
'RFXPHQW1DPH GFFVSDPHQGPHQW
'RFXPHQW7LWOH '&&OLQLFDO6WXG\3URWRFRO$PHQGPHQW
'RFXPHQW,'
9HUVLRQ/DEHO &855(17/$7(67$[ZIP_CODE]('
6HUYHU'DWH
GG000\\\\++PPµ87&¶=6LJQHGE\ 0HDQLQJRI6LJQDWXUH
)HE87& &RQWHQW$SSURYDO
)HE87& &RQWHQW$SSURYDO
)HE87& &RQWHQW$SSURYDO
)HE87& &RQWHQW$SSURYDO
CCICCI
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]